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SUMMARY
On infection with HIV-1, the host exerts a highly specific immune response 
against the virus. Despite this, HIV-1 is able to persist in the host, resulting in the 
gradual deterioration of the immune system, leading to opportunistic infections 
characteristic of HIV-infection and ultimately death of the individual. To elucidate the 
mechanisms involved in the pathogenesis and persistence of the virus, it is important to 
understand what role if any, the immune response generated against the virus has in the 
control of HIV-1 infection or progression to disease.
This thesis describes the development of branched peptides for use in the 
detection of specific antibodies and describes two studies measuring the antibody 
responses of HIV-1 infected individuals against the V3 immunodominant region of 
HIV-1 gpl20.
Branched peptides had previously been shown to be more immunogenic in rabbits 
and can detect antibodies at lower concentrations than can the equivalent monomeric 
peptides. The initial work described in this thesis, was designed to further characterise 
the observed increased sensitivity of branched peptides, to investigate the basis for it 
and to optimise branched peptides for use as serodiagnostic reagents. A series of 
experiments were performed to test the effect of varying the distance between the 
epitope and the core by introducing glycine spacers. The sensitivity of branched 
peptides in detection of specific antibodies was also compared with that of the native 
protein. Two systems were studied. The first, involved the HSV-1 UL42 protein and 
reactive monoclonal antibody Z1F11. The second, involved a peptide derived from the 
third hypervariable region (V3) of the HIV-1 gpl20 protein. These experiments clearly 
demonstrate that the progressive addition of glycine spacers between the reactive 
epitope in UL42 and the polylysine core increased the reactivity of the branched 
peptides with Z1F11. In addition , optimal reactivity of the UL42 peptides with 
monoclonal antibody Z1F11, was observed with the addition of four or five glycine 
residues and further addition of glycine residues did not significantly increase the
sensitivity of these peptides. Comparison of the reactivity of the branched peptide with 
a five glycine spacer and the native UL42 protein demonstrated that both were equal in 
reactivity with monoclonal antibody Z1F11. The branched peptide derived from the V3 
region of HIV-1 gpl20 was eight-fold more sensitive than the native protein in 
detection of antibodies in the sera of HIV-1 infected individuals.
The second study presented in this thesis was undertaken to investigate whether 
the levels and affinities of antibodies present in infected mothers, directed against the 
V3 region of HIV-1 gpl20 correlated with a lack of transmission of the virus from 
mother to child as had been previously reported. To do this, a retrospective study of the 
antibody responses in the sera taken from a cohort of seven mothers who transmitted 
HIV-1 to their children and 20 who did not, was performed. Maternal sera were titrated 
in a series of doubling dilutions and tested in an ELISA against both a V3 branched 
peptide encompassing the entire V3 loop region (amino acids 297-330) and a branched 
peptide containing an immunodominant region of gp41 (amino acids 596-614). Anti- 
gp41 titres were used to normalise the anti-V3 titres. Maternal sera were also screened 
for the presence of antibodies that bind to the V3 peptide with high affinity, using an 
antigen limited ELISA, in which the monomeric V3 peptide was titrated in a series of 
dilutions and screened for reactivity against the sera. A high affinity antibody would be 
detectable in ELISA at low peptide concentrations. No differences were observed in 
either titres or affinities of maternal antibodies to the V3 sequence from transmitters 
and non transmitters of HIV-1 to their children.
The third study was undertaken to test the hypothesis that the sequence variation 
that occurs in the principal neutralising determinant of HIV-1 gpl20 (V3) represents 
antibody escape mutants. The reactivity of successive sera from patient 82, a member 
of the Edinburgh haemophiliac cohort with his previously identified variants found 
within the V3 region of HIV-1 gpl20 during the natural course of infection was 
studied. Twelve branched peptides with a four glycine spacer, encompassing the 
immunodominant region of V3 were synthesised. These peptides correspond to the 
initial seroconversion sequence and to all subsequent variants identified in patient 82
over a seven year period. A further five branched peptides were synthesised, each 
containing just a single substituted amino acid of the multiple substitutions. Seven 
serum samples, collected over a seven year period from seroconversion, were tested in 
an ELISA to obtain their antibody titres against all of the peptides. The data indicates 
that patient 82 had high titres of antibodies against most of the V3-variants before they 
had been detected in the circulating virus population. All the sera showed very little 
reactivity against two of the peptides, nevertheless these sequences did not persist in the 
viral population. These data suggest that the newly-emerging replication-competent V3 
variants do not represent V3-specific antibody escape mutants.
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Chapter 1 INTRODUCTION
1.1 The Retroviruses
1.1.1 Description and origin
Viruses with RNA as genetic material are found in a wide variety of host species. 
They are designated retroviruses when they exhibit the ability to copy their RNA 
genome into double stranded DNA, that can be integrated into the DNA of an infected 
cell. This is catalysed by an RNA-dependent DNA polymerase or reverse transcriptase 
(RT) (Baltimore 1970, Temin and Mitzutani, 1970).
Although retroviruses have very different properties and pathogenicities they are 
structurally and genetically very similar. A retrovirus virion contains two identical 
copies of a plus strand RNA genome, 7,000-10,000 nucleotides long, enclosed in a 
nuclear core. This core is surrounded by a proteinaceous capsid layer which is in turn 
enclosed by a lipid bilayer in which are embedded the glycoproteins to form the ‘knobs 
or spikes’ of the membrane surface. The basic genes common to all retroviruses fall 
into three groups, shown in Figure 1.1: The gag gene encodes the structural proteins 
required by the virion, the pol gene encodes the reverse transcriptase, Rnase H, 
protease and integrase proteins and the env gene codes for the surface glycoproteins. 
When the virus is in the proviral state these genes are flanked by nucleotide sequences 
forming the long terminal repeats (LTR’s) shown in Figure 1.1. The LTR sequences 
contain promoter and enhancer elements that govern transcriptional initiation and 
regulation and are also required for integration into the host cellular DNA. A number of 
other open reading frames (ORF's), specific for each retrovirus are present between the 
gag, pol and env genes. These play a role in regulation of viral gene expression, virion 
maturation and infectivity.
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Chapter 1
Two subtypes of retroviruses have been identified. Retroviruses that exists as 
viral sequences, usually carried in the germline and mainly defective for replication of 
infectious virus, are known as endogenous retroviruses. These retroviruses are passed 
in the germline from generation to generation in a Mendelian fashion. Exogenous 
retroviruses, in contrast, move freely from cell to cell by the production of infectious 
virus particles (reviewed by Doolittle et al., 1989). Despite the differences in life cycle, 
endogenous and exogenous retroviruses share considerable sequence homology, which 
is perhaps surprising, as firstly, the present day strains of exogenous retroviruses, such 
as HIV appear to have been only recently introduced, whereas endogenous sequences 
are deeply rooted in primate evolution (Steele et a l, 1986; Shih et a l, 1991). 
Secondly, the mutation rate of exogenously replicating retroviruses is at least 10^ times 
greater than that of endogenously replicating retroviruses.
To account for this observed sequence similarity it has been hypothesised that 
exogenous retroviruses exist as relatively short lived bursts (lasting upto decades or 
centuries) arising spontaneously from a backdrop of germline encoded endogenous 
retroviruses. Therefore the pool of endogenous retroviral sequences periodically 
contributes to the generation of exogenous virus (Doolittle et a l, 1989). The discovery 
of human immunodeficiency virus type 1, human T cell leukemia virus type 1 and type 
2-like endogenous sequences, found in normal uninfected individuals provides 
supporting evidence for this model (Shih et al, 1989; Horwitz et al, 1992).
1.1.2 Classification of retroviruses
The family retrovirinae can be classified by a number of biological and 
morphological characteristics. Historically they have been divided into three taxonomic 
groups based on the in-vivo consequences of infection. (Teich, 1982, 1985)
Oncovirinae: These retroviruses can induce tumour formation upon infection. They 
can exist as exogenous viruses carrying one genes derived from host DNA and directly
2
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coding a protein involved in neoplastic transformation. Infection with this type of 
retrovirus usually results in rapid development of malignancy. Examples include Rous 
sarcoma virus (RSV) and Murine leukemia virus (MuLV).
Some exogenous oncoviruses can induce tumour formation without carrying a 
cellular oncogene, but rather express a viral protein that is directly involved in 
neoplastic transformation, therefore behaving more like a DNA tumour virus. 
Examples include the human T cell leukemia virus-1 (HTLV-1).
The oncoviruses can also exist as endogenous genetic material that is passed 
through the germline in a Mendelian fashion. An example of this type is the Mouse 
mammary tumour virus (MMTV), which can also exist as exogenous virus passed from 
mother to off-spring in breast milk.
Lentivirinae: These exogenous, non-oncogenic viruses are mainly found infecting 
ungulate mammals, in particular sheep (Visna virus), goats (Caprine Arthritis 
Encephalitis Virus, CAEV), cattle and horses (Equine Infectious Anaemia Virus, 
EIAV). Infection with a lentivirus is characterised by the slow appearance of the 
diseased state. In addition, infection with some types as mentioned above causes a slow 
progressive degenerative disease of the central nervous system. This group has been 
extended to include the immunodeficiency viruses found infecting cats (FIV), humans 
(HIV) and non-human primates (SIV) that cause a slow progressive degeneration of the 
immune system ultimately resulting in death.
Spumavirinae: These viruses, known as 'foamy' viruses induce persistent infection but 
are generally believed to be non-pathogenic. An example of this group is Simian foamy 
virus five (SFV5)
The retroviruses can be further classified on the basis of their morphology under 
electron microscopy into types A, B, C and D.
Type A: produce an immature form and are only found intracellularly, whereas all other 
types bud from the host cell membrane.
Type B: these have an eccentric core on budding, for example MMTV.
3
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Type C : have a central spherical core on budding, for example FeLV, HTLV-1 and 
HTLV-11.
Type D: have a cylindrical central core such as the Mason Pfizer monkey virus. This 
group has been extended to include FIV, HIV and related primate lentiviruses that have 
a conical section shaped central core (Levy et al., 1984).
Retroviruses may also be classified as being 'simple' or 'complex' depending on 
their mechanism of viral gene expression (reviewed by Cullen, 1991, 1993 in press). 
Simple retroviruses rely entirely on host DNA sequence specific transcription factors to 
regulate the level of proviral transcription. Complex retroviruses in contrast, encode 
potent transcriptional activators of their LTR promoter elements. All human 
retroviruses fall into the 'complex' retrovirus category.
1.2 Retroviral life cycle
This section describes in general the life cycle of the retroviruses, referring in 
particular to the human retrovirus HIV-1. A diagramatic representation of the retrovirus 
life cycle is shown in Figure 1.2
1.2.1 Attachment and entry
The first step in the retroviral replication cycle is the specific interaction of the 
outer membrane component of the virion glycoprotein with a specific cell-surface 
receptor. The receptor(s) therefore determine the target cell types and tissue tropism of 
the virus. After receptor binding occurs, the virion must enter the cell by a process of 
membrane fusion (reviewed by Marsh and Helenius, 1989) and it is believed that the 
hydrophobic amino terminus of the transmembrane component of the viral envelope 
(gp41 for HIV-1) mediates this process (Kowalski et al., 1987; Freed et a l,  1990). A 
series of complex conformational changes in the virus receptor complex is required to
4
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Figure 1.2 Adapted from B.R. Cullen, Human Retroviruses,in press. An overview 
of the retroviral replication cycle. Steps prior to proviral integration are indicated by 
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initiate this step. Retroviruses are known to enter cells via a pH-independent process 
(Maddon et a l, 1988; McClure et al, 1988, 1990). Therefore the conformational shift 
required is not induced by exposure to low pH: one possible mechanism leading to 
membrane fusion could be a further interaction with a second cell-surface protein. A 
proteolytic cleavage site within the third hypervariable region (V3) of HIV-1 gpl20 
(discussed in detail later) also appears to be essential for viral fusion with the host cell 
membrane (Clements et al., 1991).
1.2.2 Viral uncoating
After fusion with the host cell membrane, the retroviral virion undergoes a 
process of uncoating, resulting in the complete or partial loss of the envelope proteins 
and virion membrane. The ‘nucleoprotein complex’ is then competent to initiate the 
process of reverse transcription (Varmus and Brown, 1989). Essentially very little is 
known about retroviral uncoating in-vivo however, the recent identification of 
compounds that inhibit the process of HIV-1 uncoating in culture indicate that the 
process may be accessible to biochemical analysis (De Clercq et al, 1992).
1.2.3 Reverse transcription
The next step in the replication cycle is the initiation of reverse transcription of 
the retroviral plus strand RNA genome, contained within the viral nucleoprotein 
complex. This process usually occurs in the cell cytoplasm. The primer for reverse 
transcription is a tRNA molecule that is specifically packaged into the virion. Different 
retroviruses use different tRNA molecules as their primers. The HIV-1 tRNA primer is 
tRNA^YS (Varmus and Brown, 1989).
The complex process of reverse transcription is carried out by the retroviral 
enzymes, reverse transcriptase and RNaseH, both encoded by the pol gene (Varmus 
and Brown, 1989; Varmus and Swanstrom, 1985). The final result is the conversion of
5
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a single stranded RNA molecule into a double stranded DNA proviral intermediate, 
regenerates
This process the long terminal repeats (LTR's), containing the promoter and
enhancer elements required for viral gene expression. The mechanism involved in 
reverse transcription of the retroviral genome is highly conserved within the family 
retrovirinae.
An important aspect of the process of reverse transcription is that it provides a 
major source of rapid generation of genomic variability. This genomic variation is 
particularly apparent in the immunodeficiency viruses and is a real problem for the 
development of effective vaccines (Coffin, 1986a, b; Katz and Skalka, 1990; Hu and 
Temin, 1990).
During reverse transcription the reverse transcriptase enzyme jumps between the 
two strands of viral RNA carried in each retrovirus virion particle leading to the 
generation of a single proviral DNA intermediate (Katz and Skalka, 1990; Hu and 
Temin, 1990). However, random strand switches can also occur between the two copies 
of the viral RNA (Katz and Skalka, 1990; Hu and Temin, 1990). As a consequence of 
this random and non-random strand switching the RNA is highly resistant to agents 
designed to damage it, since any damage can potentially be avoided by transfer of the 
reverse transcriptase enzyme to the undamaged strand. This process also facilitates the 
high rate of recombination observed between similar but distinct retroviral genomes that 
may exist in dually-infected cells.
In the case of the lentiviruses HIV-1 and Visna virus, the persistence of virus in 
the face of the immune response mounted by the host and slow evolution of the disease 
can be partly explained by restriction in viral gene expression imposed at the 
transcriptional level. Most of the cells that harbor virus genomes have insufficient 
antigen to be detected and destroyed by immune surveillance, and limitation in the 
synthesis of virus gene products allows the virus to persist in the cells for extended 
periods, a feature characteristic of slow infections.
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1.2.4 Integration into the host genome
After replication, the next step is the precise integration of the linear proviral 
DNA into the genome of the host cell (reviewed by Varmus and Brown, 1989). This 
process requires an interaction of the viral integrase protein, the third gene product of 
the pol gene and the two inverted DNA repeats (LTR's) one copy of which is present at 
each end of the proviral genome (Brown et al., 1987, 1989; Katz and Skalka, 1990). 
The site at which the proviral genome is integrated into the host cell DNA appears to be 
essentially random. It has been suggested that in the case of Visna virus and SIV that 
proviral integration into the host genome may not be an essential step in the retroviral 
replication cycle (Harris et al., 1984; Prakash et al., 1992). Proviral unintegrated DNA 
from HIV-1 has been shown to be an efficient template for transcription of both core 
and envelope proteins but integration is necessary for productive infection of HIV-1 
(Stevenson etal., 1990a).
1.2.5 Control of viral gene expression
Expression of the integrated provirus is controlled by c/s-acting promoter and 
enhancer elements that act as targets for cellular and viral regulatory proteins (Varmus 
and Brown, 1989; Cullen, 1991). In simple retroviruses, expression is controlled by 
cellular proteins alone whereas, complex retroviruses encode their own potent 
transcriptional activators. In the absence of these proteins each of the LTR's induce 
only a low or basal level of proviral transcription that is sufficient to maintain a 
productive retroviral replication cycle. Regardless of whether a complex or simple 
retrovirus, efficient gene expression is dependent on host cellular transcription factors.
Transcription gives rise to a single genome length initial transcript that also serves 
as the messenger RNA for the gag and pol gene products. All retroviruses encode a 
singly spliced transcript for the envelope proteins. In contrast to the 'simple' 
retroviruses, 'complex' retroviruses express several additional multiply spliced mRNA
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species which encode the various regulatory and auxiliary proteins required by the 
virus. A summary diagram of HIV-1 and HTLV-1 gene regulation is shown in Figure 
1.3.
Extensive post-transcriptional RNA processing occurs, controlled in complex 
viruses by virally encoded regulatory proteins. This protein, termed Rev in HIV-1 and 
Rex in T cell leukemia viruses, is required for the cytoplasmic expression of the 
incompletely spliced mRNA's that encode the retroviral structural proteins. The mRNA 
encoding the retroviral regulatory proteins is expressed in a Rev/Rex-independent 
manner (Greene and Cullen, 1990).
In simple retroviruses there is little or no temporal regulation, since proviral 
expression and the pattern of viral mRNA processing is governed by the availability of 
the cellular proteins. In contrast, gene expression in complex retroviruses is subject to 
marked temporal regulation since it is also controlled by viral regulatory proteins 
(Greene and Cullen, 1990).
At early times after infection, the provirus gives rise to low levels of viral 
messenger RNA mediated by cellular transcription factors. Subsequent expression of 
the transcriptional transactivator protein Tat (HIV) results in a positive feedback loop 
(Figure 1.3). At this time, a critical level of the Rev-like post transcriptional regulatory 
protein is achieved, thereby inducing expression of the viral structural proteins and 
subsequent release of progeny virus. This pattern of temporally regulated gene 
expression, featuring early regulatory and late structural phases is also characteristic of 
DNA tumour viruses such as the human papilloma viruses.
1.2.6 Assembly and release
The last step in the retrovirus replication cycle is the formation and release of 
mature virions. The precise mechanisms are not fully understood but the process occurs 
adjacent to the plasma membrane and involves the ordered assembly of the Gag and 
Gag-Pol capsid precurser polyproteins (Varmus and Brown, 1989) which in the case of
8
HIV-l/HTLV-1
Proviral
DNA
RNA
Splicing/T ransport
Late
structural
mRNA's
Early
regulatory
mRNA’s
Gag-Pol 
• EnvN/
Tat-like
Virus
maturation
Figurel.3 Adapted from Green and Cullen (1990): An overview of the 
regulation of HIV-1 and HTLV-1 gene regulation. Infection first leads to a low 
level of viral RNA synthesis mediated by various host cell factors. The early 
viral mRNA's initially produced encode the viral regulatory proteins including 
Tat and Rev in the HIV-1 system and Tax and Rex in the HTLV-1 system. Tat 
and Tax serve as potent transcriptional activators of all genes and permit the 
'late' structural gene expression important for virus maturation and assembly of 
infectious virions. This 'early' regulatory to 'late' structural transition is 
specifically controlled at the post-transcriptional level by the HIV-1 Rev and the 
HTLV-1 Rex proteins that regulate RNA transport and splicing. The sequence 
specific action of Rev and Rex induces cytoplasmic expression of the unspliced 
and singly spliced viral mRNA that encode the gag, pol and env gene products. 
Simultaneously, Rev and Rex down -regulate expression of the multiply spliced 
early regulatory mRNAs and thus inhibit their own production.
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HIV-1 are targeted to the host cell membrane by myristylation of their amino-termini 
(Gottlinger et al,  1989). During assembly two copies of the single stranded viral RNA 
genome are incorporated into the virion. This, in the case of HIV-1 involves the 
sequence-specific association of a zinc-finger nucleic acid-binding motif located in the 
nucleocapsid component of the viral gag protein (p7) with a packaging signal in the 
leader sequence of the genomic RNA (Aldovini and Young, 1990). Subsequently 
retroviral cores bud through regions of the plasma membrane bearing high levels of the 
envelope glycoproteins. During or shortly after budding the viral protease becomes 
activated, resulting in the highly ordered and specific cleavage of the Gag and Gag-Pol 
structural proteins and viral enzymes (Skalka, 1989). These newly released virus 
particles can then themselves infect available target cells.
1.3 Biology and epidemiology of human retroviruses
1.3.1 Human T cell leukemia virus type-1 (HTLV-1).
Human T cell leukemia virus was the first retrovirus to be found infecting humans 
and was isolated from established cell lines derived from an American patient with a 
cutaneous T cell lymphoma (Poiesz et a l ., 1980). At approximately the same time a 
similar virus was isolated from a Japanese patient suffering from Adult T cell Leukemia 
(ATL) (Yoshida et al ., 1982). Both these viruses showed extensive sequence 
homology and collectively became known as human T cell leukemia virus type-1 
(HTLV-1). Infection with HTLV-1 is known to cause adult T cell leukemia, a 
malignancy of mature CD4+ T lymphocytes (Uchiyama et a l ,  1977) and is also 
associated with a slowly progressive myelopathy, characterised by paraparesis and 
spasticity of the lower extremities, known as Tropical Spastic Paraparesis (TSP) 
(Gessain et al., 1985) or HTLV-1 Associated Myelopathy (HAM) (Osame et al, 
1986). This disease can be referred to as TSP/HAM.
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Identification of HTLV-II in intravenous blood donors in both San Francisco and 
Northern California has also recently been reported (Feigel et al, 1991).
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Infection with HTLV-1 is now endemic in South Western Japan, the Caribbean 
islands and parts of Central and Eastern Africa (Wong-Staal and Gallo, 1985). In 
addition HTLV-1 has been identified in populations within South Eastern and South 
Western United States, South America, the Philippines, Europe and the Middle East. 
(Manns and Blattner, 1991).
1.3.2 Human T cell leukemia virus type-jll (HTLV-III)
Another virus sharing 65% nucleotide homology to HTLV-1 was isolated from an
American patient suffering from a rare, relatively benign, T cell variant of hairy cell
leukemia (Kalyanaraman et al., 1982) and later from another American patient with
both a T cell lymphoproliferative disease and B-cell type hairy cell leukemia
(Rosenblatt et al, 1988). This virus has been named HTLV-11.
i relatively
The geographic distribution of HTLV-11 is stilly unknown and as yet there is no 
consistent disease association with infection with HTLV-IX Serological evidence of 
HTLV-II has been found in intravenous drug users in the UK (Tedder et al., 1984) and 
New Orleans (Lee et al,  1989) and more recently in an isolated population of Guaymi 
Indians in Panama. (Lairmore e t a l ., 1990).
1.3.3 The human immunodeficiency viruses (HIV)
Infection with HIV results in a progressive disease with severe and irreversible 
immunosupression and acquired immune deficiency (AIDS) leading to eventual death. 
This chronic immunosupression results in a host defect that renders the body highly 
susceptible to opportunistic infection and malignant tumours associated with severe 
defects of cell-mediated immunity (Gottlieb etal., 1981; Masur e ta l ,  1981; Nelson et 
al,  1990). AIDS patients develop a range of infections such as persistent 
cytomegalovirus infection (CMV), persistent generalised lymphoadenopathy (PGL), 
Kaposi’s sarcoma, a relatively rare cancer of the skin and pneumocystis carinii
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pneumonia (PCP). Another feature of HIV-infection is that at least 50% of all AIDS 
patients develop encephalopathy resulting in memory loss, impaired speech and 
dementia (Price etal., 1986; Navia etal., 1986a, b).
The first cases of AIDS were described among homosexual men (Gottlieb et al., 
1981; Masur et al., 1981; Siegal et al., 1981). Following these reports AIDS cases were 
identified among haemophiliacs (CDC report, 1982a), blood transfusion patients (CDC 
report, 1982b), heterosexual intravenous drug users IVDU’s (CDC report, 1982c), 
infants born to infected mothers (CDC report, 1982d) and partners of infected 
individuals (CDC report, 1982e).
The causative agent of acquired immune deficiency syndrome (AIDS) was first 
identified by Montagnier and coworkers in 1983 (Barre-Sinoussi et al., 1983). They 
isolated a retrovirus from a patient suffering from chronic lymphoadenopathy, thus the 
original name lymphoadenopathy associated virus, (LAV). At around the same time 
two other groups identified a human retrovirus in HIV-infected individuals named 
human T cell leukemia virus type three (HTLV-III) (Gallo et al., 1984) and AIDS 
related virus (ARV) (Levy et al., 1984). HIV-1 has been adopted as the accepted 
nomenclature by the International Committee of the Taxonomy of Retroviruses (Coffin 
et a l ., 1986a, b) and is found infecting individuals in Southeast Asia, parts of Africa, 
America and Europe. Up to the end of 1991, it was estimated that approximately 9-11 
million people have been infected with HIV worldwide with 1.5 million of these people 
already diagnosed as having AIDS (Chin, 1991). This number is continuing to rise with 
countries in Africa and Southeast Asia being the worst affected.
In 1986 a retrovirus was isolated in West Africa that was similar but distinct from 
HIV-1 (Clavel et al., 1986). Antibodies directed against HIV-1 could 
immunoprecipitate the Gag and Pol products of these isolates but not the Env. This new 
virus was termed LAV-2 and is now referred to as HIV-2. It is mainly found in West 
Africa.
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Sequence analysis of HIV-1 and HIV-2 has shown that these viruses are distinct from 
one another, sharing only 42% nucleotide sequence homology (Ratner etal., 1985, 
Guyader et a l ., 1987).
The human immunodeficiency viruses share many molecular characteristics with 
the human T cell leukemia viruses, including routes of transmission, formation of large 
multinucleated cells known as syncytia, a Mg^+ dependent reverse transcriptase, p24 
core antigen and most strikingly the presence of viral encoded regulatory proteins that 
function at both transcriptional and post-transcriptional levels. Despite these 
similarities HIV is more appropriately placed in the lentivirinae sub-family of 
retroviruses on the basis of genetic and morphologic parameters (Gonda et al., 1985).
HIV-1 and Visna virus which causes a neurodegenerative disease in sheep, share 
66% nucleotide homology in the pol regions and 45% nucleotide homology in their 
transmembrane proteins (Gonda et al., 1986). Both HIV and EIAV demonstrate rapid 
genetic shift, with the generation of microvariants in the course of a single infection and 
macrovariants in the course of an epidemic.
1.3.4 Transmission of the human retroviruses
The routes of transmission are shared between the human T cell leukemia viruses 
and the immunodeficiency viruses. Virus can be transmitted via cell-free virus and 
virus-infected cells through blood-blood contact or through mucosal routes in both 
homosexual and heterosexual intercourse (reviewed by Chin, 1991). HIV infection and 
the spread of AIDS was originally labelled as a homosexual problem, however, it is 
found in haemophiliacs infected with contaminated blood products, intravenous drug 
abusers, heterosexual partners of infected individuals and can be passed perinatally 
from mother to child (reviewed by Chin, 1991). The precise mechanisms involved in 
the stochastic nature of transmission of HIV are not yet understood.
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1.4 Other primate lentiviruses
1.4.1 Simian immunodeficiency virus (SIV)
In the early 1980’s a number of lymphomas and immunodeficiency related 
disorders were identified in a colony of captive macaques in a North American primate 
centre (Letvin et al, 1983). The causative agent was identified as a retrovirus named 
SIVmac (Daniel eta l,  1985, Kanki eta l,  1985) which is similar in nucleotide sequence 
to HIV-2 (Franchini e ta l ,  1987, Chakrabarti et al, 1987, Hirsch et a l,  1987). 
However, SIV-infected macaques have not yet been identified in the wild (Lowestine et 
al, 1986, O htaetal.,  1988).
SIV has also been isolated from healthy sooty mangabeys (SIVsm) both in 
captivity in North American primate centres (Murphey-Corb et al, 1986, Fultz et al,
1986) and in the wild in West Africa (Hirsch et al, 1989) The fact that this virus is also 
closely related to HIV-2. (Hirsch et al, 1989) provides a possible explanation as to the 
origin of infection of the captive macaques. Until 1968 these sooty mangabey monkeys 
were imported into the United States from west Africa and may have been housed with 
macaques where a possible cross-species transfer could have occurred (Hirsch et al,
1989).
An HIV-1 like lentivirus has been identified in chimpanzees (Peeters et al, 1989; 
Huet et al, 1990) This virus is referred to as SIVcpz.
SIV isolated from African green monkeys (SIVagm) displays the highest genetic 
diversity (Johnson e ta l ,  1990, 1991, 1992a) compared to the human and other non­
human immunodeficiency viruses, and appears to have been widely present in the 
population in the 1950’s (Hendry et al, 1986). Both findings suggest that this is the 
oldest primate lentivirus in existence (Johnson et al, 1990; Fomsgaard et al, 1991). It 
does not appear to cause an AIDS-like illness.
SIV has also been isolated from mandrills in Africa (Tsujimoto e ta l ,  1988). 
SIVmnd appears to be another distinct non-human primate lentivirus. The primate
13
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lentiviruses can be grouped as shown in Figure 1.4, based on sequence similarity in the 
pol gene (Desrosiers, 1990).
1.5 Molecular biology of HIV-1
1.5.1 Structure of the HIV-1 virion
The HIV-1 virion is approximately lOOnm in diameter with a double lipid bilayer 
derived from the host cell membrane from which the virus has budded. Forming the 
‘knobs or spikes' on the membrane surface are the glycoproteins made up from two 
components : gp41 which spans the membrane and gpl20 the external glycoprotein 
anchored to the membrane via a non-covalent association with gp41 (Kowalski et al., 
1987; Helseth et al., 1991). This membrane surrounds an icosahedral sphere shaped 
capsid made up of pl7 (the myristylated protein) and contains the conical shaped 
nuclear core, made up of p24 (the major capsid protein). Each virion particle contains 
two identical copies of the viral RNA surrounded by p7 and p9 (the nucleocapsid 
proteins) as well as multiple copies of the enzymes reverse transcriptase, composed of 
two subunits (p66 and p51), protease (p22) and integrase (p32) (Gelderblom et al.,
1987). A schematic representation of the virus is shown in Figure 1.5.
1.5.2 HIV-1 genomic organisation
The genome of HIV-1 is approximately 10,000 nucleotides long and encodes at 
least 9 open reading frames (Ratner et al., 1985; Wain-Hobson et al., 1985; Green and 
Chen, 1990). A schematic representation of the genomic organisation of HIV-1 is 
shown in Figure 1.6. The genes encode the structural proteins Gag, Pol and Env, 
common to all replication competent retroviruses as well as genes involved in 
regulation of viral gene expression {tat and rev) and finally genes of uncertain function 
{nef, vif, vpu and vpr ). Flanking these nine genes in the proviral state are the long
14
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Figure 1.5 Schematic cross-sectional representation of a mature HIV-1 virion 
panicle.
Adapted from Torrance, 1992.
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terminal repeat sequences (LTR's) containing the promoter and enhancer elements 
involved in temporal regulation of viral gene expression (Sodroski et a l ,  1984, 1985a, 
b; Arya et al., 1985).
1.5.3 The structural proteins of HIV-1
Gag:
Expression of the HIV-1 gag gene products, p24 (the major capsid protein) and 
the core proteins pl7, p7 and p9 results from translation from a gag-pol transcript, 
p53gag and subsequent cleavage of the translated polyprotein by viral proteases into the 
relevant virion proteins. Gag protein, pl7 is myristylated at its N-terminus, therefore 
giving some indication of its function as a membrane bound protein (Veronese et al., 
1988). Phosphorylation of the p24 protein has also been described (Veronese et al., 
1988; Green and Chen, 1990). Both pl7 and p24 are immunogenic in the natural host 
however, p24 is more immunogenic than p 17 (Veronese et al., 1988). The p7 protein 
contains a putative "zinc finger" domain that may be involved in direct interaction of 
the protein with the viral RNA (Aldovini and Young, 1990). Gag protein p9 in addition 
to p7 make up the nucleocapsid proteins.
Pol:
The pol gene products of HIV-1 are translated from an unspliced Gag-Pol 
transcript by a process of ribosomal frameshifting (Jacks et al., 1987). Frameshifting 
moves the ribosome into the -1 reading frame in response to at least two sets of 
instructions in the Gag-Pol overlap region; a short sequence at the frameshift site and a 
secondary structure downstream of the site (Jacks et al., 1987; reviewed by Varmus,
1988). The resultant Pol precurser protein is sequentially cleaved to yield the reverse 
transcriptase subunits p66 and p51, protease (p22) and integrase (p32). The reverse 
transcriptase enzyme contains an RNaseH activity which is required for the degradation 
of the RNA template during the synthesis of double stranded DNA (reviewed by
15
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Varmus, 1988). The RNaseH activity is located in the C-terminal region of the p66 
subunit (Hansen etaL, 1988).
Env:
The HIV-1 env gene is transcribed as a singly spliced mRNA that on translation 
yields a precurser protein of 160KDa. This polyprotein exists in the rough endoplasmic 
reticulum-golgi complex where it is cleaved into two components; the gpl20 external 
glycoprotein and the gp41 transmembrane protein. These proteins then undergo 
extensive golgi-mediated carbohydrate modifications converting N-linked mannose- 
type glycans into complex oligosaccharides (Stein and Engelman, 1990). The heavily 
glycosylated gpl20 molecules present on the surface of the virion particle as a 
multimeric unit are non-covalently linked to the transmembrane protein gp41 (Helseth 
et al., 1991; Kowalski et a l,  1987). Gp41, as previously discussed, is involved in viral 
fusion with the host cell membrane via its hydrophobic N-terminal (Kowalski et al., 
1987; Freed et al., 1990). The properties and functions of gpl20 are discussed in detail 
later in this thesis.
1.5.4 The regulatory proteins of HIV-1 
Tat:
In addition to the structural genes gag,pol and env, HIV-1 encodes two potent 
regulatory proteins Tat and Rev. The 14KDa Tat protein is translated from a double­
spliced mRNA species and is comprised of 86 amino acids (reviewed by Cullen 1990, 
1991; Sheridan et al,  1993). This protein is primarily localised in the nuclei of infected 
cells (Hauber et al,  1987) and is expressed early in the viral life cycle. The presence of 
the Tat protein dramatically increases the expression of all genes linked to the HIV-1 
LTR's (Sodroski et al., 1984, 1985a,b; Arya et a l ,  1985). Tat exerts its effect by 
binding directly or indirectly to a 59 nucleotide RNA stem loop structure located 
between +1 and +60 in the viral RNA (Rosen et al., 1985) both in vitro and in vivo
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(Feng and Holland, 1988). This stem loop structure is transcribed from the TAR 
(transactivation response element) sequence downstream of the HIV-1 5' LTR. The 
TAR element is therefore located in the 5'-untranslated region of all HIV-1 mRNA's and 
functions in a position and orientation dependent manner (reviewed by Cullen, 1990, 
1991; Sheridan e ta l ,  1993).
Nuclear run-on assays using plasmid constructs of the chloramphenicol 
acetyltransferase gene (CAT) under the control of the HIV-1 LTR were used to 
demonstrate that in the absence of Tat, transcripts that are initiated from the basal 
promoter are elongated inefficiently and are not terminated at discrete sites, but rather 
declined in a gradual manner as the distance from the promoter increased (Kao et al., 
1987; Laspia et al., 1989). In contrast, highly processive transcription throughout the 
length of the region transcribed was found in the presence of Tat in both cultured cell 
lines (Kao et al., 1987; Laspia et al., 1989) as well as in infected primary T 
lymphocytes (Feinberg et al., 1991). The function of Tat is therefore believed to 
enhance the ability of the RNA pol II initiation/elongation complex to efficiently 
traverse the length of the proviral genome. In the absence of Tat, a less processive form 
of the RNA pol II elongation complex is thought to be assembled at the HIV-1 promoter 
(Marciniak and Sharp, 1991; reviewed by Sheridan et al., 1993). The precise 
mechanism by which Tat interacts with the TAR sequence is not fully understood but 
involves other cellular transcription factors not discussed in this summary.
Rev:
For efficient replication and production of infectious virion particles, three classes 
of mRNA must be produced corresponding to the unspliced genomic RNA also 
encoding the gag and pol  gene products, the singly spliced mRNA encoding the 
envelope proteins and the multiply spliced mRNA encoding the various regulatory 
proteins including Rev (reviewed by Greene and Cullen 1990). Within the first 12-16 
hours after experimental infection of human CD4+ T lymphocytes the multiply spliced 
mRNA species encoding the regulatory proteins predominate in a one step growth curve
17
Chapter 1
(Kim et a l,  1989). With longer culture periods, a progressive increase in the singly 
spliced env and unspliced genomic RNA’s occurs, with peak levels obtained between 
24 and 48 hours after infection (Cullen and Greene, 1989). This transition from ‘early 
regulatory’ to ‘late structural’ gene expression is controlled by the Rev protein 
(reviewed by Greene and Cullen 1990; Cullen, 1991).
As with Tat and Nef, Rev is translated from a double spliced 2kb transcript. 
Translation of this transcript yields the 19KDa Rev polypeptide composed of 116 amino 
acids (reviewed by Greene and Cullen 1990). Indirect immunofluorescence using 
polyclonal anti-Rev antiserum has shown that Rev is primarily localised in the nucleus 
(Cullen et al., 1988) and predominantly in the nucleolus (Malim et a l ,  1989a). The 
function of the Rev protein is to promote the nuclear export and cytoplasmic expression 
of the unspliced and singly spliced mRNAs that encode the various viral structural 
proteins. This is mediated through the direct binding to a specific response element, the 
RRE (Rev response element) (Zapp and Greene, 1989; Daly et a l,  1989; Malim et a l,  
1989b, 1990) located within the env gene (Malim et a l,  1988). This element must be 
present in the mRNA species for Rev to act. The RRE forms an RNA stem loop 
structure (Malim et al, 1989b; Hanly et a l,  1989) as does the TAR sequence, however 
the position of this element is flexible but must be present in the sense orientation to 
function (Hanly e ta l ,  1989; Malim e ta l ,  1989b).
The Rev regulatory protein activates the cytoplasmic expression of the larger 
mRNA’s, simultaneously down regulating the expression of the smaller RNA species, 
thereby inhibiting its own expression via an autoregulatory feed-back loop. The 
interaction of Tat and Rev have been previously summarised in Figure 1.3.
Host cellular factors also play a role in HIV-1 gene regulation:
In addition to the viral regulatory proteins, host cell factors also play a role in the 
regulation of HIV-1 viral gene expression. The HIV-1 LTR contains a typical, albeit 
compact, inducible RNA pol II promoter that can be activated by physiological agents 
including mitogenic stimulation and ultraviolet light (reviewed by Sheridan et a l,  1993)
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as well as the HIV-1 trans-activator protein Tat. In addition, the HIV-1 promoter 
contains 3 tandem binding sites located between nucleotides -77 to -46, upstream of the 
TATA box, for the ubiquitous transcription factor Spl. Mutation of these sites leads to 
a substantial reduction in HIV-1 LTR activity both in vitro and in vivo (Jones et al., 
1986). Immediately upstream of the Spl binding sites lie two tandem binding sites 
between nucleotides -104 and -81 (Rosen etal., 1985) for the transcription factor NFfc- 
B (Nabel and Baltimore, 1987), a dimeric protein that becomes released from an 
inhibitory complex IkB as a result of T cell activation (Bauerle and Baltimore, 1988). 
Deletion or site-directed mutagenesis of this region impairs HIV-1 LTR activation 
induced by the NFk-B protein (Greene and Chen, 1990). Other transcription factors 
such as the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) 
interleukin-2 and a potent T cell-specific activator, TCF-1 alpha, can also bind to 
sequences upstream of the NFk-B sites, activating the HIV-1 LTR (Sheridan et al., 
1993). The HIV-1 TATA box is also recognised by TFIID, a general initiation factor 
that consists of a TATA binding protein (TBP) and a collection of diverse adaptor 
proteins termed TAF’s, for TBP-associated factors, which mediate responsiveness to 
Spl (Dynlacht etal., 1991).
1.5.5 HIV-1 proteins of poorly or undefined function 
Nef:
Another protein encoded by HIV-1 is Nef, the product of the nef gene. This 
27KDa protein is translated from a multiply spliced mRNA transcript resulting in a 
polypeptide constituted by 200-205 amino acids, depending on the virus isolate (Harris 
et al., 1992). Nef is myristylated at the N-terminus (Allan et al., 1985) and this 
acylation is required for its location on the cytoplasmic face of the plasma membrane of 
infected cells (Yu and Felsted, 1992). The precise role of myristylation and indeed of 
the Nef protein is not yet known and remains the subject of controversy. Suggested 
functions for Nef include: as a repressor of viral replication (Fisher et al., 1986;
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Terwilliger et al., 1986), a component of the signal transduction pathway suggested by 
the protein’s ability to bind and hydrolyse GTP (Guy et al., 1987) and as a down- 
regulator of the surface expression of CD4 (Guy et al., 1987; Garcia and Miller, 1991). 
Other workers have failed to confirm any of these attributed functions (Barchalerie et 
al., 1990; Harris et al., 1992; Cheng-Mayer et al., 1989). It has been hypothesised that 
the apparent discrepancies observed in Nef function may be due to the significant 
degree of amino acid variability observed between different Nef isolates both in vitro 
and in vivo (Harris etal., 1992).
Vif:
The precise function of this protein still remains unknown, however, homologues 
of the gene have been found in all lentiviruses with the exception of EIAV, suggesting 
an important functional role (Oberste and Gonda, 1992). The vif  (viral infectivity 
factor) gene encodes a 23-27kDa polypeptide (Kan et al., 1986; Lee et al., 1986) and 
HIV-1 mutants with deletions of the vif gene showed delayed growth kinetics in CD4+ 
T lymphocytes. In addition the virus produced from these cells was approximately 
1000-fold less infectious than the wild type (Sodroski et al., 1986). Vif is therefore 
thought to be important for viral infectivity (Strebel et al,  1987).
Vpu:
The vpu gene encodes a 16KDa polypeptide (Strebel et al., 1988) and in 
retroviruses examined to date, is only found in the HIV-1 and SIVcpz. Several studies 
have shown that the absence of the vpu gene results in a decreased release of virion 
particles from infected cells and accumulation of the virion proteins in these cells 
(Strebel et al., 1989; Terwilliger et a l ,  1989; Klimkait et al., 1990). Electron 
microscopic examination has revealed that mutations in the vpu gene lead to an 
accumulation of mutant virion particles at the membrane surface of infected cells 
indicating a role of Vpu in proper virion assembly, budding and release of infectious 
particles (Klimkait et al., 1990). Recent reports have shown that the vpu protein
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induces rapid degradation of CD4 in the endoplasmic reticulum (Willey et al., 1992; 
Chen et al., 1993). The mechanism(s) and biological significance of the observed CD4 
degradation are not understood.
Vpr:
Essentially nothing is known about the function of this llK D a protein, however, 
like vif, the vpr gene or a homologue of it is present in all known primate lentiviruses, 
suggesting an important function for this protein. Western blotting of subcellular 
fractions prepared from HIV-infected cells has indicated that Vpr is a membrane 
associated virion component, not present in high concentrations in the cytosol or 
nuclear fractions of the cell (Sato et al., 1990). The Vpr protein is also not required for 
the formation and release of mature virions (Dedera et a l,  1989)
1.5.6 CD4 molecule as the principal receptor for HIV-1
Following the observation that infection with HIV-1 resulted in a numerical and 
functional depletion of T helper/inducer cells (Gottlieb et a l ,  1981; Klatzmann et al.,
1984) it was hypothesised like the human T cell leukemia viruses, HIV-1 infected 
primarily CD4+ bearing T lymphocytes, a vital subset of the host immune mechanism. 
HIV-1 infection however, does not cause neoplastic transformation of T cells as do 
HTLV-1 and HTLV-11 (Chen et al., 1983) but has devastating cytotoxic effects 
(Popovic et a l,  1984). The major surface receptor for HIV-1 was subsequently defined 
as the CD4 molecule, present on the surface of T lymphocytes and cells of the 
monocyte/macrophage lineage, by a number of experiments described below.
Receptor-positive cells were identified by assessing induction of multinucleated 
cells, termed syncytia, and the susceptibility of various cell types to infection with 
psuedotypes of the vesicular stomatitis virus (VSV) bearing envelope antigens derived 
from HIV-1. This approach implicated the CD4 molecule as an essential component 
involved in HIV-1 attachment and tropism to target cells (Dalgleish et a l ,  1984).
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Involvement of CD4 in viral attachment was demonstrated directly through the use of 
monoclonal antibodies directed against CD4. These monoclonal antibodies inhibited 
HIV-1 activity in a variety of in-vitro assays (reviewed by Sattentau and Weiss, 1988). 
Firstly, anti-CD4 mab’s prevented formation of syncytia, that result from fusion 
between HIV-infected and CD4+ uninfected cells, and inhibited the infectivity of VSV 
psuedotypes carrying the HIV-1 envelope glycoprotein (Dalgleish et al., 1984). 
Secondly, they reduced the infection of human peripheral blood mononuclear cells 
(PBL’s), measured by decreased reverse transcriptase activity in cultures containing 
antibody (Klatzmann et a l ., 1984). Thirdly, they inhibited binding of fluoresceinated 
HIV to CD4+ cells (McDougal, 1985).
Further evidence of direct binding of HIV-1 to CD4 came from the observation 
that the external glycoprotein gpl20  and the CD4 molecule could be 
immunoprecipitated as a complex from HIV-1-infected cells. Cross-linking prior to 
precipitation did not reveal any additional molecules in the complex, implying that only 
CD4 was necessary for infection with HIV-1 (McDougal et aL, 1986). Transfection 
experiments in which human CD4" cells, previously refractory to HIV infection, 
became permissive when a cloned CD4 cDNA was introduced by transfection, gave 
further evidence that CD4 acted as the receptor for HIV-1 (Maddon et a l ,  1986). 
However, mouse cells manipulated in the same way to express human CD4, bound 
HIV-1 on their surface but were not infected by the virus. Therefore unlike human 
cells, the mere presence of CD4 on their surface does not render these cells permissive 
to HIV infection. The introduction of HIV-1 DNA into mouse fibroblast cells, allowed 
efficient replication and production of infectious virus, indicating that the block of 
infection of CD4+ mouse cells occurs at an event prior to viral replication (Levy et al., 
1986). This observation confirms that the process of membrane fusion might well be 
mediated by the specific interaction of the retroviral envelope with a second cell surface 
receptor.
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1.5.7 The CD4 molecule
The CD4 antigen is expressed as a 55KDa protein on the surface of mature 
thym us-derived lymphocytes and to a lesser extent on cells of the 
monocyte/macrophage lineage. T lymphocytes expressing CD4 act as helper cells, to 
promote antibody production or induce proliferation of CD8 bearing cytotoxic T cells. 
The best defined function of CD4 is that of an adhesion molecule binding with the 
class-11 major histocompatibility complex (MHC) (present on the surface of most cell 
types and in particular on antigen presenting cells) and the T lymphocyte. It has been 
proposed that the CD4 binds a conserved region of MHC class 11 molecules, and 
thereby stabilises the MHC class IIT  cell receptor complex. The function performed by 
CD4 on the surface of macrophages is not clear.
The molecule itself, a member of the immunoglobulin supergene family, consists 
of several structural domains: an N-terminal extracellular region containing a leader 
sequence and four immunoglobulin-like domains; a transmembrane region and a 
cytoplasmic region that is highly charged (Maddon et al., 1987). The region of CD4 
reactive with HIV gpl20 has been mapped by monoclonal antibodies to the outermost 
VI immunoglobulin-like region (Sattentau e ta l ., 1986).
1.5.8 Infection via Fc and complement receptors
Although the primary receptor for HIV-1 is the CD4 molecule, HIV-infection can 
be mediated in vitro by two additional mechanisms. The Fc and complement receptors 
present on the surface of macrophages and other cells of the immune system, can act to 
facilitate HIV-infection independently of one another in the presence of viral antibodies 
or complement factors (Takeda et al., 1988, 1990; Homsy et al., 1989; Boyer et a l , 
1991; Robinson et al., 1991; Haubrich et al., 1992). This increased effciency of viral 
entry into cells in the presence of antibodies against the virus is termed "antibody- 
mediated enhancement". Two regions on the transmembrane protein gp41 have been
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shown to elicit antibodies that enhance infection with HIV-1 (Robinson et al, 1991). 
These findings imply that caution should be used when developing vaccine strategies 
that involve generating an antibody response against viral antigens (Takeda et a l,  1988, 
1990; Homsy et a l,  1989; Boyer et al, 1991; Robinson et a l,  1991; Haubrich et al., 
1992).
The expression of IgG Fc receptors can be induced in cells infected with some 
viruses. McKeating et a l  (1990) demonstrated that the Fc receptors induced by 
cytomegalovirus infection allowed immune complexes of HIV-1 to infect fibroblasts 
not otherwise permissive to HIV-infection. Infection could be blocked by 
preincubation of the cells with human IgG but not soluble CD4 or anti-CD4 
monoclonals. This finding indicates that the cellular tropism of HIV-1 might be altered 
by the presence of other viruses in HIV-infected individuals, however in vivo evidence 
for this speculation has yet to be obtained.
1.5.9 CD4 independent infection
A number of cell lines that do not detectably express the CD4 antigen on their 
surface are susceptible to HIV-infection, albeit less efficiently. These include a 
neuroblastoma cell line (Li et a l ., 1990) and, as previously described, a fibroblast cell 
line (Tateno et al,  1989: McKeating etal., 1990). To identify other potential receptors 
involved in infection of neuronal cells with HIV-1, antibodies against neuronal cell- 
surface components were screened for their ability to inhibit viral internalisation 
(Harouse et al, 1991). Antibodies against galactosyl ceramide (Gal C), a glycolipid 
common to oligodendrocytes and Schwann cells, blocked infection of neuronal cell 
lines. In addition, gpl20 was shown to bind to Gal C but not to other glycolipids. 
Recently, antibodies against the third hypervariable region (V3) of HIV-1 gpl20 have 
been shown to block the binding of gpl20 to galactosyl ceramide (Cook et a l,  1993). 
The binding site for Gal C on gpl20 has recently been mapped to amino acids 206-275, 
outside the V3 region , which together with the findings of Cook et a l  (1993) suggest
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an interaction of the this Gal C binding site with the V3 loop (Bhat et a l,  1993). It 
would appear that Gal C can bind HIV-1 as efficiently as can CD4 but facilitates less 
efficient viral entry. (Harouse et a l ., 1991).
1.5.10 Persistence of HIV-1
Following infection with HIV-1 there is an initial viremia with or without clinical 
symptoms at the time of seroconversion. Then follows an asymptomatic period that can 
last many years during which the virus infection seems to be controlled by the host 
immune system. During the long asymptomatic phase and in some cases during the 
symptomatic phase of infection, HIV-1 is not readily isolated from the CD4+ cells 
present in the peripheral blood. This apparent lack of virus in the cells that are 
drastically depleted in patients with AIDS, was the main argument of HIV sceptics, led 
by Dr Peter Duesberg against HIV being the etiological agent of AIDS.
It was first argued that HIV existed, during the asymptomatic period, in a non­
replicating latent form, probably persisting in resting T cells that are deficient in the 
various cellular factors required either for efficient conversion of the viral RNA into 
double stranded DNA (Fritsch and Temin, 1977; Varmus et al., 1977) or efficient 
integration of the double stranded DNA into the host genome (Green and Chen, 1990; 
Zack et al., 1990, 1992; Stevenson et a l,  1990b). In addition, the virus may exist as a 
fully integrated proviral DNA in the small proportion of activated T cells that return to 
the Go phase to become memory T cells (Simmonds et al., 1991). Because of the 
unlimited life span of these memory T cells, HIV may persist indefinitely in them, 
making the virus very inaccessible to potential antiviral agents and perhaps providing a 
viral reservoir during the long asymptomatic phase seen in HIV-infected individuals.
More recent data has shown, that although the virus can exist in the forms 
mentioned above, the virus population as a whole does not go completely latent, as viral 
mRNA can be isolated, reverse transcribed and amplified by PCR from the peripheral 
blood of individuals throughout the course o^ infection suggesting replication of the
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virus in these tissues (Schnittman et al., 1991). Virus has also been found actively
replicating in the lymph nodes, not surprisingly the place where the CD4+ cells usually 
(Tenner-Racz etal., 1986). 
reside (Pantaleo et al., 1993; Embretson et al., 1993). It is hypothesised that the
observed depletion of CD4+ cells can be partly explained by active replication of the
ln»s
virus in the lymph nodes, depleting the T cells in these organs and^partly explains the 
lack of infected T cells found in the peripheral blood (Pantaleo et al., 1993; Embretson 
etal., 1993;,Tenner-Racz etal., 1986).
Macrophages and monocytes are also believed to act as reservoirs for HIV-1 as 
these cells are relatively resistant to the cytolytic effects of HIV (Nicholson et al., 1986; 
Harper et al., 1986; McElrath et al., 1989). In addition, infected macrophages and 
monocytes in the central nervous system (Ho et al., 1985; Koenig et al., 1986) may 
escape detection by certain immune effector cells because the MHC class 1 molecule is 
not expressed on their surface (Joly et al., 1991). Some activated CD4+ cells can also 
survive the cytolytic effects of HIV-1 infection further contributing to the pool of 
"latent" virus (Schnittman etal., 1989).
The extensive sequence variation displayed by the virus may also play a role in 
the persistence of HIV-1 infection. During the asymptomatic phase, the highly specific 
humoral and T cell response mounted against the virus fails to clear it from the host. It 
is hypothesised that the host exerts an immune selection pressure against the virus that 
drives these sequence changes. This hypothesis has been supported by the in vivo 
isolation of viruses from individuals that were resistant to neutralisation by autologous 
sera (Albert et al., 1990; Montefiori et al., 1991). In addition, the cytotoxic T cell 
response against the virus has been shown to influence the sequence diversity in the gag 
gene products p 17 and p24. (Phillips et al., 1991). Wolfs et al. (1991), have shown that 
the sequence variants that occur within the V3 region of HIV-1 gpl20 are accompanied 
by the emergence of a new population of V3-specific antibodies. Work presented in 
this thesis was designed to investigate the hypothesis that the sequence variants that 
arise in the V3 region during the course of infection represent antibody escape mutants.
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1.5.11 Pathogenesis of HIV-1
It is known that during the asymptomatic phase of HIV-1 infection, slowly 
replicating, relatively non-cytopathic variants, that display tropism for macrophage 
derived cells predominantly exist, which, during the later stages of infection are either 
replaced by or evolve into, highly virulent viruses that display T cell tropism, the 
appearance of which, usually signals the rapid onset of disease. An important feature of 
infection with HIV-1 is the progressive depletion of the CD4+ T lymphocytes (Gottlieb 
et al. ,1981; Barre-Sinoussi et a l,  1984; Popovic et a l,  1984), a subset of cells that in 
uninfected individuals constitute 50-70% of the circulating T cell population (Lifson 
and Engelman, 1989). The precise mechanisms by which these relatively non- 
cytopathic variants of HIV-1, present throughout the course of infection, cause this 
depletion of CD4+ cells are as yet not fully understood, however, a number of 
mechanisms have been proposed.
As discussed in section 1.5.10 above, recent observations that HIV-1 is actively 
replicating in cells of the lymph nodes during the asymptomatic phase, may partly 
explain this observed depletion of CD4+ cells in the apparent absence of high titres of 
virus in the peripheral blood of infected individuals (Embretson et a l,  1993; Pantaleo, 
e ta l ,  1993yTenner-Racz e ta l ,  1986).
Direct cell killing by HIV-1 can occur by budding of infectious virus particles 
from the host cell membrane and it has been proposed that an interaction of gpl20 and 
CD4 on the surface of HIV-1 infected cells, may result in both metabolic and osmotic 
disruption, ultimately leading to cell death (Haseltine, 1988). In addition, the presence 
of gpl20 on the surface of infected cells can cause fusion with uninfected cells via 
interaction with the CD4 molecule, resulting in the formation of large multinucleated 
cells called syncytia (Lifson e ta l ,  1986a, b).
Immune responses resulting in the killing of uninfected CD4+ cells, triggered by 
HIV-infection have also been suggested. Free gpl20, that has been shed from the 
surface of virally infected cells or from the virus itself (Moore et a l ,  1990) may be
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selectively absorbed onto the surface of uninfected CD4-expressing cells through 
gpl20-CD4 interactions. This is postulated to render CD4+ cells expressing viral 
envelope determinants susceptible to lysis by gp 120-specific cytotoxic T lymphocytes 
(Lanzavecchia et al., 1988; Germain, 1988; Siliciano et al., 1988), or killing via 
antibody-dependent cell mediated cytotoxic (ADDC) mechanisms (Lyerly et al., 
1987b).
Autoimmunity models of AIDS pathogenesis have also been suggested. These 
hypothesis are based on the fact that both gpl20 and MHC class II bind to CD4 and that 
their binding sites must overlap in the outermost immunoglobulin like domain of CD4 
(Sattentau et al., 1986; Rosenstein et al., 1990) as both recombinant gpl20 and 
monoclonal antibodies that recognise the gpl20 binding site on CD4 can block binding 
to MHC class n  (Sattentau et al., 1986; Rosenstein et a l,  1990). Therefore it has been 
hypothesised that antibodies against gpl20 may cross-react with host MHC class II or 
elicit anti-idiotypic antibodies against CD4 (reviewed by Hoffman et al., 1991). In 
support of this hypothesis, sequence homologies have been identified between MHC 
class II and a conserved region in gpl20 (Young, 1988). Sequence homologies have 
also been identified between a region in the HIV-1 Nef protein and MHC class II which 
might contribute to pathogenesis in a similar fashion (Vega et a l ,  1990). In addition, 
foreign T lymphocytes that are commonly passed during the transmission of HIV-1 may 
also induce antibodies or anti-idiotypic antibodies that may react with host MHC or 
other host cell surface components (reviewed by Hoffman et al., 1991).
If these models of HIV-1 pathogenesis have any validity, then therapeutic 
interventions aimed at generating antibodies against gpl20 may have adverse effects.
Selective depletion of CD4+ T cells that bear specific V-beta sequences has been 
observed in HIV-1 infected individuals, suggesting that HIV-1 may encode a potential 
“superantigen” (Imbreti etal., 1991). Most antigens, displayed on antigen presenting 
cells, are recognised through an interaction of the variable regions of the T cell receptor 
alpha and beta chains. Superantigens are however, recognised on the basis of the 
expressed B-beta chain only. This leads to a greater than 5-fold stimulation of T cell
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proliferation, most of which are non-productive and may attack host cells resulting in a 
depletion of cells expressing that particular V-beta sequence, as has been observed in 
HIV-1 infected individuals (reviewed by Johnson et a l,  1992). CD4+ T cells are a vital 
part of the immune repertoire and their function is intimately linked with most other cell 
types of the immune system, such that T cell dysfunction resulting from infection with 
HIV-1, will manifest a multitude of immunological deficits rendering the host 
susceptible to opportunistic infections, a feature characteristic of AIDS.
Polyclonal B-cell activation, as reflected by hypergammaglobulinaemia was 
documented in early descriptions of patients with AIDS (Gottlieb et al., 1981). High 
levels of immunoglobulin (Pahwa et a l,  1985) and a poor response to novel antigens 
(Mizumi et a l,  1988) are characteristic in AIDS patients. This overproduction of non­
specific gammaglobulin may also result in autoimmunity against cellular proteins 
(Lyerly et a l,  1987a, b; Endelman and Zolla Pazner, 1989).
Another mechanism has been proposed for the depletion of CD4+ cells. 
Apoptosis or programmed cell-death is a process that occurs during the normal 
maturation of thymus-derived T lymphocytes and is required to eliminate autoreactive T 
cells, in order to establish self tolerance (reviewed by Gougeon and Montagnier, 1993). 
It has been proposed that binding of gpl20 to CD4 primes the T cells to undergo 
apoptosis in response to further stimulation with antigen. Thus gpl20 on the surface of 
infected cells may prime neighbouring uninfected T cells to undergo apoptosis. In 
addition, HIV-1 infected macrophages show altered cytokine production and can secrete 
high levels of tumour necrosis factor (TNF), which is known to induce apoptosis 
(reviewed by Levy, 1993). T cells taken from HIV-1 infected individuals can be 
induced in vitro to undergo apoptosis in response to antibodies against the T cell 
receptor, however this results in the depletion of both CD4 and CD8 bearing T cells, a 
phenomenon not reflected in the in vivo situation (reviewed by Gougeon and 
Montagnier, 1993). Therefore, the relevance of this hypothesis has yet to be fully 
understood.
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HIV-1 not only infects CD4+ T lymphocytes and cells of the monocyte-derived 
macrophage lineage in the peripheral blood and lymph nodes but is found in the 
macrophage cells present in several tissues of the perivascular compartment including 
brain, lung, gastrointestinal epithelium, skin, heart and kidney (Armstrong and Horne, 
1984; Ho e ta l ,  1984, 1985; Levy e ta l ,  1985a, b; Koenig etal., 1986; Popovic and 
Gartner, 1987; Koyanagi e ta l ,  1987; Nelson e ta l ,  1988; Cohen etal., 1989). The 
clinical symptoms of AIDS, such as wasting, neurological and gastrointestinal 
dysfunction could be due, directly to primary infection of the corresponding tissues or 
to an indirect mechanism not yet determined. In either case, development of the disease 
appears to correlate with an increase in viral load and the emergence of HIV-1 variants 
that are more cytopathic and replicate in a wider variety of human cells (Cheng-Mayer 
et al., 1988; Fenyo et al., 1988; Asjo et a l ,  1988; Tersmette et al ., 1988). This 
probably occurs when the CD4+ T cells and the immune repertoire has been sufficiently 
depleted, allowing the unrestricted emergence of the rapidly replicating, cytopathic 
variants of the virus.
1.6 Genetic variability of HIV-1
1.6.1 Mechanisms of HIV variation
The high mutation rate of HIV-1 and other retroviruses reflects the infidelity of 
the RNA polymerase II, reverse transcriptase, and their lack of a proofreading activity 
(Moriyama et al., 1991; Preston et a l ., 1988; Roberts et al, 1988; Coffin, 1992). In 
HIV-1 and other retroviruses, there is a high rate of mutation between adenine (A) and 
guanine (G) residues and in particular changes from G to IA in both the gag and env 
genes (Moriyama et al., 1991). This high rate of substitution between A and G appears 
to be specific for retroviruses and has been attributed to the poor recognition of 
pyrimidine residues by the reverse transcriptase enzyme during replication of the 
HIV-1 genome (Moriyama et al., 1991). The rate of fixation of mutations (the
30
Chapter 1
evolution rate) in the viral population is not only dependent on the mutation rate but 
also on environmental selection pressures such as the immune response and antiviral 
drugs and restrictions imposed by the functional constraints on the viral proteins. The 
observation that the rates of substitution are not constant across the HIV-1 genome but 
are high in the envelope gene (Li et al., 1988) suggests that the probability of mutation 
fixation is not simply a reflection of the intrinsic mutation rate.
Recombination of retroviral genomes, requiring a heterozygous virion RNA 
(section 1.2.3) adds further to the complexity of genetic variation of HIV-1 (Hu and 
Temin, 1990). Based on experimental replication rates Hu and Temin (1990) estimated 
that at least one of three, two stranded 10-kb RNA viruses would experience at least one 
recombination event. In dually infected cells the possibility exists for recombination 
between similar but distinct viruses leading to a single proviral intermediate and adding 
further to the variation of the HIV-1 genome (Katz and Skalka, 1990; Hu and Temin,
1990).
1.6.2 Evolution of viral quasispecies
An hypothesis based on Darwin's theory of Natural Selection would imply that 
molecules that replicate with limited fidelity will generate enough diversity to code for 
some variants that may have a phenotypic selective advantage in the host at any 
particular time and that these variants would then replicate and become dominant in the 
virus population. Because of the error-prone replication machinery, not only these 
mutants would exist, but a swarm of other genotypes would also exist. The 
representation of each of these mutations in such a swarm is dependent on the rate at 
which that mutation occurs and the relative "fitness" of that mutation in the viral 
population. This distribution around a predominant sequence is termed the quasipecies 
distribution and was first described for the evolution of macromolecules in general by 
Eigen et al. (1971, 1988) and is applicable to the sequence distribution observed in most 
lentiviruses including HIV-1. This distribution allows the virus to adapt rapidly to host
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selection pressures by allowing a switch in quasipecies distribution to favour the 'fittest' 
mutant. Because of the extensive sequence variation displayed by HIV-1, every 
genome has to be considered unique and consequently must be described in terms of 
populations of closely related genomes or quasispecies (Goodenow et al., 1989).
1.6.3 Variation between HIV-1 isolates
The genomic diversity of HIV-1 was first shown using restriction enzyme 
mapping and analysis of thermal denaturation of heteroduplexes to compare various 
geographically distinct viral isolates, including the MN and RF strains to the original 
HTLV-IIIB cloned isolate (Shaw et al., 1984, 1985; Hahn et a l ., 1984, 1985). These 
studies demonstrated that virus isolated from patients with AIDS or AIDS related 
complex (ARC) displayed considerable genetic variation and that this variation was 
predominantly found in the envelope coding region rather than the gag and pol coding 
regions. Later studies confirmed that among 18 isolates from individuals with AIDS, 
each showed a different restriction enzyme pattern (Wong-Staal et al., 1985). The 
complete genomic sequence for the original isolates of HIV-1 (Barre-Sinoussi et al., 
1983; Gallo et al., 1984) was later identified (Ratner et al., 1985; Wain-Hobson et al.,
1985). Further diversity than previously observed between the North American and 
European isolates was seen in the nucleotide sequences obtained from two Zairian 
patients infected with HIV (Alizon et al., 1986) indicating a divergent evolution of the 
virus in Africa. The sequence diversity of HIV-1 is now well documented (Simmonds 
et al., 1991; Leigh Brown, 1991; Coffin, 1992). These findings along with analogous 
data for the Equine Infectious Anaemia Virus (EAIV) and Visna virus, two lentiviruses 
in which it has been suggested that variation in the envelope region correlates with 
demonstrable changes in antigenicity and pathogenicity, and the finding that variants 
arise progressively during infection (Scott et al., 1979; Montelaro et al., 1984; 
Salinovich et al., 1986; Clements et al., 1988) suggested perhaps that the genetic
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variation in HIV-1 could alter viral pathogenesis via the emergence of immunological 
escape mutants and mutants with altered tissue tropism and virulence.
1.6.4 Variation within the envelope protein
The comparison of independent HIV-1 isolates has shown that the region of the 
envelope gene encoding gp l20 is characterised by considerable sequence variation 
(Hahn etal., 1986; Simmonds et al., 1990; Leigh Brown, 1991; Coffin, 1992). This 
variation is not uniformly spread across the whole protein but is clustered into five 
hypervariable regions (VI-V5) displaying less than 30% sequence homology, 
interspersed between four highly conserved sequences (C1-C4) and regions of 
intermediate variability (Starcich etal, 1986; Willey et al., 1986; Modrow et al., 1987). 
These regions have been mapped and are shown schematically in Figure 1.7. The 
precise numbering of the individual amino acids varies depending on the virus strain.
Despite its high divergence, the 21 cysteine residues present in the uncleaved 
gpl60 molecule are completely conserved in all reported isolates including SIV and 
HIV-2, which share only 30-40% identity with HIV-1 (Tschachler et al., 1990). 
Substitution of these cysteine residues by other amino acids resulted in non-infectious 
virus that were blocked in the viral life cycle (Tschachler et al., 1990) indicating that 
they have an indispensable role in viral function, probably at least in part through the 
contribution of disulphide bridges to the tertiary structure of the envelope protein.
1.6.5 Variation within an individual
An important feature of HIV-1 infection is that genetic variation exists not only 
between viral isolates from different individuals but between isolates from within 
individuals and that this heterogeneity becomes more apparent during the course of 
infection (Saag et al., 1988; Fisher etal., 1988; Simmonds et al., 1990, 1991; Balfe 
et a l ., 1990; Wolfs et al., 1992). Hahn et al. (1986) examined sequential isolates from
33
am
in
o 
ac
id
 
po
si
tio
ns
u->
>
>
X>
cd
•
c9
>
O)>C/3
g
X<D
<4 -1o
C/3
g
o
*toft
0304
t^
uI
y
C/3
gO
• *“Htofta)t-H
T3
03>*-i
03
c /3
GO
u
x
cd
c3
>
a
Cd
T 3
03
03
■I—»
.a
C/3
GO
toft
0304
>
u
cdaW)
♦cn
r - OO O
G" Os ftO
CO <N G- uo
1 G- uo o
OO O f-H r-~
CO <N G- G -
cd cd cd cd
cd cd cd cd
N CO T f
u u U u
^tU~)
lo
CO
CO ftO G- ov
o CO r*H VO
c s CO G- G-
CO VO ON
VO Ov On W
—H CN CO G-
cd cd cd cd
cd cd cd cd
CS CO T t m
> > > >
c/0
GO
’ t o f t
a
3
cd
c3>
T3
G
cd
T 3
O)
£
03C/3
GO
03
03
'B
<4 -1
o
GO
•4-> •
cd ^G ^  G OO
&<*3 —-I
03 O
c wa «
03 ^3
'S £ 
6  s
03
o  °
£ 3
2
^  toft Ai C
H  T3S ^
5 )8
Chapter 1
three individuals infected via different routes of transmission and identified single 
amino acid changes in the hypervariable regions of gp l20 and found that the level of 
heterogeneity appeared to increase over time. This is consistent with the more recent 
findings that on initial infection with HIV-1 the virus population appears to be relatively 
homogenous in the envelope region (Wolfs e ta l ,  1991, 1992; Zhang et a l,  1993). 
Indeed, virus isolated from pre-seroconversion samples from nine infected patients 
showed no heterogeneity in either the V3 or V4 regions of gpl20, in contrast to major 
variability observed in the gag gene or in the regions flanking V3 and V4 (Zhang et al, 
1993). Similarly, the observed reduction of sequence variability of the env gene found 
on mother-child transmission (Wolinsky et a l,  1992) suggests, a selection for specific 
env sequences either upon transmission or in the interval between exposure and 
seroconversion. This apparent requirement for a specific env determinant on primary 
infection may play a part in the stochastic nature of virus transmission.
During the long asymptomatic phase the viral population is highly heterogenous 
in the envelope region (Hahn et al., 1986; Simmonds et a l,  1990, 1991; Balfe et a l,  
1990; Wolfs et a l,  1992). Sequence variation in HIV-1 isolates between individuals 
infected from a common source has also been reported (Simmonds et al,  1990; Balfe et 
a l ,  1990; Burger et a l,  1990). Such variation was less extensive than the variation 
observed between epidemiologically unlinked individuals. Within these patients 
infected from a common source, heterogeneity in the envelope region again increased 
over time. It was also found that although sequence variants were detected within both 
the viral RNA isolated from blood plasma and the proviral DNA isolated from PBMCs, 
the novel sequence variants appeared first in the plasma RNA populations and then 
subsequently in the proviral population and the proviral sequences persisted in the 
population for much longer periods of time (Simmonds et a l,  1991). Furthermore, the 
evolution of HIV-1 sequences does not appear to accumulate steadily with time. In a 
patient of the Edinburgh haemophiliac cohort (p82), also studied in the work presented 
in this thesis, sequence variation over a five year follow-up period consisted of a series 
of replacements in three hypervariable regions of gp l20 of one particular sequence type
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with another, not directly derived by a single substitution from the previously observed 
sequence. This suggests either the existence of a hidden mechanism of evolution such 
as a requirement for covariance between specific amino acids for the sequence changes 
in HIV-1 gpl20 (Korber et al., 1993) or that the interval between sampling sequential 
isolates is such that intermediate sequences have been missed (Simmonds et a l ,  1991).
Nowak et a l  (1991) hypothesise that there is a threshold level of diversity that can 
be supported by the host immune system. Beyond this diversity threshold, the 
individual is unable to mount an effective immune response against new variants, 
resulting in the outgrowth of the most virulent viruses and the subsequent progression to 
AIDS.
1.6.6 Effect of variation on biological phenotype
The sequence variation that occurs in gpl20, in particular within the V3 region, 
has an effect on the pathological phenotype of the virus in terms of tropism, ability to 
induce syncytia and ability to replicate in vitro (Levy et a l ,  1984; Anand et a l,  1987; 
Asjo e ta l ,  1986; Evans e ta l ,  1987; Briesen e ta l ,  1987; Tersmette et a l,  1988; Fenyo 
et a l ,  1988). Virusesisolated from early stages of infection in general, grow more 
slowly, do not induce syncytia between infected cells (non syncytium-inducing or NSI) 
and replicate in primary macrophages as well as in activated CD4+ cells but do not 
grow well in immortalised T cell lines. Isolates recovered from patients with AIDS or 
ARC however, show higher replication rates than isolates recovered from asymptomatic 
individuals , can induce syncytia (syncytium-inducing or SI) and are also capable of 
replicating in immortalised T cell lines but not in primary macrophage cell lines (Asjo 
e ta l ,  1986; Evans e ta l ,  1987; Briesen e ta l ,  1987; Tersmette e ta l ,  1988, 1989; Fenyo 
et a l,  1988). Although these three properties of HIV-1 are distinct, it is likely that 
rapid-high, T cell tropic and SI, all define the same state, which is distinct from the less 
virulent state characterised as slow-low, macrophage tropic and NSI. It is also unlikely 
that all HIV-1 isolates can be unambiguously assigned to one or other of these two
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distinct groups, and more probable that some isolates will display a spectrum of these 
properties (Simmonds-personal communication). In longitudinal studies, it has been 
shown that disease progression is linked with a transition from NSI isolates such as the 
primary macrophage tropic isolates to SI T cell tropic isolates (Cheng-Mayer et al., 
1988; Tersmette etal., 1989a, b; Schuitemaker et al., 1991, 1992). In one study, 3 out 
of 19 virus isolates collected before seroconversion were SI and non-macrophage tropic. 
The detection of this more virulent phenotype correlated with a more rapid progression 
to AIDS than observed in those patients infected with NSI variants (Roos et al., 1992). 
It has also been argued that macrophage tropic, NSI isolates are responsible for the 
persistence of HIV-infection (Meltzer et al., 1990).
1.7 Properties and functions associated with the V3 region 
of gpl20
1.7.1 Structure of the V3 loop
The V3 loop region consists of 33-35 amino acids, depending on the HIV-1 strain, 
bound to form a loop structure by a disulphide bridge between two invariant cysteines 
(Rusche et al., 1988; Goudsmit et al., 1988a; Palker et al., 1988; Leonard et al., 1990). 
Although this region is highly variable, it is better described as a mosaic of variable and 
conserved regions with a highly conserved amino acid triplet, Gly-Pro-Gly, common to 
all HIV-1 strains at the tip of the loop (La Rosa et al., 1990). It has been predicted from 
a consensus of V3 sequences that the loop structure is: cysteine-beta strand-type II beta 
turn-beta strand-alpha helix-cysteine (La Rosa et al., 1990).
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1.7.2 The V3 loop as the principal neutralising determinant of HIV-1
Patients infected with HIV elicit potent neutralising antibodies against the 
external glycoprotein gpl20 (reviewed by McKeating, 1992) and in particular the V3 
loop (Palker et al., 1988; Goudsmit et a l,  1988a; Rusche et al., 1988; Matsushita et al, 
1988; Javaherian et al., 1989). Initial findings identified antibodies that could cross 
neutralise a number of laboratory isolates of HIV-1 (Weiss et a l,  1985; Robert-Guroff 
et al., 1985), however, as more isolates became available both isolate restricted and 
non-isolate restricted neutralising antibodies were observed (Weiss et al., 1986). 
Antibodies that can cross neutralise divergent strains of HIV-1, the so-called "group- 
specific" antibodies are in general directed against conserved conformational epitopes 
on gpl20 (Haigwood et al., 1990a; Profy et al., 1990; Steimer et al., 1991; Kang et a l,  
1991; Hariharan et al., 1993) and in particular against the CD4 binding site that has 
been mapped to between amino acids 397-439 in the C-terminal portion of gpl20 
(Lasky et al., 1987). These antibodies show the capacity to inhibit the binding of gpl20 
to the cellular receptor molecule CD4 (Steimer et al., 1991; Kang et al., 1991). 
Antibodies that neutralise autologous virus, the so-called “type-specific” neutralising 
antibodies in general map to the V3 loop (Palker et al., 1988; Goudsmit et al., 1988a; 
Rusche et al,  1988; Matsushita et al, 1988; Javaherian et al., 1989) and are produced 
early in infection. More recently however, a number of monoclonal antibodies that 
recognise conserved features of the V3 domain can neutralise a broader range of 
isolates (Javaherian et al., 1989; Ohno et al., 1991; Gorny et al., 1992). The 
neutralisation ability of HIV-1 infected sera appears to broaden with time (Nara et al., 
1987; Zagury et a l ,  1988; Goudsmit et a l ,  1988b), probably in response to the 
exposure of the individual to extensive sequence variation in gp l20 during the course of 
infection.
Antibodies that are reactive against the V3 region can account for up to 50% of 
the total native gp 120-specific antibodies in infected sera and can account for nearly all 
of the antibodies that bind to denatured gpl20, suggesting that V3 acts as a linear
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determinant. (Moore and Ho, 1993). In addition, peptides mimicking the V3 region of 
the MN strain of HIV-1, elicit high titres of virus neutralising antibodies and can, when 
attached to a solid phase support absorb out most of the neutralising activity of 
HIV-lMN infected sera (Profy et al., 1990). For these above reasons the V3 region of 
HIV-1 is defined as the principal neutralising determinant or PND (La Rosa et al., 
1990).
The reactive epitope in V3 has been mapped to a stretch of 8-14 amino acids, 
incorporating the highly conserved Gly-Pro-Gly-Arg domain and amino acids that 
directly flank this region (Goudsmit et al., 1988a; Javaherian et al., 1989; Meloen et al.,
1989). The in vivo relevance of neutralising antibodies against the V3 loop has yet to 
be fully established. Monoclonal antibodies directed against the PND prevent HIV-1 
infection of MT4 cells in vitro , while antibodies in polyclonal IgG when pre-incubated 
with the IIIB strain of the virus were shown to inhibit infection of chimpanzees in vivo 
(Emini et al., 1990). Immunisation of chimpanzees with recombinant forms of gpl20 
were protected from challenge with HIV-1 and were shown to contain high titres of 
neutralising antibodies directed against the V3 region (Berman et al., 1990; Emini et al., 
1990; Girard et al., 1991). The role V3 antibodies have in the observed protection of 
chimpanzees from infection was not directly measured in these experiments, however, a 
mouse monoclonal antibody specific for the V3 loop domain could protect chimpanzees 
against infection with HIV-1 when administered before or after challenge (Emini et al.,
1992). Vaccine trials in rhesus macaques has however, shown no correlation between 
the level of neutralising antibodies and protection from infection with challenge SIV 
(Desrosiers et al., 1989).
Viruses that can escape neutralisation by V3 monoclonal antibodies have been 
identified in vivo in HIV infected chimpanzees (Emini et al., 1990; Nara et al., 1990) 
and in vitro with V3-specific monoclonal antibodies (McKeating etal., 1989). In most 
cases, sequence changes in the V3 region can account for the differences in 
neutralisation however, sequencing of the V3 region of resistant viruses that emerged in 
chimpanzees, experimentally infected with H IV -lniB , revealed that some of these
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mutants had no amino acid changes in the V3 region or that amino acid changes that 
emerged in the V3 region, occurred at positions outwith the monoclonal antibody 
binding site (Nara et al., 1990). This finding suggests, that other regions of gpl20 may 
interact with the V3 region in some way altering its conformation and neutralisation 
ability.
1.7.3 Other neutralisation epitopes in gpl20
In addition to the well defined neutralisation epitopes located in both the V3 
region and the CD4 binding site, a linear neutralisation epitope in the V2 region and a 
discontinuous epitope, dependent on the structure of the V1/V2 region, have been 
identified using monoclonal antibodies (Fung etal., 1992; McKeating et al., 1993). Of 
the monoclonal antibodies that were dependent on the structure of the V1/V2 region, 
additional mutations in the C4 region of gpl20 could be shown to have an effect on the 
neutralisation properties of these monoclonal antibodies (McKeating et al., 1993). It 
w'as therefore suggested, that amino acid changes in the C4 region may alter the 
structure of the V1/V2 domain recognised by conformation-dependent antibodies 
(McKeating et al., 1993). The conformation of gpl20 is therefore important for the 
efficient neutralisation of HIV-1. Recent studies have identified discontinuous epitopes 
in gpl20, proximal to or overlapping the CD4 binding site that only become properly 
exposed to neutralising antibodies upon binding to CD4 (Thali et al., 1991, 1992,
1993). Linear neutralisation epitopes have also been identified in the V4 and V5 
regions of HIV-1 gpl20 (Haigwood e ta l ,  1990b).
1.7.4 The role of the V3 region in viral entry into target cells
Monoclonal antibodies against the V3 region (Matsushita et al., 1988; Scott et al., 
1990) do not act to neutralise the virus by blocking binding to the CD4 molecule but are 
believed to work via a post binding event (Javaherian et al., 1990). Deletion of most of
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the V3 region does not appear to affect the binding of monomeric gpl20 to CD4 
(Pollard et al., 1992). These findings implicate V3, acting directly or indirectly, as 
having an important role in viral fusion (Freed et al., 1991a, b). It is hypothesised that 
V3 interacts with cell surface proteases on target cells which may act to facilitate 
infection. This hypothesis is based on experiments showing that both HIV-1 and HIV-2 
have proteolytic cleavage sites at the tip of the V3 loop (Stephens et al., 1990; Clements 
et al., 1991) and that neutralising antibodies raised against this region can block the 
proteolytic cleavage of the V3 loop by thrombin (Clements et al., 1991) In addition, a 
serine protease inhibitor, trypstatin, has been shown to block HIV infection in vitro 
(Kioto et al., 1989; Hattori et al., 1989; reviewed by McKeating, 1992). This suggests 
that neutralising antibodies against V3 interfere with the cleavage event required for 
viral entry. Sattentau and Moore (1991) have also shown that the V3 loop on the 
surface of virions is not accessible to proteolytic cleavage (thrombin) until the virus has 
bound sCD4, confirming the hypothesis that a conformational change is required in 
gpl20 to allow viral entry. If this model is correct then viral tropism could be 
influenced by the presence of specific-cellular proteases on the surface of target cells.
1.7.5 Involvement of the V3 region in viral tropism and biological 
phenotype of HIV-1
As discussed previously in 1.6.5 and 1.6.6, virus isolates obtained from infected 
individuals during the course of infection, display not only considerable genetic 
diversity (Hahn et a l,  1986; Saag et al., 1988; Fisher et al., 1988; Simmonds et al., 
1990, 1991; Balfe et al ., 1990; Wolfs et al., 1992) but also differences in their 
biological phenotype (Levy et al., 1984; Anand et al., 1987; Asjo et al., 1986; Evans et 
al., 1987; Briesen etal., 1987; Tersmette e ta l ,  1988, 1989a, b; Fenyo et al., 1988; 
Cheng-Mayer et al., 1988; Schuitemaker et al., 1991, 1992). The existence of 
macrophage tropic isolates early in infection may suggest that viruses of this type are 
transmitted more frequently from individual to individual perhaps due to their inability
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to induce syncytia and slow replication in both macrophages and PBMCs and therefore 
decreased recognition by the host immune system as compared to the more virulent T 
cell tropic isolates. Evidence supporting this hypothesis has not yet been obtained and 
the importance of these macrophage tropic clones is not fully understood.
A number of studies aimed to determine the minimum region of the HIV-1 
genome that conferred this macrophage tropism (Chesebro et al., 1991; Hwang et a l,  
1991; O’Brien etal., 1990; Shioda etal., 1991; Westervelt etal., 1991, 1992). These 
studies followed essentially the same protocol, involving chimeric g p l20 molecules 
with different regions of the protein derived from macrophage tropic clones, cloned into 
T cell tropic clones by the use of shared restriction enzyme sites. These chimeric 
viruses were then tested for their ability to grow in primary macrophages, PBMCs and 
transformed T cell lines. The studies showed that amino acids between 202-358 
incorporating the V3 loop were sufficient to confer macrophage tropism. Hwang et al. 
(1991) further determined the minimal region capable of controlling macrophage 
tropism to be a 20 amino acid sequence contained within the V3 loop. In addition, 
similar studies have shown that amino acid changes both in the highly conserved Gly- 
Pro-Gly-Arg motif and flanking amino acids in the V3 region were sufficient to change 
virus tropism to a T cell tropic cell line and to confer syncytium inducing properties 
(Chesebro et al., 1992; De Jong et al., 1992a). Evident from all these studies was that 
no consensus V3 sequence can determine macrophage tropism, as T cell tropism could 
be eliminated by site directed mutagenesis with concomitant replication in macrophages 
with as few a two or three amino acid substitutions in the V3 region, none of which 
appeared in any of the macrophage tropic isolates (Chesebro et al., 1992). More recent 
studies have identified the VI and V2 regions in addition to the V3 region of gpl20 of 
to be involved in tropism of HIV-1 (Kioto et al., 1993; Andeweg et al., 1993; Sullivan 
etal., 1993 ; Boyd etal., 1993).
Studies have also been performed to assess the role of the V3 region in syncytium 
formation. De Jong et al. (1992a) provide evidence that SI viruses have a higher net 
charge associated with their V3 sequences than do NSI viruses. This has been further
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extended by comparison of the V3 sequences from sets of biological clones isolated 
sequentially from 12 patients. These sequences showed a correlation between a basic 
charge (usually R or H) at amino acid position 11 (gpl20 amino acid 306, based on the 
MN strain of HIV-1) and R or K at amino acid position 28 (gpl20 amino acid 320) in 
the V3 region and the transition form an NSI to an SI phenotype. In NSI variants, the 
amino acid residue at position 11 was uncharged (in general S or G) and the residue at 
position 28 was either negatively charged (E or D) or uncharged (A or Q) (Fouchier et 
al., 1992). In addition, these mutations were shown to potentially alter the structure of 
the V3 region, suggesting that SI and NSI variants may have distinct V3 structures. 
Mutational analysis of these two amino acids abolished syncytium-inducing ability of 
these clones (De Jong et a l,  1992b). In a recent study it was shown that changes 
outwith V3 are also capable of altering the biological phenotype, and that an interaction 
between several regions of gpl20 may be required (Cheng-Mayer et al,  1991; 
Stomatatos and Cheng-Mayer, 1993). This suggests that the overall conformation of 
gpl20 is important for its biological functions. Amino acid changes in the VI and V2 
region in addition to V3 have been shown to alter the replicative capacity of viral 
isolates (Groeninke ta l ,  1993).
1.8 Factors affecting maternal-foetal transmission of 
HIV-1
The rate of mother to child transmission of HIV appears to vary depending on the 
study cohort. Transmission rates ranging from 7-65% have been reported, with the 
highest transmission rates being reported from African countries (Rubinstein
and Bernstein, 1986; Piot et a l,  1988; Mok et a l,  1989; Blanche et a l,  1989; Ades et 
a l ,  1991). The factors that affect this transmission rate are not yet understood, 
however, the European collaborative study (1992), set up to analyse transmission data 
from nineteen European countries between December 1984 and August 1991, aimed to 
focus on the risk factors associated with maternal-foetal transmission. This study
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established that low CD4 counts, p24 antigenemia and high virus load in the mothers 
were predictive markers of vertical transmission in this study group. In addition, this 
and one other study (Goedert et al., 1991) established that infants born before 38 weeks 
gestation were more likely to have acquired HIV-1-infection from their mothers. This 
finding could be compatible with these infants having been infected in-utero and HIV- 
infection having affected foetal development, causing premature birth. Goedert et al  
(1991) also reported that these HIV-1 infected infants born prematurely had low 
concentrations of maternal anti-gpl20 antibodies, raising the possibility that antibodies 
against gpl20 may have a protective role in vertical transmission of HIV-1. A number 
of studies discussed in detail in results section 2 , suggested that high titre or high 
affinity antibodies against the V3 region of HIV-1 gpl20 correlated with a lack of 
transmission of the virus to the child (Broliden et a l,  1989; Rossi et a l,  1989; Devash 
et a l,  1990). Work presented in this thesis and^fhers (Parekh et a l,  1991; Geffin et a l,  
1992; Halsey e ta l ,  1992) however, contradicts these findings.
The precise time at which vertical-transmission occurs is not yet known, however,
transmission data collected from twin-studies (Goedert et a l,  1991) has suggested that
transmission occurs in as many as 50% of the infants in their studies at the time of birth.
These studies involved 66 sets of twins from 9 countries. HIV-1 was diagnosed in 50%
of first born twins delivered vaginally and in 38% delivered by caesarian section,
compared with only 19% for both modes of delivery in the second born twins. This
increased risk for the first born twin may be due to increased exposure of that infant to
maternal blood and fluids in both the birth canal and via caesarian section. The data
from this study and others (Chiodo et al., 1986; Lindgren et al., 1991) shows no
significant difference in the relative risk of transmission between the two modes of
delivery, however, a more recent study, which analysed all the published data, suggests
that birth by caesarian section may reduce the risk of vertical HIV-1 transmission
I by
(Villari et al., 1993). If this is the case, then modification of obstetric techniques used 
on HIV-infected women , advising a planned caesarian section may help reduce the risk 
of vertical HIV-1 transmission.
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Vertical transmission of HIV-1 has also been reported to occur through breast 
feeding, following primary infection of the mother after delivery (Van de Perre et al., 
1992). In an extension to this study, a correlation was found between increased vertical 
transmission and higher numbers of HIV-1 infected cells in early breast milk (Van de 
Perre et al., 1993). It was also found that none of the mothers in this study had any 
detectable HIV-1 specific IgA (IgA being the main component of humoral immunity in 
breast milk (Welsh and May, 1979)). However HIV-1 specific IgM appeared to 
compensate for the absence of IgA, in that mothers with higher levels of IgM had a 
decreased risk of vertical transmission of the virus. The results of these finding are 
howevef difficult to interpret, as it is not known if infection of the child occurred either 
before or after delivery. The authors recognise this limitation and conclude only that 
the presence of HIV-1 in breast milk is a risk factor for vertical transmission of the 
virus.
1.9 Vaccination against AIDS
1.9.1 Approaches to AIDS vaccines
The minimal elements of an effective HIV-1 prophylactic or therapeutic vaccine 
are, safety, long term protective immunity and the ability to protect against globally 
diverse isolates (reviewed by Barrett and Domer, 1993). A number of strategies have 
generally been used for the development of viral vaccines including, the use of whole 
inactivated viruses, live attenuated viruses, live recombinant viruses, subunits purified 
from whole virus or subunits derived by recombinant DNA technology and synthetic 
peptides. Prophylactic vaccination has proved highly successful in the control of a 
range of diseases caused by viruses such as smallpox, yellow fever and poliomyelytis. 
The nature of HIV-1 infection makeseffective vaccination against this virus both 
scientifically and ethically more difficult. HIV-1 has mechanisms that enable it to 
establish a persistent infection in man which are more elaborate than those of viruses
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against which successful vaccines have been produced. Non cytopathic deletion 
mutants of HIV-1 could be developed that could grow and induce immune responses 
against HIV-1 without causing disease. However, as HIV-1 can integrate into the host 
genome, these viruses could be retained for life and may result in malignant 
transformation. In addition, inactivation of HIV-1 could present problems as the viral 
genome could remain functionally intact following inactivation and integrate into the 
host genome resulting in latency or virus production. Due to the ethical restrictions of 
vaccinating seronegative individuals with live attenuated or non cytopathic deletion 
mutants most of the vaccine development studies involve viral protein subunits derived 
by recombinant DNA technology.
It is important to note that infection with HIV-1 can result from transmission of 
both cell-free virus and through virus-infected cells that display little or none of the 
viral antigens on their surface. Therefore a successful vaccine against HIV-1 must 
induce both humoral and cellular immunity. This again is no simple task as 
immunogenic regions of the virus have been shown to induce both antibody-mediated 
enhancement of viral infection (Takeda et al., 1988, 1990; Homsy et al., 1989; 
Robinson et a l,  1991.; Haubrich et a l,  1992) and anti-idiotypic antibodies against 
cellular components (Hoffman et al, 1991).
At present both prophylactic and therapeutic vaccines are being tested with the 
aim of either protecting against or controlling HIV-1 infection and the progression to 
AIDS.
1.9.2 Prophylactic vaccine trials
The majority of prophylactic vaccine trials that have been initiated in America, 
Europe and Africa involve immunisation of seronegative individuals with preparations 
of either recombinant HIV-1 gpl20 or the uncleaved gpl60 molecule. These trials so 
far demonstrate the production of high titres of neutralising antibodies and memory T 
cells against HIV-1 (Barrett et al., 1989; Dolin et al., 1991; reviewed by Barrett and
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Dorner, 1993) with the most recent vaccine trial reporting induction of both neutralising 
and syncytium-inhibiting antibodies (Schwartz et al, 1993). However, without actually 
challenging these individuals with live HIV-1 it is impossible to assess the preventative 
capacity of these preparations. Animal models are therefore important in the 
development of potential vaccines against HIV-1. Monkeys infected with HIV-1 show 
none of the clinical signs of disease associated with infection in humans and for this 
reason SIV-infection in both chimpanzees and macaques which do show AIDS-like 
symptoms are widely used animal models. However, given the dissimilarity of the 
principal neutralising epitopes for HIV-1 and HIV-2 /SIV and differences in cell 
tropism for these viruses operating at the level of entry (Clapham et a l ,  1991) 
experiments on SIV may not be predictive of humoral protection against HIV-1 (Moore 
and Weiss, 1991).
As discussed previously in section 1.7.2, monoclonal antibodies against the 
principal neutralising determinant of gp l20 protect chimpanzees from infection when 
administered either before or 10 minutes after virus challenge (Emini et a l ,  1992). 
However, immunisation of chimpanzees with attenuated SIV showed no correlation 
between the in vitro level of neutralising antibodies and protection against challenge 
virus (Desrosiers, et a l,  1989).
Several groups have independently demonstrated that macaques could be 
protected from infection with SIV by immunisation with inactivated vaccines, based on 
either whole inactivated SIV or fixed SIV-infected cells (Desrosiers et al., 1989; 
Murphey-Corb et al,  1989; Stott et al,  1990) raising expectations that the development 
of a vaccine against HIV-infection in man could be possible. However, it has now been 
shown that inactivated SIV-based vaccines were unable to protect against challenge 
with SIV grown in monkey cells but could protect against SIV grown in human cells. 
In addition, vaccination of monkeys with uninfected human cells protected against 
challenge against SIV derived from human cells, despite the fact that all the monkeys 
had specific SIV neutralising antibodies (Stott, 1991; Langlois et a l ,  1992; Le Grande 
et a l,  1992; Osterhaus et a l,  1992; Cranage et a l,  1992). The protection conferred
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against virus grown in human cells is now known to be due to the recognition of human 
HLA type 1 on the surface of these virions as foreign molecules by the monkey immune 
system. These studies demonstrate the absolute necessity of designing vaccine 
experiments where viruses used for challenge are grown in PBLs from the target host 
species and bring into question the importance of neutralising antibodies in protection 
against HIV-infection.
The current experimental vaccine studies using recombinant gpl20 or gpl60 have 
overlooked a number of important features of infection with HIV-1 (reviewed by Sabin,
1992). Firstly, the two most important vehicles of infection in humans are semen and 
blood. These contain large numbers of virus-infected cells that display little or none of 
the viral antigens on their surface. Such virally-infected cells would not be detected by 
neutralising antibodies against gpl20 or gpl60. Indeed, Johnson et al  (1992b) reported 
that an inactivated whole SIV vaccine that protected macaques against an intravenous 
challenge of 50 ID50 of cell-free SIV did not protect against challenge with 50 ID50 of 
SIV-infected PBMCs. Secondly, one of the major routes of transmission of HIV-1 is 
via the introduction of semen into the colorectal area of men and women through 
receptive anal intercourse. A successful vaccine must be able to prevent infection via 
this route.
In addition to the prophylactic vaccine studies, studies to develop a vaccine that 
will have a therapeutic effect in those individuals already infected with HIV is of vital 
importance and the subject of much investigation. Vaccine therapy could either clear 
the virus from the host, prevent the progression to AIDS or improve the quality of life 
for those patients with AIDS.
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1.10 Antiviral agents against HIV-1
1.10.1 Inhibition of HIV-1 infection with soluble recombinant CD4 
(sCD4)
The observation that the CD4 molecule is the principal receptor for HIV-1, HIV-2 
and SIV in both T lymphocytes and monocytic macrophages led to the hypothesis that 
a soluble form of the CD4 receptor might inhibit infection. To test this hypothesis a 
number of groups made recombinant soluble CD4 and demonstrated its ability to block 
HIV-1 infection in vitro (Smith et al., 1987; Deen et al., 1988; Hussey et al., 1988; 
Traunecker et al., 1988; Clapham et al., 1989; Byrne et al., 1989). The effect of 
recombinant CD4 was tested in Rhesus macaques infected with SIVmac- Virus could 
be readily isolated from PBLs and bone marrow cells of these animals prior to treatment 
but became difficult to isolate after treatment with sCD4. In addition, diminished 
growth of granulocyte/macrophage and a rise to normal levels of erythrocyte progenitor 
colonies in the bone marrow during treatment was observed (Watanabe et al., 1989). 
This evidence and the finding that sCD4 could also protect chimpanzees against 
experimental infection with HIV-IIIB (Ward et al., 1991) implicated sCD4 as a 
potential therapeutic agent in infected individuals (Kahn et a l,  1990; Schooley et al.,
1990). Soluble CD4 may act to neutralise HIV-1 in a number of ways. At low 
concentrations, sCD4 binds competitively for the gpl20 on the virion
surface to weakly neutralise the virus (Lasky et al., 1987). However, at higher 
concentrations of sCD4, the virus is effectively neutralised by a process of shedding of 
the gpl20-sCD4 complex from the surface of the virion, rendering it non-infectious 
(Moore et al., 1990, 1991). In addition, the binding of soluble CD4 could alter the 
conformation of g p l20 such that viral fusion with the host cell membrane cannot occur. 
Inaccessibility of the V3 loop to proteolytic cleavage may be one of the mechanisms 
involved (O’Brien e ta l ,  1992).
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The initial enthusiasm for the use of sCD4 in HIV-infected individuals was 
perhaps dampened by the observations that some viral isolates even from the same 
individual are more susceptible to neutralisation by sCD4 than others (Daar et al, 1990; 
Gomatos et al., 1990; Byrne et al., 1989). Primary isolates of HIV-1 which are 
generally believed to be macrophage tropic (Gartner and Popovic, 1990; Schuitemaker 
et al., 1991, 1992) were found to be less susceptible to neutralisation by sCD4 in vitro 
than laboratory isolates that have been selected for efficient replication in transformed T 
cell lines (Daar et al., 1990). The concentrations of sCD4 required to neutralise primary 
isolates was 100- 1000-fold higher than that required to neutralise laboratory strains 
(Daar et al., 1990; Moore et al., 1991) This is probably due to the lower binding 
affinity of the primary isolates to sCD4 (Moore et al., 1991). Recent studies have 
shown that adaptation of two HIV-1 primary isolates to grow in transformed T cell lines 
also results in the viruses becoming more sensitive to neutralisation by sCD4 (Moore et 
al., 1993). It is important to note that progression to disease is believed to be associated 
with a gradual switch from a virus population that is in predominantly macrophage 
tropic to one which is T cell tropic (Schuitemaker et al., 1992). The observed 
phenotypic differences between macrophage and T cell topic viruses and their 
susceptibility to neutralisation by sCD4, has been attributed to sequence variation found 
in the V3 loop and does not include regions of gpl20 that are directly involved in 
binding to the CD4 binding site (Hwang et al., 1992; O’Brien et al., 1992).
1.10.2 Chemotherapeutic inhibitors of HIV reverse transcription
The current therapeutic compounds being tested for their inhibitory properties of
HIV replication fall into two categories. Firstly, the deoxynucleoside analogues, with
y
AZT (zidovudine, 3’-azido. 3’deo^thymidine), ddC (zalcitabine, 2’3’-dideoxycytidine) 
and ddl (didanosine,2’3’-dideoxyinosine) being the most well known, which inhibit the 
retroviral enzyme reverse transcriptase, and secondly, non-nucleoside inhibitors of 
reverse transcriptase (NNRTI) such as neviraprine and TIBO (tetra hydro-
49
Chapter 1
imadazo[4,5,l-l-jk][l,4]-bezodiazepin-2(lH)-one and thione) (reviewed by Richman,
1993). Initial studies on the efficacy of AZT, the only currently licensed drug against
HIV, concluded that treatment of HIV-infected individuals with this drug, prolonged the
disease-free interval in asymptomatic patients, improved the quality of life and delayed
death. However, these studies based their conclusions on data obtained from a trial that
was cut short in the first year (Volberding et a l ,  1990). This was due to the initial
findings that the patients who were receiving AZT showed | a lower mortality rate and a slower
d e c l i n e  in CD4 counts)believed to be an accurate marker for disease progression. The
results of the recently published Concorde trial (Aboulker and Swart, 1993), that
involved over 1700 asymptomatic patients, in which some were given AZT and the rest
were given a placebo until the onset of disease, showed no significant difference in
disease progression and eventual death in the patients from the two groups, even though
patients who were receiving AZT maintained higher levels of CD4 cells than those
taking the placebo drug. These findings have proved very disheartening for both AIDS
researchers and ultimately individuals infected with HIV and suggest caution in using 
as
the CD4 count^a reliable marker for the progression of AIDS in infected people 
(Maddox, 1993).
The failure of these drugs to effectively inhibit viral replication for extended 
probably
periods of time is^due to the emergence of mutants that show resistance to these 
compounds (Larder et al., 1989a, b, c; Nunberg et al., 1991; Richman et al., 1991).
Mutations in the RT of HIV-1 that account for the reduced susceptibility to drugs have 
been identified by sequencing isolates of resistant virus, and the contribution of 
identified mutations confirmed by using site-directed mutagenesis to place these 
mutations in an infectious plasmid containing a sensitive HIV-1 genome (reviewed by 
Richman, 1993). Mhori et al. (1993), have recently identified isolates that show 
resistance to AZT from patients that were never treated with the drug. These variants 
will be selected for rapidly on treatment with AZT. Chow et a l  (1993a), have proposed 
the concept of combination therapy, which implies that simultaneous multiple-inhibitor 
therapy against the HIV-1 reverse transcriptase would delay the emergence of multiply
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resistant virus strains. They also reported the emergence of a variant in the presence of 
multiple-inhibitors that was non-viable in human cells, concluding that the mutations 
that arose in that variant, in response to combination therapy, were not compatible with 
one another. Based on this finding they put forward a strategy to turn this evolutionary 
survival mechanism against the virus. They proposed that by selecting certain 
combinations of mutations for drug resistance, that it may be possible to force the virus 
into inviability. However, other studies have failed to confirm these results, 
demonstrating that the variant described by Chow et al. (1993a) was in fact resistant to 
combination therapy and exhibited growth kinetics similar to the wild type, indicating 
that drug resistant variants are likely to be selected eventually during combination 
therapy. (Emini et al., 1993; Larder et al., 1993). Chow et al. (1993b) have now 
revealed that other unintended mutations in reverse transcriptase could explain why 
viruses derived from these clones were not viable.
1.10.3 Other potential antiviral targets
In addition to the reverse transcriptase inhibitors, molecules or chemicals that 
could inhibit either the retroviral protease enzyme, essential for the generation of 
mature infectious virions or the retroviral regulatory protein Tat are being investigated 
(Reviewed by Crumpacker, 1992). Peptide analogue-based inhibitors that mimic the 
sites at which the protease enzyme acts could inhibit HIV-1 replication in infected cells 
by blocking proteolytic processing and virion maturation. A favourable feature of 
pro tease inhibitors is that they could lead to a decreased frequency of drug resistant 
mutants arising as the protease molecule recognises different stretches of amino acids 
during its normal function and therefore single amino acid substitutions may not have 
an effect on its ability to bind to peptide analogues. Current peptide based protease 
inhibitors have low solubility and are readily degraded in human serum (reviewed by 
Crumpacker, 1992).
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Inhibition of the Tat protein would effectively render pro viral DNA unable to 
produce infectious virus or efficient quantities of viral proteins. A recent study, based 
on the knowledge that Tat exerts its effects through the TAR sequence present 
downstream of the HIV-1 LTR (Feng and Holland, 1988) has shown that the 
introduction of plasmids expressing copies of TAR in transient transfection assays in a 
human T cell line, when challenged with HIV-1 or SIV, inhibited viral replication by as 
much as 99% (Lisziewicz et a l,  1993).
The demonstration of the efficacy of a candidate vaccine, whether for therapeutic 
or prophylactic purposes as discussed in section 1.9 and 1.10, must await the results of 
phase 1 studies designed to determine the safety, phase II studies which determine 
immunogenicity, and phase three trials which determine the efficacy in protecting 
against infection or the onset of disease. This requires the monitoring of a large 
volunteer group over an extended period of time. Therefore despite the extensive 
studies aimed at developing an effective vaccine, licensing for general use is probably 
still many years away.
1.11 Structure of branched or multiply antigenic peptides 
(MAPs)
Branched or multiply antigenic peptides (MAPs) were originally described by 
Tam (1988) and their antigenic properties together with the initial observations which 
suggested their potential for serodiagnosis are discussed in detail in results section 1. 
The octameric structure of these peptides is achieved by the sequential addition of three 
bivalent lysine residues onto an alanine core attached to the resin on which the peptide 
is to be synthesised. This branched configuration, shown in Figure 1.8, allows the 
sequential addition of amino acids by solid-phase peptide synthesis onto eight free 
amino groups rather than one as with the monomeric peptides.
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1.12 Aims of the work presented in this thesis
The aims of the work presented in this thesis are three fold. The initial studies 
aimed to optimise branched peptides for use as serodiagnostic reagents based on the 
observation in our laboratory that peptides made with this configuration could detect 
antibodies at lower concentrations than could monomeric peptides (Owsianka and 
Marsden-personal communication). The work performed, aimed to examine the nature 
of this increased sensitivity and to optimise the form of branched peptide that would 
give maximal reactivity with specific antibodies. In addition to this I sought to compare 
the reactivity of these branched peptides corresponding to a known epitope with that of 
the native protein from which the epitope is derived. The information obtained from 
this work was then applied in two separate studies that involved the synthesis of 
branched peptides derived from the V3 region of HIV-1 gpl20. The first of these 
studies aimed to determine whether antibodies against the entire V3 region of HIV-1 
gpl20 correlated with protection against matemal-foetal transmission of HIV-1, as had 
been previously suggested on the basis of limited data (Broliden et al., 1989; Rossi et 
a l,  1989; Devash et al., 1990). The second study aimed to test the hypothesis that the 
sequence variants that arose in the V3 region of HIV-1 gpl20 during the course of 
infection in a patient of the Edinburgh haemophiliac cohort represented antibody escape 
mutants. This work involved the synthesis of all the peptides corresponding to 
sequence variants that emerged in patient 82 over a seven year period. These peptides 
were tested for their reactivity against sequential sera taken from patient 82. The 
finding of these studies are of considerable interest in terms of the use of peptide based 
assays for serodiagnosis and in the design of vaccines against HIV-infection.
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Figure 1.8 Schematic representation of a branched or multiple antigenic peptide 
(MAP) (Tam, 1988)
Chapter 2 MATERIALS
2.1 Oligopeptide synthesis
Dimethylformamide, t-amyl alchohol, Rathburn Chemicals Ltd,
piperidine, triflouroacetic acid, acetic acid Walkerbum, Scotland, UK.
diethyl ether.
Anisole, thioanisole, dichloromethane, EDTA, Aldrich Chemical Company,
phenol, triisopropysilane. Gillingham, Dorset, UK.
Fmoc amino acids Novabiochem (UK) Ltd,
1-hydroxybenzotriazole (HOBt), Nottingham, UK.
Fmoc Ultrosyn C resin
Fmoc8 K7A resin Peptide and Protein
Research,
Exeter, Devon, UK.
2.2 High pressure liquid chromatography (HPLC)
HPLC grade methanol and acetonitrile Rathburn Chemicals Ltd,
Walkerbum, Scotland, UK.
HPLC reverse phase columns: 
Dynamax 300A C8 analytical column 
(4.6mm internal diameter x 250mm) 
catalogue number 83-303-C.
Anachem, Luton,
Bedfordshire
UK.
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Vydak-FB1520 preparative column 
(20mm internal diameter x 50cm)
HiChrom Ltd, Reading 
Berkshire, UK.
catalogue number C-8-83-323-C
2.3 Fast performance liquid chromatography (FPLC)
Double stranded deoxyribonucleic acid (DNA) cellulose Sigma Chemical Company,
Poole, Dorset, UK.
2.4 Enzyme-linked immunosorbant assay (ELISA)
Immunlon-2 flat bottom UV irradiated plates Dynatech Laboratories,
2,2’Azino-bis (3-ethylbenz-thiazoline-6-sulphonic acid), Poole, Dorset, UK. 
(ABTS), HRP conjugated goat-antimouse IgG, 30% 
hydrogen peroxide solution
Billingshurst, West Sussex,
UK.
HRP conjugated-protein A, Sigma Chemical Company,
HRP conjugated goat-antihuman IgG Scottish Antibody
Production Unit,
(SAPU) Carluke, Lanarkshire
Scotland
2.5 Tissue culture
TC-100 medium, penicillin/ streptomycin, 
neomycin, foetal calf serum
Gibco- Biocult, Paisley, 
Scotland, UK.
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Acrylamide, BDH Laboratory Supplies,
N,N’-methylene bisacrylamide Poole, England,UK.
Ammonium persulphate, BioRad Laboratories Ltd,
N,N,N*N- tetramethylethylenediamine Richmond, California, USA.
TEMED
Rainbow markers (Mwt range 2,350-46,000) Amersham International
PLC, Amersham, UK.
2.7 Micellaneous materials
Gpl20 protein from insect cells infected Kindly provided by the
with recombinant baculovirus MRC AIDS Reagent Project.
Peptide 284: (GCSGKLICTTAVPWNAS G5)sK7A Made in house by Dr Susan
Graham.
Peptide 216: VSHGDPEDLDGAARAGE Made in house by Dr Ania
Owsianka.
Monoclonal antibody Z1F11 Made in house by Dr Anne
Cross from hybridoma 
cells provided by H. Ludwig 
(Schenk etal., 1988)
HIV-1 Western blotting diagnostic strips DuPont (USA)
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2.8 Human sera
Control HIV-1 negative sera were provided by Dr E. Follet, Ruchill Hospital, Glasgow 
and Dr Karin Froebel, HIV Immunology Unit, Edinburgh. These sera were defined 
negative by Western blot analysis.
Maternal Sera described in section 2 of the results were provided by Dr Jackie Mok and 
Dr Shiela Burns of the City Hospital, Edinburgh. These sera were defined positive by 
Western blot analysis.
Patient 82 sera described in section 3 of the results were provided by Dr Andrew Leigh 
Brown, Institute of Cell and Population Biology, Edinburgh. These sera were defined 
as positive firstly, by Western blot analysis and subsequently, by detection of viral 
RNA using PCR.
2.9 Commonly used solutions 
Phosphate buffered saline:
170mM NaCl, 3.4mM KC1, lOmM Na2HPC>4 , pH7.2 supplemented with 6 .8mM CaCl2 
and 4.9mM MgCl2 .
Tris buffered saline:
20mM Tris, pH 7.5, 500mM NaCl.
Electrophoresis buffer:
52mM Tris, 53mM glycine, 0.1% SDS.
Denaturation buffer:
50mM Tris , pH6.7, 2% SDS, 700mM 2-mercaptoethanol, 10% glycerol, bromophenol 
blue to colour.
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Protein Stain:
0.2% coomassie brilliant blue R250 in methanol:water:acetic acid (50:50:7).
Destain:
5% methanol ,7% acetic acid in water.
PBS Tween 20 wash buffer x 10
1.45 MNaCl, 0.075M Na2HPC>4 , 0.028M NaH2PC>4 +0.5% glycerol, pH adjusted to 7.2 
with NaOH or HC1.
Blocking buffer:
lxPBS + 2% bovine serum albumin.
Antibody dilution buffer:
lxPBS + 0.5% bovine serum albumin.
Citrate phosphate buffer:
0.1M Na2HPC>4 , 0.08M citric acid, pH adjusted to 4.0 using citric acid or NaOH. 
Extraction buffer:
20mM hepes,pH 7.9, 0.5mM DTT, 0.5mM MgCl2 , lOmM NaHS03 + protease 
inhibitors 0.5mM PMSF, l.OuM pepstatin
High salt extraction buffer:
As above + 3.4M NaCl.
Dialysis buffer:
20mM hepes, pH7.5, 0.5mM DTT, 0.5mM EDTA, 10% glycerol, 50mM NaCl 
+protease inhibitors, 0.5mM PMSF, l.OuM pepstatin.
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Buffer A:
20mM hepes, pH 7.6, 0.5mM DTT, 0.5mM EDTA, 10 % glycerol, 50mM NaCL + 
protease inhibitors, 0.5mM PMSF, l.OuM pepstatin
Buffer B:
As A + 0.7 mM NaCl.
Buffer C:
As A + 1.0 M NaCl.
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Chapter 3 METHODS
3.1 Oligopeptides
3.1.1 Oligopeptide synthesis
All the peptides used in the following studies were made by continuous flow 
Fmoc chemistry on Kieselguhr polyamide resin (Atherton and Sheppard 1989), using a 
Novabiochem peptide synthesiser. This involves sequential addition of Fmoc protected 
amino acids. The Fmoc group was removed at the end of every cycle using 20% 
piperidine in DMF for 15 to 20 minutes. DHBT or PFP esters in conjunction with 
HOBt were used for coupling most amino acids except where stated in the text. For the 
latter stages of the work described in this thesis PyBOP amino acids became 
commercially available. This form of amino acids is highly reactive and permits a 
reduction of standard coupling times from 4 hours to 1.5 hours and was therefore used 
in preference to the DHBT and PFP esters. Side chain protecting groups were as 
follows: trityl (trt), side chains of asparagine, cysteine, glutamine and histidine; 
butlyoxycarbonyl (Boc), side chains of tryptophan and lysine; tertiary-butyl (t-Bu), side 
chains of aspartic acid, glutamic acid, serine and tyrosine. Two forms of arginine were 
used that differed in side chain p ro tecting  groups. A rg(m tr) 
(methoxytrimethylbenzenesulphonyl) was used for synthesis performed using DHBT 
and PFP esters and Arg(pmc) (pentamethylchromanesulphonyl) was used in synthesis 
performed using PyBOP chemistry.
3.1.1.1 Synthesis of octameric peptides: These peptides were synthesised on a 
branched polylysine core allowing the formation of 8 chains of homologous peptide 
(Tam, 1988).
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3.1.1.2 Synthesis of monomeric peptides: These peptides were synthesised on 
Ultrosyn C which is specifically designed to make peptide carboxy amides.
In all cases, the scale of synthesis was approximately 0.1 mmol of free Fmoc 
groups at a concentration of 0.1 mmol per gram of functionalised resin for monomeric 
peptides and 0.02  mmol per gram of functionalised resin for branched peptides. 
Sometimes up to three peptides were synthesised at the same time using three columns 
of the synthesiser in series. In these cases the amount of resin was adjusted to keep the 
total scale at 0.1 mmol. Prepacked vials containing 0.5 mmol of Fmoc amino acid esters 
were used giving a 5-fold excess of amino acid during coupling reactions.
3.1.2 Cleavage and deprotection
After synthesis, the peptide resin was removed from the column and transferred 
into a sintered glass funnel and washed with the following solvents: DMF, t-amyl 
alcohol, acetic acid, t-amyl alcohol and finally diethyl ether. The resin was then 
transferred to a 100ml round bottomed flask and dried in an evacuated desiccator. At 
this point half the resin was stored at -20 °C in case of an unsuccessful cleavage.
For peptides that did not contain Arg(Mtr), Cys(Trt), Met or Trp a 95% aqueous 
solution of TFA was used, while for peptides containing any of the above amino acids, 
appropriate scavengers were used as summarised in Table 3.1. Peptides were cleaved 
from the resin and side chain protecting groups removed using 25 ml of the cleavage 
solution. After the reaction time, the mixture was poured into a sintered glass funnel 
and allowed to drip through into a 100 ml round bottomed flask. Any residual peptide 
on the resin was washed through with approximately 5 ml of TFA. The filtrate was 
reduced on a rotary evaporator to a volume of 1-2 ml and the peptide precipitated out of 
solution by the addition of 25ml of diethyl ether. The precipitate was centrifuged, the 
ether removed and washed thoroughly a further twice with 25ml of ether. The peptide 
was then dissolved in 25ml of milli-Q water and after removal of any residual ether by 
rotary evaporation, shell frozen and lyophilised overnight.
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Table 3.1 PEPTIDE CLEAVAGE CONDITIONS
Arg Cys Met Trp TFA (%) Scavengers (%) T im e(hrs)
- - - - 95 Water (5) 1-1.5
+ - - - 95 Phenol (5) >6
- + - - 95 EDT (5) 1-1.5
- - + - 95 EMS (5) 1-1.5
- - - + 1-1.5
- + - + 94 Phenol (5) EDT (1) 1-1.5
+ + - - >6
+ + + - 93 Phenol(3) >6
+ - + - EDT (1) EMS (3)
+ - + + TMSB (12.5)
+ + - + 71 EDT (4.5) 0.5
+ + + + m-creosol (1)
Thioanisole
Scavenger abbreviations
EDT Ethanedithiol
EMS Ethylmethylsulphide
TMSB Trimethylsilylbromide
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Arg(pmc) was used in place of Arg(mtr) in PyBOP amino acids as this side chain 
protecting group can be removed in less than two hours rather than overnight as with 
Arg(mtr), As a simplification to peptide cleavage Novabiochem recommended a single 
cleavage mixture for all peptides made with the PyBOP amino acids. This mixture is 
termed reagent K and contains 81.5% TFA, 5% phenol, 5% thioanisole, 5% water, 
2.5% EDT and 1% TIPS. Peptides were cleaved in this reagent for 1.5 hours and are 
then treated as above.
3.1.3 Analysis of peptides
3.1.3.1 Mass spectrometry
The molecular weight of the monomeric peptides was determined by M-Scan Ltd, 
Ascot, England, using the fast atom bombardment (FAB-mass) ionisation technique 
(B arbers al, 1981).
3.1.3.2 Amino acid analysis
Amino acid analysis was carried out on the branched peptides by Cambridge 
Research Biochemicals Ltd, Cheshire England, UK. This provides the molar ratio of 
each amino acid contained in the peptide.
3.1.3.3 Reverse phase high pressure liquid chromatography (HPLC).
The purity of each peptide was determined by reverse phase HPLC monitored at 
225nm on a Beckman System Gold HPLC using a dynamax 300 A C8 analytical 
column (4.6mm internal diameter x 250mm, catalogue number 83-303-C). A gradient 
of 0-95% acetonitrile (plus 0.05% TFA) in water (plus 0.1% TFA) run over 20 minutes 
at a flow rate of 0.5ml/min.
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3.1.4 Purification of peptides
Peptides were purified by reverse phase HPLC on a Beckman System Gold 
system using a Vydak-FB1520 preparative column (20mm internal diameter x 50cm, 
catalogue number C-8-83-323-C) and a gradient of 0-95 % acetonitrile (plus 0.05% 
TFA) in water (plus 0.1% TFA), run over 20 minutes at a flow rate of 10 ml/min. 
Fractions were analysed by reverse phase HPLC as above, peak fractions were pooled, 
lyophilised and reanalysed by reverse phase HPLC. The purified peptide, depending on 
whether it was in the monomeric or branched form was sent for either FAB-mass 
spectrometry (M-Scan Ltd, Ascot) or amino acid analysis (CRB, Cheshire) 
respectively.
3.1.5 Storage of peptides
Peptides were stored at -20 °C in a dry sealed universal. When required, the 
peptides were warmed to room temperature prior to opening to prevent any moisture 
damaging the peptide.
3.1.6 Dissolution of peptides
Most peptides were dissolved in Milli-Q water, for analysis and purification and 
most dissolved in PBS for use in assays. Those peptides insoluble in water were treated 
as follows: acidic peptides were suspended in water and bubbled with ammonia vapour, 
basic peptides were dissolved in a small amount of either 10% formic acid or 33% 
acetic acid and made up to the required volume with water or PBS.
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3.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)
Vertical polyacrylamide gels with a gradient either 5-12% or 10-20% acrylamide 
were used to analyse purified peptides and the UL42 protein Stocks of 30% and 60% 
acrylamide were prepared in water with a 20:1 ratio of acrylamide to the crosslinking 
agent, N,N'-methylene bisacrylamide. After filtering through Watman N°1 filter paper 
these solutions were used to prepare the appropriate gel concentration in a buffer of 
final concentration 375mM Tris.HCl, pH8.9, 0.1% SDS. Glycerol (final concentration 
15 %) was added to the 60% acrylamide solution to stabilise the gradient. The gel 
solutions were polymerised with a final concentration of 3.65mM ammonium 
persulphate and 2.75mM TEMED. Following polymerisation a stacking gel consisting 
of 5% acrylamide in 122mM Tris.HCl, pH 6.7, 0.1% SDS w'as added and a teflon comb 
inserted to form the sample wells.
The peptide or protein samples to be run were boiled for 3 minutes in denaturing 
buffer, final concentration 50mM Tris.HCl, pH 6.7, 2% SDS, 700mM 2- 
mercaptoethanol and 10% glycerol with sufficient bromophenol blue to see the dye 
front. Electrophoresis was carried out in a buffer containing 52mM Tris, 53mM 
glycine and 0.1% SDS at 12 mA overnight or 60 mA for 3-4 hours.
3.2.1 Coomassie brilliant blue staining
Following electrophoresis gels were stained for 30 minutes in methanol:acetic 
acid:water (50:7:50) containing 2% Coomassie brilliant blue R250. The gels were then 
destained for at least an hour in 5% methanol and 7% acetic acid.
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3.3 Human sera
3.3.1 Heat inactivation of human sera
To comply with Institute safety regulations, all HIV-1 positive sera were heat 
treated at 56°C for one hour. This was performed before sera were brought into the 
Institute. : HIV-1 negative sera
were heated in the same way.
3.3.2 Storage of human sera
All human sera were stored at -20°C in small sealed aliquots. When required, the 
sera were allowed to warm to room temperature before being made up to the required 
dilution in 0.5% BSA in PBS. A fresh aliquot of serum was used in each experiment.
3.3.3 Confirmation of HIV-1 negative control serum by Western blot
All human HIV-1 negative control sera used in the studies of the human sera 
analysis described in this thesis were confirmed to be negative for antibodies to HIV-1 
by Western blot analysis using commercially available strips of nitrocellulose 
membrane with the HIV-1 proteins already attached. Free protein binding sites on the 
membrane were blocked with PBS containing 2% for an hour at 37 °C. The sera to be 
tested were diluted 1:50 in PBS containing 0.5% BSA. They were then incubated with 
individual strips at room temperature for 1 hour. The strips were then washed 5 times 
(5 minutes each wash) in PBS-Tween 20 wash buffer and reacted with an 1:1000 
dilution of horseradish peroxidase conjugated-protein A in 0.5% BSA in PBS for 1 hour 
at room temperature and washed a further 5 times in PBS-Tween 20. 60mg of colour 
development reagent (DuPont) were dissolved in 20ml of ice cold methanol and added 
to 100ml PBS + 60ul of 30% hydrogen peroxide solution immediately before use and
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the resulting solution incubated with the strips for no longer than 40 minutes. None of 
the negative control sera described in this thesis reacted to any of the HIV-1 proteins 
present on the strips. An HIV-1 known positive sera was tested as a control and 
showed reactivity against the proteins bound to the strips.
3.4 Enzyme linked immunosorbant assay (ELISA)
Peptides were dissolved as described above (section 3.1.6) at the desired 
concentration (see results) and allowed to adsorb to microtitre ELISA plates overnight 
at 37°C. The plates were then washed five times in PBS-Tween 20 solution and 
blocked with 2% BSA in PBS for 1 hour at 37°C. Antibodies or human semtfwere 
diluted in PBS containing 0.5% BSA and 50ul of the appropriate dilution added to the 
wells. After incubation at room temperature for 1 hour, the plates were then washed 
five times in PBS-Tween 20 solution. Horseradish peroxidase conjugated-goat 
antimouse or antihuman IgG or horseradish peroxidase conjugated-protein A (see 
results) was diluted 1:1000 in PBS containing 0.5% BSA and 50ul added to each well. 
After incubation for 1 hour at room temperature the plates were then washed a further 
ten times in PBS-Tween 20 solution and reacted with lOOul of a 50mg/ml solution of 
enzyme substrate 2,2,’Azino-bis (3-ethylbenzthiazoline-6-sulphonic acid) in citrate 
phosphate buffer (0.1M N a2H P04, 0.08M citric acid, pH4), containing 0.01% 
hydrogen peroxide. After 15-30 minutes of colour development the absorbance at 
405nm was read on a Multiskan plate reader (Titertek; ICN Biomedicals, High 
Wycombe, UK). In most cases the results are means of duplicate determinations. The 
background absorbance for each serum dilution was determined by
incubating the sera on a well with no peptide Where stated this background value was 
subtracted from the appropriate readings.
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3.5 Statistical analysis
Statistical analysis was performed on the data produced in the maternal antibody 
study (results section 2) by Dr Karin Froebel (HIV Immunology unit, Edinburgh). 
Where the data from two groups does not show normal distribution, a non-parametric 
test must be used. The test employed was the Mann Whitney U-test, described by 
Goldstein (1965). The anti-V3 and anti-V3/gp41 titres collected from the two groups 
are placed in rank order and the sum of the rank order values calculated for each group. 
From this, the median value from each group is obtained. The null hypothesis states, 
"the difference in the median values for each of the two groups is no greater than can be 
reasonably explained by random sampling fluctuations". In other words this test 
calculates the probability of two sets of data points coming from the same or different 
populations.
3.6 Purification of HSV-1 UL42
3.6.1 Growth of insect cells
Spodoptera frugiperda (sf) insect cells were grown in 800 ml flasks in TC-100 
medium containing 5% foetal calf serum, 1% penicillin/streptomycin and 0.5% 
neomycin at 28°C until confluent. The cells were split 1:4 by gently knocking them off 
the flask bottom and pipetting them into the desired number of flasks. 50mls of fresh 
medium were then added and the cells placed at 28°C until confluent again. This was 
repeated until a minimum of 10 flasks of confluent cells were obtained.
3.6.2 Infection of cells with recombinant baculovirus
The recombinant baculovirus expressing the HSV-1 UL42 gene was supplied by 
Dr Nigel D Stow. (Stow 1992). The medium was poured off the cells and 1ml of virus
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suspension added to each of the 10 flasks to give a m.o.i of approximately 5 p.f.u./celL 
Virus was allowed to adsorb to the cells for 1 hour at room temperature. The cells were 
then overlaid with 20ml of fresh TC-100 medium containing 5% foetal calf serum 1% 
penicillin/streptomycin and 0.5% neomycin and incubated at 28 °C for 50 hours (a 
time found by Mrs Mary Murphy to be optimal for the yield of UL42 protein). Sterility 
checks on blood agar plates were carried out on cells after each passage and on the 
virus stock used for infection.
3.6.3 Harvesting the UL42 protein
Infected cells were agitated off the flasks and transferred to 50ml conical tubes. 
The flasks were then rinsed with cold TBS and the remaining cells collected with a 
pipette. * The cells were pelleted by centrifugation at l,000rpm for 5 minutes and the 
supernatant was removed under low vacuum. Fresh TBS was added to the tubes and 
the cells were resuspended by pipetting up and down.* The process *, * was repeated a 
further three times. If a virus stock was to be made, the supernatant from the first 
centrifugation step was aliquoted and stored at -70°C. After the final centrifugation the 
cells were resuspended in 10ml of extraction buffer containing 20mM HEPES pH7.9, 
0.5mM MgCl2 , 10mM NaHSC>3 . 0.5mM PMSF, luM pepstatin and 5uM bestatin and 
allowed to swell on ice for 10 minutes. The cells were then lysed on ice using a dounce 
homogeniser and the nuclei pelleted by low speed centrifugation (5 minutes at 
4,000rpm). The supernatant was discarded and the nuclei were lysed by the addition of 
5ml of high salt extraction buffer (as above containing 3.4mM NaCL) and incubation 
on ice for 30 minutes. The nuclear extract was obtained by centrifugation at 40,000rpm 
for 1 hour. The supernatant was collected, and either stored at -70°C or further 
processed as following.
The nuclear extract was then dialysed extensively overnight in a buffer containing 
20mM HEPES, 0.5 mM DTT, 0.5mM EDTA, 10% glycerol, 50mM NaCl plus the 
protease inhibitors, 0.05mM PMSF, luM pepstatin and 5uM bestatin. The extract was
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aliquoted, stored at -70^C and one aliquot was thawed then analysed on a 5-12% SDS 
polyacrylamide gradient gel.
3.6.4 Preparation of the DNA cellulose column
The column was prepared from 4g of double stranded DNA cellulose (Sigma 
Chemicals Ltd) which was first washed three times in PBS and twice in buffer A in a 
sintered glass funnel. The DNA cellulose slurry (15ml) was poured into a 1.5cm 
diameter column.
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Chapter 4 RESULTS: Section 1
Optimisation of branched peptides for use as serodiagnostic reagents.
Branched or multiply antigenic peptides (MAP's) were originally developed by 
Tam (1988). Following immunisation, animals were found to have higher titres of 
antipeptide and antiprotein antibodies than sera obtained using equivalent monomeric 
peptides covalently linked to a carrier protein (Tam, 1988; Posnett et al., 1988; McLean 
et a l, 1991; Wang et a l, 1991). Tam and Zavala (1989) observed that antibodies could 
be detected by lower amounts of branched peptides than monomeric peptides. Whilst 
titrating sera from animals immunised with branched or monomeric peptides it was 
observed that branched peptides could detect lower amounts of antibodies than could 
monomeric peptides (Owsianka and Marsden-personal communication). Work 
described in this chapter was designed to further characterise the observed increased 
sensitivity of branched peptides, to investigate the basis for it and to optimise branched 
peptides for use as serodiagnostic reagents. It was considered that the increased 
sensitivity might be due in part to bivalent binding between the two arms of the 
antibody and epitopes on two arms of the branched peptide. Such bivalent binding 
would give a considerable increase in stability compared to the monovalent binding of 
the antibody to a monomeric peptide. Such a model would predict that if the epitope 
contained within the peptide lies too close to the polylysine core then the paratopes on 
the two arms of the reactive antibody may not be able to contact two epitopes 
simultaneously. A series of experiments were therefore performed to test the effect of 
varying the distance between the epitope and the core by introducing glycine spacers. 
The sensitivity of branched peptides was also compared with that of the of native 
protein for detection of antibodies. Two systems were studied. The first, the HSV-1 
UL42 protein and reactive monoclonal antibody Z1F11, was chosen as the reagents 
were either readily available or could be readily generated
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Gene UL42 of HSV-1 is one of seven (UL5, UL8 , UL9, UL29, UL30, UL42 and 
UL52) essential for origin dependent viral DNA synthesis (Wu et al., 1988) The UL42 
gene product is necessary for viral growth and DNA synthesis (Marchetti et al., 1988; 
Johnson et al., 1991). It physically associates with Pol to form a heterodimer (Gallo et 
al., 1988; Crute and Lehman, 1989; Gottlieb et al., 1990) and functions as an accessory 
protein to increase the rate of incorporation of deoxyribonucleoside triphosphates into 
activated DNA (Gallo et al., 1989) and to increase Pol processivity on a defined 
template primer (Gottlieb etal., 1990); Hernandez etal., 1990).
The second involved a branched peptide derived from the third hypervariable 
region (V3) of the HIV-1 gpl20 protein. The peptide sequence shown in Table 4.1 
(peptide 306) j  is similar to the consensus sequence of the MN strain of the virus, which 
is representative of the population of HIV-1 found infecting individuals in both North 
America and Europe and was the subject of detailed studies described later in this 
thesis.
4.1 HSV-1 UL42 protein
The effect of varying the distance between the epitope and the core on the
was tested
reactivity of branched peptide with detecting antibody using as a model system 
monoclonal antibody Z1F11 (Schenk et al., 1988) previously shown to recognise the 
sequential epitope GDPEDLD on HSV-1 UL42 protein (Murphy et al., 1989). A 
series of peptides were synthesised in which different numbers of glycine residues were 
added to the lysine core followed by the sequence GDPEDLD on each of the branches. 
These peptides can be represented by the general formula (GDPEDLDGn)s K7 A and 
are shown in Table 4.1 where the number of glycine spacers n = 0,1,2,4,5,7,10,15 and 
20.
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Chapter 4
4.1.1 Amount of peptide required to detect MAb Z1F11
In the first experiment shown in Figure 4.1, the peptides were tested in ELISA 
assays at concentrations ranging from lOOug down to lOOfg for reactivity with Z1F11 
(diluted 1:2000). The controls used included: monoclonal antibody HCMV-3, peptide 
171 (Table 4.1) in the monomeric (A) and branched (C) forms and monomeric peptide 
216 (VSHGDPEDLDGAARAGE) which corresponds to amino acids 357-373 of the 
UL42 protein (McGeoch et al, 1988a, b) and contains the Z1F11-reactive epitope. The 
figure shows that all branched peptides containing the sequence GDPEDLD reacted 
more strongly with Z1F11 than did the monomeric peptide 216. However, there was a 
marked difference between the branched peptide with no glycine spacer (Go), which 
was only about ten fold more reactive than the monomeric peptide, and the branched 
peptide with one glycine spacer (Gi): at lOOug peptide per well G i gave twice the 
absorbance produced by Go, while lO^-fold more Go than G i was needed to produce 
an absorbance of 0.5 units. Additional glycine residues progressively increased the 
absorbance for amounts of peptide above 10‘^ug per well although peptides G5 and G7 
were most sensitive at low concentrations. The controls behaved as expected: firstly, 
the non-related antibody HCMV-3 did not react with any peptide at any concentration 
(only the data from G 10 is plotted); secondly, Z1F11 did not react with unrelated 171A 
(monomeric) and 171C (branched) peptides; and thirdly, in the absence of peptide, 
Z1F11 was not reactive.
4.1.2 Sensitivity of detection of MAb Z1F11
In the experiments shown in Figures 4.2A, B and C, the effect of glycine spacer 
length on the sensitivity with which the branched Go, G5 and G 10 peptides could detect 
monoclonal antibody Z1F11 was examined. Three different amounts of peptide were 
tested (lOOug, lug and 0.01 ug) against doubling dilutions of Z1F11 ranging from 
1:250 to 1:64,000. Because the controls included in Figure 4.1 behaved as expected
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Figure 4.1 Effect of spacer glycines on recognition of monoclonal antibody Z1F11 at a 
dilution of 1:2000, by peptides containing the epitope GDPEDLD in an ELISA. 
Peptides G0-G20  which are labelled on the right hand side of the figure, represent 
branched peptides containing 0-20  spacer glycines preceding the reactive epitope. 
Peptide 216, VSHGDPEDLDGAARAGE, is monomeric and represents the natural 
sequence of HSV-1 protein UL42 and contains the Z1F11-reactive epitope. Control 
peptides 171A (monomeric) and 171C (branched) (Table 4.1) do not react with Z1F11. 
HCMV3 is an unrelated antibody and was unreactive with all of the peptides. Only the 
data for G 10 is plotted.
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they were not retested in this experiment. At all concentrations tested) the G5 and G10 forms 
of the branched peptide were significantly more sensitive than the monomeric peptide 
216 (Fig 4.2). In addition, the G10 peptide was more sensitive in detecting Z1F11 than 
the G5 peptide, which in turn was more sensitive than the GO peptide as would be 
expected according to the data shown in Figure 4.1. lOOug of peptide/well is however 
an amount considerably above that normally used for coating microtitre plates with 
proteinaceous material (Fig 4.2A). Therefore some the observed binding of Z1F11 to 
the peptides at low antibody concentrations could be due to a non specific interaction of 
the antibody with such high amounts of peptide. At the lower concentrations of peptide 
(Figures 4.2B and C) the conditions are more stringent and the observed reactivity of 
the peptides with Z1F11 should not represent any non-specific interaction . This 
experiment was extended to measure the sensitivity of all the branched peptides, Go- 
G20 at a concentration of lug peptide per well with doubling dilutions of Z1F11 from 
1:250 to 1:64,000. The results are shown in Figure 4.3. All the branched
peptides showed greater sensitivity than the monomeric peptide. The effect was 
particularly marked with four or more glycine spacer residues. When diluted 64,000- 
fold, Z1F11 yielded an absorbance of 0.5 with G4 peptide whereas to produce the same 
absorbance with peptide Go the antibody could only be diluted 250-fold. Additional 
glycine residues did not significantly increase the reactivity of the branched peptide. It 
was concluded from these results that a spacer of 4 or more glycine residues optimally 
increases the sensitivity for detection of antibody Z1F11 by 256-fold. The observed 
reactivity of the GO peptide is considerably higher than that obtained in the previous 
experiment at the same peptide concentration, shown in Figure 4.2B. It might be that 
around lug/well is close to some critical concentration of the GO peptide required for 
detection of Z1F11, which was sufficient for some reactivity shown if Figure 4.3 but 
not in the experiment shown in Figure 4.2B.
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Figure 4.2 Effect of spacer glycines on the sensitivity of detection of monoclonal 
antibody Z1F11 by Go (■), G5 (▲) and G 10 ( • )  branched peptides containing the 
epitope GDPEDLD at lOOug (A), lug (B) and O.Olug (C) per well, tested by ELISA. 
Z1F11 is titrated in a series of doubling dilutions (1:250-1:64,000). Peptide 216 (O), 
VSHGDPEDLDGAARAGE is monomeric and represents part of the natural sequence of 
HSV-1 protein UL42 and contains the Z1 FI 1-reactive epitope.
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Figure 4.3 Effect of spacer glycines on the sensitivity of detection of monoclonal 
antibody Z1F11 branched peptides containing the epitope GDPEDLD used at lug per 
well in an ELISA. Peptides G0-G20 which are labelled on the right hand side of the 
figure, represent branched peptides containing 0-20 spacer glycines preceding the 
reactive epitope. Peptide 216, VSHGDPEDLDGAARAGE, is monomeric and 
represents pan of the natural sequence of the HSV-1 protein UL42 and contains the 
ZlFli-reactive epitope. Z1F11 is titrated in a series of doubling dilutions from 1:250- 
1:6400. The final point on each curve is a measure of the reactivity of the peptide 
incubated with 0.5% BSA in PBS alone to give a “no antibody'’ control. This showed 
no reactivity as expected.
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4.1.3 Purification of the UL42
To compare the reactivity of the branched peptides with that of the native UL42 
protein, the protein was purified from a nuclear extract of 10 flasks of confluent insect 
cells infected with recombinant baculovirus expressing UL42 (Stow et al., 1992) 
according to the protocol described in section 6 of the methods. Figure 4.4 shows the 
partially purified extract (track 6 ) and a previously purified UL42 preparation used as a 
marker for the protein. This partially purified extract was run through a double 
stranded DNA cellulose column and the resulting fractions collected and run on a 10- 
15% gradient SDS polyacrylamide gel and stained with Coomassie brilliant blue. 
Unfortunately however, the protein had degraded and was not apparent on the gel. Due 
to time limitations a previously quantified preparation of the UL42 protein purified by 
Mrs Mary Murphy was used in the following experiments.
4.1.4 Relative sensitivity of the branched G5 peptide and native UL42 
protein
In the experiment shown in Figure 4.5, the reactivity of the branched peptide with 
5 glycine spacers and the native UL42 protein with monoclonal antibody Z1F11 was 
compared in ELISA. The peptide and protein were coated to microtitre plates at a 
concentration of 25ng per well and the reactivity of both the peptide and protein tested 
against doubling dilutions of Z1F11 ranging from 1:500 to 1:512,000. A negative 
control peptide, 306 (Table 4.1), derived from the V3 region of HIV-1 gpl20 was also 
tested in the ELISA assay with Z1F11. The data show that at antibody dilutions greater 
than 1:16,000 the reactivity of the peptide and protein are indistinguishable (Figure 
4.5). At the higher concentrations of Z1F11 the native protein shows slightly greater 
sensitivity to Z1F11 than the peptide, giving an absorbance reading at 405nm 
approximately 0.05 units higher than the peptide. These finding suggest the use of 
branched peptides as serodiagnostic reagents as the relative cost and time to produce the
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Figure 4.4 Coomassie blue stained 10-15% SDS polyacrylamide gradient gel of 
baculovirus expressed, HSV-1 gene UL42 protein: Track A shows a previously purified 
and quantified extract provided by Mrs Murphy. Track B shows the partially purified 
extract prior to purification on a double stranded DNA cellulose column.
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Figure 4.5 Comparison of the sensitivity of the branched G5 ( • )  peptide containing 
the epitope GDPEDLD and the baculovirus expressed and purified UL42 protein (■) 
used at 25ng per well, tested in an ELISA. Monoclonal antibody Z1F11 is titrated in 
a series of doubling dilutions (1:500-1:512,000). Control V3 peptide (306, Table
4.1) (A) shows no reactivity with monoclonal antibody Z1F11. The final point on 
each curve is a measure of the reactivity of the peptide incubated with 0.5% BSA in 
PBS alone to give a “no antibody” control. This showed no reactivity as expected.
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peptide is far less than that involved in making preparations of recombinant protein. In 
addition the branched peptides should have greater specificity (fewer false-positives) 
than native protein.
4.2 HIV-1 gpl20 peptide
4.2.1 Oligopeptides
A peptide spanning the entire third hypervariable region (V3) of the HIV-Im N 
strain between amino acids 297-330 was synthesised in branched (Table 4.1, peptide 
306) and monomeric (peptide 347) forms. Both peptides were used in the study 
presented in section 2 of the results. In this case a four glycine spacer was not inserted 
between the peptide and the lysine core, as the region reactive with HIV-1 infected sera 
is located in the middle third of the peptide (results, section 3) and is therefore pushed
4out from the core by the natural amino acid sequence. Figure 4.6, shows an analysi^the 
branched peptide by reverse-phase HPLC. The trace indicates that this peptide is 
99.7% pure. The yield of peptide was 345mg and its sequence was confirmed by amino 
acid analysis performed by Cambridge Research Biochemicals.
The monomeric form of the peptide (347) was also analysed by reverse-phase 
HPLC (Figure 4.7). Multiple peaks were observed suggesting a heterogenous mixture 
of peptides. These peaks were assigned numbers 1-12, shown if Figure 4.7, with 
retention times in minutes of 12.8, 13.8, 14.6, 14.8, 15.5, 16.0, 16.5, 17.1, 17.8, 18.4, 
18.9 and 19.8 respectively. Preparative HPLC was used to isolate the individual peaks 
and fractions from the preparative run were collected and rerun on an analytical 
column. Those fractions corresponding to each individual peak were pooled, dried and 
peaks 6-12 were sent to M-Scan Ltd for fast atom bombardment mass spectrometry. 
Peaks 1-5 were not sent for analysis as the quantities and retention times suggested that 
they were unlikely to represent the desired peptide. The molecular weights obtained for 
each pooled fraction suggested that one of the peaks (peak 7) represented the desired
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Figure 4.6 Chromatogram of the analysis of branched V3 peptide 306 (Table 4.1) by 
reverse-phase HPLC . The eluate was monitored at 225nm and the peak represents 
99.7% of the total material.
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Figure 4.7 Chromatogram of the analysis of the monomeric V3 peptide 347 (Table
4.1) by reverse-phase HPLC. The eluate was monitored at 225nm and the trace 
indicates a heterogenous mixture of peptide. The peaks labelled 1-12 with retention 
times in minutes of 12.8, 13.8, 14.6, 14.8, 15.5, 16.0, 16.51, 17.13, 17.8, 18.4, 19,0 and 
19.8 respectively were further separated by preparative HPLC. Fractions corresponding 
to peaks 6-12 were sent for FAB-mass spectrometry analysis.
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peptide with a molecular weight of 3,757. The chromatographic analysis for this 
peptide is shown in Figure 4.8 and indicates a purity of 92%, Sufficient peptide was 
obtained to perform the experiments discussed in section 2 of the results.
The molecular weights of the remaining six peaks were larger by multiples of the 
molecular weight of the Mtr side chain protecting group, present on arginine residues, 
indicating that each peak represented the desired peptide with one or more of the 
uncleaved Mtr groups. To remove the remaining Mtr groups, the peptide was recleaved 
overnight in a mixture containing 95% TFA plus 5% phenol and the resulting peptide 
rerun on an analytical reverse-phase HPLC column. Figure 4.9 shows the HPLC trace 
for this peptide and indicates that the retention time (16.15 minutes) for the 
predominant peak is identical to the retention time for peak 7 (16.15 minutes). To 
further confirm that the peptides are the same, a mixture containing the peptide 
obtained from peak 7 and the recleaved peptide were analysed by reverse-phase HPLC 
(Figure 4.10). The trace indicated one predominant species. The experiments using 
the monomeric peptide described in this chapter all involved the recleaved peptide.
4.2.2 Analysis of the branched and monomeric peptides by SDS-PAGE
To further analyse the branched and monomeric peptides, both were run on a 10- 
20% SDS-polyacrylamide gradient gel. Figure 4.11, shows the Coomassie blue stained 
gel run with low molecular weight rainbow markers, 2,350-46,000 molecular weight 
(Amersham) (track M). Track A, contains the branched peptide, calculated molecular 
weight 30,898 and track 6 , contains the monomeric peptide, molecular weight 3,757. 
Both peptides migrate to positions on the gel compatible with their calculated molecular 
weight. The branched V3 peptide shows a slight laddering effect, possibly arising from 
amino acid deletions in some of the chains. This slight heterogeneity was not detected 
by analysis on reverse-phase HPLC, perhaps suggesting that the analytical column was 
not sufficiently resolving enough to detect these minority species. A possible not 
mutually exclusive cause for the apparent heterogeneity may be incomplete
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Figure 4.8 Chromatogram of the analysis of peak 7 of the monomeric V3 peptide after 
purification by reverse-phase HPLC. The eluate was monitored at 225nm and the peak 
with a retention time of 16.15 minutes represents 92.4% of the total mixture.
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Figure 4.9 Chromatogram of the unpurified monomeric V3 peptide recleaved 
overnight in 95% TFA, 5% phenol by reverse-phase HPLC. The eluate was monitored 
at 225nm and the retention time of the predominant peak is identical to that of the 
purified monomeric peptide (Fig 4.8 ) eluting from the column at 16.15 minutes.
Figure 4.10 Chromatogram of a mixture of the recleaved monomeric V3 peptide and 
the purified peak 7 of the monomeric peptide analysed by reverse-phase HPLC. The 
eluate was monitored at 225nm. The chromatogram indicates one predominant peptide 
species with a retention time of 16.05 minutes, almost identical to the retention times 
for the purified monomeric peptide (peak 7) and the recleaved monomeric peptide 
individually shown if Figures 4.8 and 4.9 respectively.
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Figure 4.11 Coomassie blue stained 10-20% SDS-polyacrylamide gradient gel run 
with low molecular weight markers (2,350-46,OOOKDa) (track M). Track A is the 
branched V3 peptide (306) molecular weight 30,898KDa. Track B is the monomeric V3 
peptide (347) molecular weight 3,757KDa. Both peptides migrate to the expected 
positions on the gel.
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Dilution of human sera
Figure 4.12 ELISA showing comparison of the sensitivity of the branched V3 peptide 
(panel A) and monomeric V3 peptide (panel B) at lOOng per well. HIV-1 positive sera 
(▲ ,■) and HIV-1 negative sera ( A fD) ,  were titrated in a series of twelve doubling 
dilutions from 1:50 to 1:488,281,250.
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denaturation of different conformational forms of the branched peptide. The 
monomeric V3 peptide runs as a single band confirming its homogeneity.
4.2.3 Relative sensitivity of the V3 branched and monomeric peptides 
for detection of antibodies
To compare the sensitivity of each of the two peptides, both were tested in ELISA 
with HIV-1 positive and negative human sera. The peptides were dissolved in PBS and 
coated to microtitre plates at a concentration of lOOng per well and tested with the 
control sera titrated in a series of 5-fold dilutions from 1:50 to 1:488,281,250. Figure 
4.12 shows the readings at 405nm for the branched (A) and monomeric (B) peptides 
tested with HIV-1 positive and negative sera. The results indicate that the branched 
peptide shows greater sensitivity than the monomeric peptide, detecting HIV-1 specific 
antibody at a maximum dilution of 1:31,250 compared to 1:1,250 for the monomeric 
peptide. It is also clear that the difference between the signal produced by positive and 
negative sera is greater with the branched peptide.
4.2.4 Relative sensitivity of the V3 branched peptide and native gpl20  
for detection of antibodies
The reactivity of purified gpl20 and branched V3 peptide with HIV-1 positive 
and negative sera were examined by ELISA. Both peptide and protein were compared 
at three concentrations (lug, lOOng and lOng of peptide or protein per well). The 
results are the readings at 405nm of HIV-1 positive and negative sera in a series of 2- 
fold dilutions (Figure 4.13A, B and C). Both peptide and protein were incubated with 
0.5% BSA in PBS alone to give "no antibody" controls., shown as the last point on each 
of the curves . At all three concentrations, the branched V3 peptide shows greater 
sensitivity for detection of antibodies^HIV-1 positive sera than does gpl20 At a 
concentration of lug per well (Figure 4.13A) the maximum dilution of HIV positive
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Figure 4.13 Comparison of the sensitivity of the branched V3 peptide (triangle 
symbols) and recombinant HIV-1 gpl20 (square symbols) with an HIV-1 positive 
(filled symbols) and an HIV-1 negative (empty symbols) serum at three different 
peptide and protein concentrations, lug per well (A), lOOng per well (B), lOng per well 
(C). The HIV-1 positive and negative sera were titrated in a series doubling dilutions 
from 1:200-1:102,400. The final point on each curve is a measure of the reactivity of 
the peptide incubated with 0.5% BSA in PBS alone to give a “no antibody” control.
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sera which gives an absorbance at 405nm of 2.0 OD units is 1:800 for the protein
compared to 1:6,400 for the branched V3 peptide, indicating weight for weight that the
peptide is 8 times more sensitive than gpl20. A similar conclusion can be drawn for
peptide and protein coated at a concentration of lOOng per well (Figure 4.13B).
I dilution
Therefore the maximum^of HIV positive sera which gives an absorbance at 405nm of 
between 1.0 and 1.5 OD units with the protein is, 1:200 compared to 1:1,600 with the 
branched V3 peptide. In Figure 4.13C, where the peptide and protein are at a 
concentration of lOng per well the reactivity of both is greatly reduced giving a 
maximum absorbance of 1.5 and 0.5 OD units respectively. Again however , the 
branched V3 peptide shows greater sensitivity. The higher optical densities obtained 
for the branched V3 peptide in this experiment compared with those shown in Figure 
4.12A is due to the use of HRP conjugated-protein A rather than goat anti-human IgG 
as the second antibody.
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4.3 DISCUSSION
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4.3.1 Effect of glycine spacers on the reactivity of branched peptides 
with specific antibodies
The work presented in this chapter was undertaken to further understand and 
increase the sensitivity of branched peptides for the detection of specific antibodies. To 
do this branched peptides were synthesised with varying numbers of glycine spacers to 
test the effect of increasing the distance of the reactive epitope from the polylysine core. 
The initial experiments involved the epitope GDPEDLD, derived from the HSV-1 
UL42 protein and its monoclonal antibody Z1F11. The results shown in Figures 4.1 
and 4.3, clearly demonstrate that a spacer of four or five glycine residues markedly 
increased the reactivity with the monoclonal antibody Z1F11.
This increased sensitivity might also be achieved with the use of alternative 
spacers, such as other small uncharged amino acids or non-natural amino acids. The 
natural sequence of the peptide could also act as a spacer depending on where the 
epitope lies in the peptide. For the branched V3 peptides used in this study, which 
encompasses 33 amino acids spanning the entire V3 region of HIV-1 gpl20, the 
addition of a glycine spacer would probably have no effect on its reactivity with HIV-1 
infected sera as the reactive epitope lies in the central eight to fifteen amino acids of the 
peptide (Goudsmit et al. , 1988a; Javaherian et a l ,  1989; Meloen et a l,  1989 and this 
thesis). This expectation was not tested. Both peptides derived from the V3 region of 
HIV-1 gpl20 and the HSV-1 UL42 when synthesised in the branched form were 
considerably more reactive with their respective antibodies than the monomeric 
peptides, confirming the initial observations of Marsden, Graham and Owsianka 
(personal communication) that branched peptides can detect lower concentrations of 
antibody than can their monomeric equivalent. This increased sensitivity and overall 
superiority of branched peptides might be due to a number of factors. Firstly, if one 
imagines the steric interaction of both branched and monomeric peptides with the
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surface of a microtitre plate, it is easy to hypothesise that the octameric structure of
branched peptides, when immobilised to the plate might allow multimeric binding sites
to remain freely exposed to antibodies. In contrast, the binding of the antibodies to
monomeric peptides may be impaired by the physical constraints imposed on the
peptide by binding to the surface of the plate and prevent it from freely interacting with
the antibody. Secondly, multivalent binding between antibody and branched peptides
could result in an increase in stability of the antibody-peptide interaction, with both
arms of the antibody binding to separate chains of the peptide, compared to the simple
monovalent binding of the antibodies to monomeric peptides. Thirdly, branched
peptides may bind more readily to the plate than monomeric peptides (Tam and Zavala,
1989) and therefore the observed increased sensitivity in ELISA may be due to the
presence of more peptide actually bound to the plate. To test this hypothesis, branched
and monomeric peptides would have to be labelled in some way so as to provide a
quantitative measure of the relative binding capabilities of each type. This will be an
Jb
important experiment to do however^will not explain the observed increase in 
immunogenicity of branched peptides in animals.
The increased sensitivity of the GDPEDLD, UL42 branched peptides, observed with 
the addition of varying numbers of glycine spacers preceding the reactive epitope 
(Figures 4.1 and 4.3) could be due to the epitope being extended away from any 
physical constraints imposed on antibody binding imposed at the polylysine core, 
thereby making the epitope more accessible to binding by Z1F11.
4.3.2 Comparison of the reactivity of branched peptides with that of 
the native protein.
The reactivity of the branched peptides were compared in ELISA with the 
recombinant native protein from which the epitope is derived. The reactivity of the 
(GDPEDLDG5 )8 K7 A peptide and the baculovirus expressed UL42 recombinant 
protein demonstrated that on a weight for weight basis both showed equal reactivity
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with the monoclonal antibody Z1F11 (Figure 4.5). In a similar experiment, the 
comparison of the branched V3 peptide and the native HIV-1 IIIB gpl20 protein at 
three different concentrations indicated that the peptide is a least 8-fold more sensitive 
than the native protein (Figure 4.13). Caution must be applied when interpreting this 
result, as this increase in sensitivity may be in part due to the fact that the MN strain of 
HIV-1, from which the peptide is derived is the predominant strain found infecting 
individuals from both North America and Europe. In contrast, the recombinant gpl20, 
is derived from the IIIB strain of the virus, which is not commonly found and contains 
two additional amino acids (QR), conserved in all IIIB isolates, close to the highly 
conserved GPGR in the immunodominant region of V3. It is unlikely that the 
Edinburgh donors of the HIV-1 positive sera used in this experiment will have been 
infected with the IIIB strain of HIV-1.
The relative sensitivities of branched and monomeric peptides and the native protein 
can also be considered on a molarity basis. With equal weights of a monomeric peptide 
and a branched peptide with 8 arms, the monomeric peptide contains approximately 8 
times more molecules. However, because each branched peptide contains 8 epitopes, 
the molarity of epitopes in equal weights is approximately the same.
The experiments described in this chapter indicate that branched peptides have 
considerable potential advantages over the use of both monomeric peptides and native 
proteins as serodiagnostic reagents. Peptides can be synthesised relatively 
inexpensively and purified to yield large quantities that can be easily stored at -20°C or 
possibly even room temperature for extended periods of time without losing reactivity. 
This contrasts with the labour intensive and relatively costly protein production and 
purification protocols and the more demanding conditions, lyophilisation or storage at 
-70°C, required for stability of the protein. Because peptides contain only few amino 
acids they are less likely than proteins to elicit false-positive reactions with spurious 
cross-reactive antibodies. Peptides will also be free of other contaminating proteins 
from the overexpression system which might also give false positives. All of these
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aspects suggest that branched peptides should become the preferred reagent of choice 
they therefore
for serodiagnosis and were.used in the following studies described in this thesis.
/  A
4.3.3 Future studies
A better understanding of the properties of branched peptides, should make it 
possible to further improve them for use as serodiagnostic reagents. It may well be that 
peptides with fewer branches would be equally, or even more sensitive, in 
serodiagnosis. Fewer branches might have additional potential advantages as it might 
be expected that some branched peptides will present difficulties in synthesis and/or 
epitope detection due to steric hindrance caused by close proximity of the peptide 
chains. Reducing the number of peptide chains to four, six or even two, could relieve 
any steric constraints on the peptide and open up the structure, making it more 
accessible for recognition by specific antibodies. For long peptides (greater than fifteen 
amino acids), reducing the number of peptide chains may have detrimental effects on 
the peptides reactivity with specific antibodies and will depend on how the reactive 
epitope is recognised in that particular peptide. For long peptides the interaction of 
eight chains may stabilise the linear structure of the peptide. Four branches however 
could reduce any steric constraints imposed on the peptide and may result in the 
individual peptide chains folding in on themselves. Depending on the epitope 
contained in the peptide, this could increase or decrease the recognition of that 
particular epitope with specific antibodies. Although these possibilities are highly 
speculative, it will be important to test how sensitivity is affected by the number of 
branches using a number of different epitopes and their cognate monoclonal antibodies 
or polyclonal sera.
The future for branched peptides as serodiagnostic reagents so far looks very 
promising. In the last year of this project the peptide chemistry available for the 
automated synthesis of oligopeptides improved so much as to have allowed the 
reduction in time taken to synthesise and cleave the peptide from the resin by at least
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one third. In addition, the purity of the peptides obtained is now improved (Susan
Graham, personal communication) At present, many of the serodiagnostic kits
available for screening HIV-1 infected blood rely on the reactivity of sera against
HIV-1 proteins by Western blot. From the data presented in this chapter one could
imagine that a panel of HIV-1 peptides derived from immunodominant regions of the
virus, precoated to microtitre plates could provide a more sensitive test for the detection
of HIV-1 specific antibodies in human sera. An experiment not described in this thesis,
where the branched V3 peptide was used to screen blindly a panel of 30 HIV-1 infected
and uninfected human serum samples, demonstrated that this peptide could successfully
distinguish between infected and uninfected sera (collaboration with Dr E. Follet,
Ruchill Hospital, Glasgow.). The high reactivity of the HIV-1 infected sera and total
unreactivity of HIV-1 negative sera against the V3 peptide, suggest that this peptide
o
itself may prove very useful in the development of serdiagnostic kits.
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Chapter 5 RESULTS:Section 2
Maternal antibody levels to the V3 region of HIV-1 gp l20  and 
transmission of HIV-1 to the foetus
This study was undertaken to investigate whether high levels of maternal 
antibodies present in the mother, directed against the V3 region of HIV-1 gpl20 
correlated with lack of vertical transmission of HIV-l.
A significant proportion of children born to HIV-infected mothers are infected in 
utero and transmission rates vary between 7% and 65% depending on the study cohort 
(Rubinstein e t a l , 1986; Mok etal., 1989; Ades etal., 1991; Piot et al, 1988; Blanche 
et al, 1989). It has been reported that mothers who have high-affinity antibodies to the 
V3 domain of HIV-1 gpl20 are less likely to transmit HIV-1 to their children (Broliden 
et al, 1989; Rossi e ta l,  1989; Devash etal., 1990). In contrast, Parekh et a l  (1991) 
found no correlation between levels of maternal antibodies against the V3 loop and 
maternal-foetal transmission. The resolution of these apparently contrasting results is 
of importance for prognostic serodiagnosis and vaccine development. Such a 
correlation would be helpful in predicting the outcome of at-risk pregnancies and would 
lend support to vaccine strategies aimed at increasing antibody levels to the V3 region.
The work presented in this chapter aimed to further examine the relationship 
between maternal antibodies to the V3 sequence and the risk of vertical transmission by 
examining the titres of antibodies against a branched V3 peptide in sera from two 
groups of mothers, identified as transmitters or nontransmitters. The study differs from 
earlier studies in three aspects. First, antibody titres were determined as opposed to 
classifying sera as positive or negative on the basis of whether a single dilution of 
maternal serum gave an ELISA titre above a cut-off value. Second, a long peptide 
representing the whole of the V3 sequence between the conserved cysteines was used, 
as it might have been expected to contain conformational as well as sequential epitopes.
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In the event, this potential advantage was not realised as the V3 region is now believed 
to behave as a sequential epitope as denaturation of the native gpl20 does not reduce 
binding of antibodies to this region (Moore et al., 1993). Third, this study was 
designed to investigate whether differences in antibody levels to the V3 sequence 
reflected differences in the overall antibody levels or were peculiar for those against 
V3. To do this the antibody levels to a peptide corresponding to an immunodominant 
and conserved domain of gp41 were also measured. In this way the maternal antibody 
levels against the variable V3 loop could be normalised to the antibody levels against 
the constant gp41 region.
5.1 Oligopeptides
Three peptides were used in this study. The branched and monomeric V3 
peptides, 306 sequence (TRPNNNTRKRIHIGPGRAFYTTGQIIGDIRQAH)8K7A and 
347 with sequence TRPNNNTRKRIHIGPGRAF YTT 3QIIGDIRQAH respectively are 
described in the previous chapter and shown in Table 4.1. This V3 sequence is 
essentially that described by LaRosa e ta l  (1990) and corresponds closely to amino 
acids 297-330 of the HIV-ImN strain gpl20. This sequence was chosen because it 
corresponds most closely to that of isolates from the Edinburgh area and it is likely that 
the women enrolled in this study would have been exposed to virus containing such 
sequences. The monomeric V3 peptide was used for the antibody-affinity assays. 
Another peptide, 284 with sequence (GCSGKLICTTAVPWNASG5 )8 K7 A, was 
synthesised by Dr Susan Graham. The sequence GCSGKLICTTAVPWNAS in this 
peptide corresponds to residues 596-614 , the immunodominant region of gp41 (Gnann 
etal, 1987; Narvanen et al, 1988; Yamada et al, 1991). Both forms of the V3 peptide 
were purified to greater than 92% homogeneity and their sequences were confirmed as 
described in the previous chapter. The gp41 peptide, synthesised by Dr Susan Graham 
was found to be 91% pure and its sequence was confirmed by amino acid analysis 
performed by CRB. This peptide is insoluble in water and was dissolved in a lOOul of
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33% acetic acid and made up to volume with PBS for use in the experiments discussed 
in this chapter.
Before beginning the study on the maternal sera it was important to optimise the 
conditions for the experimental assay. As sera is in such short supply it is of the utmost 
importance to maximise its use. The following experiments were designed to optimise 
the amount of peptides to be used for screening the sera.
5.2 Determining the optimal concentration of branched V3 peptide
Branched V3 peptide was titrated in a series of eight 10-fold dilutions against two 
HIV-1 positive control sera (EBH6 and EBH4), kindly provided by Ruchill Hospital 
and four HIV-1 negative sera (1,2,3 and 4) diluted 1:100 (Figure 5.1). Serum, EBH6, 
showed high reactivity with the V3 peptide, giving an absorbance at 405nm of 1.0 OD 
unit with as little as lOng of peptide. Serum, EBH4 showed lower reactivity with the 
peptide compared to EBH6 but also reached an optimal absorbance at a peptide 
concentration of lOng. All the HIV-1 negative sera behaved as expected, giving lower 
reactivity than with the HIV-1 positive sera. At peptide concentrations greater than 
lOng per well the reactivity of the HIV-1 negative control seiyuincreased in all cases to 
give a background absorbance of around 0.2 OD units. At peptide concentrations of 
lOng per well there is good discrimination between the HIV-1 positive and negative 
sera giving background absorbance of < 0.1 OD unit with each of the negative controls. 
Therefore a concentration of V3 peptide of lOng per well was used in subsequent 
experiments.
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Figure 5.1 ELISA reactivity of HIV-1 positive control sera EBH4 ( ■ )  and EBH6 
(▲) and HIV-1 negative control sera, 1 (A ), 2, (□ ) ,  3 (O ), and 4 («+• ).The sera were 
used at a d ilu tion of 1:100 against the branched V3 peptide 
(TRPNNNTRKRIHIGPGRAFYTTGQGDIRQAH)8K7 A, titrated in a series of eight 
10-fold dilutions.
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5.3 Determining the optimal concentration of the gp41 branched 
peptide
To optimise the amount of gp41 peptide, it was titrated in a series of eight, 5-fold 
dilutions from an initial concentration of lug per well to 1.28xl0'^ug per well against a 
single dilution (1:100) of HIV-1 positive and negative sera . The results shown in 
Figure 5.2 indicate that like the V3 peptide, the concentration of gp41 peptide required 
to give optimal absorbance without giving high background readings with the HIV-1 
negative control sera was lOng per well.
5.4 Screening a larger panel of HIV-1 human sera against the V3 
branched peptide
Before the V3 peptide was used to screen the HIV-1 infected maternal sera it was 
considered important to examine its reactivity with a larger number of HIV-1 negative 
sera and so establish mean and standard deviation values for the background. The 
peptide was screened in ELISA at the concentration of lOng/well established by the 
previous experiment, against a panel of 14 HIV-1 negative sera and 2 HIV-1 positive 
sera (EBH4 and EBH6) all diluted in 0.5% BSA in PBS at dilutions of 1:10 and 1:100. 
The results for the V3 peptide are shown in Figure 5.3. At both serum dilutions the two 
positive sera EBH4 and EBH6 show high reactivity with the peptide. The fourteen 
negative control sera again behaved as expected giving low reactivity with the peptide. 
At the lo_wer dilution of sera (1:10), the background absorbance increased to 
approximately 0.2 OD units. In both cases however, the discrimination between 
positive and negative sera is clear. At a serum dilution of 1:100 and a peptide 
concentration of lOng/well the ODs at 405nm for both the V3 and gp41 peptides 
against the fourteen seronegative controls were OD= 0.040+/- 0.026 (from Figure 5.3) 
and 0.066+/- 0.030 (data not shown) respectively.
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Figure 5.2 ELISA reactivity of an HIV-1 positive control sera, EBH6 ( ▲ ) and two 
HIV-1 negative sera ( D , a  ) at a dilution of 1:100 against the gp41 peptide with 
sequence (GCSGKLICTTAVPWNAS)8K7A. The peptide was titrated in a series of 
eight 5-fold dilutions. Peptide alone without human sera ( O ) was included to give a 
“no antibody” control.
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Figure 5.3 ELISA reactivity of two HIV-1 positive control and fourteen HIV-1 
negative control sera at dilutions 1:10 ( ■ )  and 1:100 (@ ) against the V3 branched 
peptide with sequence (TRPNNNTRKRIHIGPGRAFYTTGQIIGDIRQAH)8K7A at a 
concentration of lOng per well.
Chapter 5
5.5 Test titration of control human sera against the V3 branched 
peptide
This preliminary experiment was done to ensure that the assay system proposed 
for the maternal antibody study, using this V3 branched peptide would effectively 
discriminate between positive and negative sera and enable titres to be determined. 
Figure 5.4 shows an ELISA titration of HIV-1 positive and negative sera against the V3 
peptide at a concentration of lOng per well using a series of twelve 2-fold dilutions of 
the sera from 1:25 to 1:51,200. All HIV-1 negative control sera showed low reactivity 
with the peptide even at the lowest: dilution of 1:25. A cut-off value (0.118) was 
calculated from the optical densities obtained with the negative sera as the mean plus 3 
standard deviations. Both HIV-1 positive sera react strongly with the peptide. In the 
case of sample EBH6, which is consistently more reactive in all the experiments 
described so far, detection of specific antibody can be demonstrated at dilutions of sera 
as high as 1:25,600. Antibodies present in EBH4 can be detected at a 1:1,600 dilution 
of sera. These.data suggests that the assay should provide meaningful data when used 
to screen the maternal sera.
5.6 The study cohort
The maternal sera used in this collaborative study were provided by Dr Jacqueline 
Mok and Dr Shiela Burns of the City Hospital in Edinburgh, who also collected the 
clinical data.
All infants born to HIV-1-infected women in the Lothian region of Scotland were 
enrolled in a prospective study to examine the risk of mother-child transmission of 
HIV-1, as well as to evaluate the natural history of vertically acquired HIV-1 disease 
(Mok et a l , 1989). All women were clinically well during pregnancy, with the 
exception of two, who had the opportunistic infection common to HIV-1 infected 
individuals, pneumocystis carinii pneumonia at the time of delivery. After a median
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Figure 5.4 Test titration of HIV-1 positive control sera, EBH4 (■ )  and EBH6 (A ) and 
negative control sera , 1 (A ), 2 (□ ), 3 (O ), and 4 (-p) in a series of doubling dilutions 
(1:25-1:51,200) against the V3 branched peptide at a concentration of lOng per well in 
an ELISA.
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follow-up of 48 months (range 4-73), infants were diagnosed as HIV-1-infected on the 
basis of two of the following criteria : persistence of HIV-1 antibody beyond 18 months 
of age, positive HIV culture or HIV antigen tests on more than two occasions, and 
clinical evidence of HIV infection. Children were presumed uninfected when the were 
> 2 years old, remained clinically healthy, had normal immune function tests and tested 
negative for HIV antibody, antigen and culture.
Mothers were divided into 2 groups: Group 1 (n=7) were those who had given 
birth to infected children (HIV-1 transmitters); group 2 (n=20) were those who 
delivered uninfected children (HIV-1 nontransmitters). Maternal sera were collected 
during pregnancy or soon after delivery. Also present in the study cohort were two 
women who had each given birth to both an infected and uninfected child from separate 
pregnancies. Sequential serum samples were available from these women during the 
time that each child was born.
In the following study the sera were coded by Dr Mok and screened blind against 
the branched V3 and gp41 peptides. Only after all the data had been collected was the 
code broken.
5.7 Measuring maternal antibody titres against the V3 and gp41 
peptides
Both peptides were coated to microtitre ELISA plates at the optimal concentration 
of lOng per well. Each of the 27 maternal sera were tested for reactivity against both 
peptides on the same day in a series of twelve 2-fold dilutions from 1:25 to 1:51,200. 
Controls for the experiment included adding each serum dilution to wells with no 
peptide bound. These readings (typically 0.1+/-0.03) were subtracted as background 
from each of the corresponding test readings at 405nm. The subtraction of background 
from each reading should compensate for any difference in time between addition of 
enzyme substrate solution and reading at 405nm on a Multiskan plate reader.
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After screening all the sera against the V3 and gp41 peptides, the code was 
broken and each of the samples placed into the categories, transmitter or nontransmitter. 
Representative data from 6 transmitters and 6 nontransmitters are shown in Figure 5.5. 
High titres of antibody to the V3 peptide were seen in both groups of mothers 
regardless of whether their children were infected (panel A and C). Sera from both 
transmitters (panel B) and nontransmitters (panel D) also reacted with the gp41 peptide 
although the maximum optical densities were lower than with the V3 peptide. One 
point clearly demonstrated in panel B, is the importance of titrating the sera rather than 
defining the sera as reactive or non-reactive based on a single dilution. Sample 2995 at 
a dilution of 1:25 would be defined as non-reactive with the gp41 peptide yet is 
strongly reactive at a 1:400 dilution.
To allow a better interpretation of the data, the maximum dilution of each of the 
27 sera which would to give an absorbance of 0.4 OD units with both peptides were 
measured from each of the graphs. Table 5.1 gives the titre defined as the reciprocal of 
this maximum dilution and the ratio of the titres against the V3 and the gp41 peptides 
for each sample.
5.8 Statistical analysis of the median values
To determine whether there was any statistical difference in antibody titres to the 
V3 peptide between the two groups of mothers, the non parametric Mann-Whitney 
statistical test was performed on the data by Dr Karin Froebel according to the method 
described by Goldstein (1965). The test showed no significant difference between the 
median values for anti-V3 titres (p= 0.82) or the anti-V3/anti-gp41 titres (p=0.21) at 0.4 
OD units. Similar analysis was done for the anti-V3 titres at 1.0 OD units, but not for 
the gp41 titres as the reactivities of some of the sera did not reach an absorbance of 1.0 
OD units. Again no significant difference was seen between the median values for the 
anti-V3 titres.
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Figure 5.5 Titration of maternal sera against the V3 and gp41 branched peptides. 
Maternal sera, representative of 6 HIV-1 transmitters ( A , B )  and 6 HIV-1 
nontransmitters (C, D) were titrated in an ELISA against the V3 peptide (A, C) and 
gp41 peptide (B, D). Individual sera for A and B: 1384 ( □ ) ,  2924 ( •  ), 2995 ( □ ) ,  
2017 ( O ), 737 ( ■ )  and 2961 (□ ) ;  for C and D: 432 ( 0 ) ,  847 ( • ) ,  2084 ( d ), 3625 
( O ), 1896 ( ■ )  and 2751 ( □ ). Reactivity of 1 representative seronegative subject is 
also shown ( ▲ ). The sera were titrated in a series of doubling dilutions from 1:25- 
1:51,200.
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Table 5.1 Maternal antibody titres against the branched V3 and gp41 
peptides
Titre giving absorbance of 0.40 OD @ 405 nm
Mother (Patient No.) gp!20-V3 peptide gp41 peptide ratioa
Transmitters^
737 1:1200 1 800 1.50
1384 1:3200 1 1200 2.66
2017 1:3200 1 800 4.00
2924 1:12800 1 4800 2.66
2961 1:1200 1 800 1.50
2995 1:12800 1 2400 6.33
3164 0 0 NC
Nontransmittersd
343 1:6400 1 1200 5.33
393 1:3200 1 800 4.00
432 1:3200 1 200 16.00
613 1:3200 1 1600 2.00
847 1:800 1 100 8.00
888 1:12800 1 6400 2.00
1373 1:3200 1 50 64.00
1633 1:3200 1 800 4.00
1896 1:6400 1 1600 4.00
2017 1:3200 1 800 4.00
2084 1:12800 1 3200 4.00
2601 1:800 1 100 8.00
2632 1:3200 1 800 4.00
2652 1:6400 1 3200 2.00
2751 1:6400 1 800 8.00
2898 1:25600 1 12800 2.00
3100 1:600 1 800 0.75
3309 1:200 1 200 1.00
3625 1:1600 1 400 4.00
3938 0 0 NC
a gpl20 V3 loop peptide titre divided by gp41 peptide titre 
b HIV-1 infected mothers with an infected child 
NC not calculatable
d HIV-1 infected mothers with an uninfected child
Chapter 5
5.9 Measurement of V3 titres in sequential maternal serum samples
Anti-V3 and anti-gp41 titres were measured as described above for sera from two 
women who each gave birth to 1 infected and 1 uninfected child (Figure 5.6). The x- 
axis represents months from the birth of the first child. Panel A shows the anti-V3 
titres from a mother who 3 months after delivery of an uninfected child had low titres 
against the V3 peptide and during a period of increasing anti-V3 titres, gave birth to an 
infected child. Panel B demonstrates that 5 months after giving birth to an infected 
child this woman had high titres of antibodies against the V3 region and during a period 
of decreasing anti-V3 titre gave birth to an uninfected child. The data presented here 
shows no positive correlation between anti-V3 titre and transmission of HIV-1 to the 
child.
5.10 Antigen-limited V3 ELISA
To test for the presence of high affinity antibodies, the antigen-limited ELISA described 
by Devash etal (1990) was tested on eight of the maternal sera (four transmitters and 
four nontransmitters). This test measures the reactivity of a fixed dilution of human 
sera against different amounts of peptide. Antibodies are classified as being of high- 
affinity or avidity if they reacted with low amounts of peptide. Typically, Devash et al. 
(1990) designated a serum as having high affinity if it retained 50% of the maximum 
observed reactivity at a peptide concentration of 5x10"^ ug/well. For this assay the 
monomeric V3 peptide was used (peptide 347, Table 4.1) to follow the conditions of 
the published assay and because branched peptides probably detect low-affinity 
antibodies more readily (Marsden etal.} 1992). The mean reactivity of the monomeric 
V3 peptide with fourteen seronegative controls was 0.082+/-0.037.
Four transmitter and four nontransmitter maternal samples were chosen at random 
from the 7 transmitters and 20 nontransmitters at and tested in the antigen-
limited ELISA at a dilution of 1:100. The peptide was titrated in a series of seven 10-
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Chapter 5
fold dilutions from an initial concentration of lug per well to 10‘^ug per well. No 
differences were observed in the affinities of antibodies in the maternal sera from the 
four transmitters and four nontransmitters in the study group (representative data are 
shown in Figure 5.7).
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Figure 5.7 Reactivity of maternal sera with varying amounts of the monomeric V3 
peptide with sequence TRPNNNTRKRIHIGPGRAFYTTGQIIGDIRQAH. Sera from 
HIV-1 transmitters ( ^ , B  ) and HIV-1 nontransmitters ( £ ,□  ) were diluted 1:100 for 
use in the ELISA. The monomeric peptide was titrated in a series of ten, 10-fold 
dilutions.
5.11 DISCUSSION
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5.11.1 Maternal antibody levels against the V3 region of HIV-1 gpl20
Prior to this investigation several reports had been published suggesting that the 
presence of maternal antibodies against specific epitopes in the V3 region of HIV-1 
gpl20 correlated with protection of the foetus against HIV-1 infection in utero 
(Broliden et al., 1989; Rossi et al., 1989; Devash et al., 1990). The peptides used to 
screen the mothers or infants sera are listed in Table 5.2. Broliden et al. (1989) 
examined the reactivity of childrens sera taken prior to six months of age, as ttestsera 
will still contain maternal antibodies', with a series of eight peptides spanning the 
consensus sequence peptide from the HIV-IIIB strain of the virus. The sera from the 
infants born to the HIV-1 infected mothers were screened at a single dilution for 
reactivity against each of these peptides. Peptide C57, which encompasses the far right 
hand side and extends beyond the V3 loop region was found to react with sera from 6 
out of 19 uninfected infants, but showed no reactivity with sera from any of fourteen 
infected children. Similarly, among the four peptides used by Rossi et a l (1989) to 
screen sera of newborn children or HIV-1 positive mothers, peptide C57 showed 
significantly greater reactivity with sera from 5 out of 19 uninfected children and no 
reactivity with any of the sera from fourteen infected children. When sera from HIV-1 
positive mothers were screened against the four peptides, peptides C51 and C57, but 
not C53 or C58 showed significantly greater reactivity with the sera from mothers who 
gave birth to uninfected children than that from mothers of infected children. The 
reactivity seen against peptide C57 and not other peptides spanning the conserved 
GPGR motif, common to all HIV-1 isolates is perhaps surprising as the 
immunodominant epitope of gpl20 encompasses this tetrameric domain (LaRosa et al.,
1990) and it would be expected that infected sera should recognise this region.
In another study (Devash et al., 1990), the reactivities of both maternal and 
neonatal sera (age less than four weeks) were measured in an antigen-limited ELISA.
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Using this technique they demonstrated a correlation between high-affinity or high- 
avidity antibodies in the sera of both mothers and infants with a lack of transmission of 
HIV-1 from mother to child. All the groups were able to establish that low 
immunoreactivity to the principal neutralising determinant was not due to an overall 
loss of humoral response by demonstrating reactivity to other HIV-1 peptides derived 
from other immunogenic proteins of the virus.
During the course of the work described in this chapter, Parekh et al. (1991), 
reported a study of maternal antibody levels, using peptides similar to that of Rossi et 
al. (1989), but derived from the MN rather than the MB strain. They found that only 
the peptide KRIHIGPGRAFYT, the same as used by Devash et al. (1990) was 
recognised by the maternal sera. Using the same antigen-limited ELISA, these authors 
found no correlation between transmission and V3 antibody affinity or avidity. In 
addition, Parekh sent coded sera to the laboratory of Devash et al., who was unable to 
correctly classify them as from transmitting or nontransmitting mothers.
The experiments described in this chapter were designed to examine 
quantitatively whether there is a correlation between maternal antibodies to the V3 
peptide and lack of transmission of the virus to the child. Antibody titres to the V3 
peptide were determined against doubling dilutions of the maternal sera. No correlation 
was observed with reactivity against this peptide, nor was any observed when the anti- 
V3 peptide titres were normalised by anti-gp41 peptide titres. When the relative 
affinities of the antibodies from four representative samples taken from each of the two 
groups were assayed using the antigen-limited ELISA as described by Devash et al. 
(1990), no differences in antibody affinity were found. These results support the 
findings of Parekh et al. (1991) and not those of Devash et a l, (1990). Two other 
studies also fail to show a correlation between maternal antibodies against V3 and lack 
of transmission to the foetus (Geffin et a l, 1992; Halsey et al., 1992).
The V3 peptide described in this study contains all the amino acids between the 
two conserved cysteines of the V3 loop and encompasses the peptides used by both 
Devash et al. (1990) and Parekh et al. (1991). It only part overlaps the C57 peptide
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with which Broliden et a l (1989) and Rossi et a l (1989) detected a correlation, as the 
carboxy-terminal 7 amino acids of C57 lie outside the V3 loop. The use of different 
peptides from the V3 sequence could perhaps explain the apparent conflict between 
these results and those of Broliden et al. (1989) and Rossi et a l  (1989) but cannot 
explain the disagreement with the findings of Devash et a l  (1990). If there is a 
correlation between reactivity of peptide C57 (spanning gpl20 amino acids 323 to 337) 
and vertical transmission then the data presented in this study imply that the important 
epitopes on peptide C57 is specific for the IIIB strain, GNMRQ, versus GTIRQ in the 
MN strain or includes residues that lie outside V3.
5.11.2 The involvement of other factors in vertical transmission of 
HIV-1 from mother to child
The data presented in this chapter do not support the view that high levels or high 
affinity antibodies to sequences in the V3 region of HIV-1 gpl20 correlate with 
protection against vertical transmission. The cases of twins in which one was infected 
and one was not (Goedert et al., 1991 and this study) argues strongly for the 
involvement of other factors in the protection against vertical transmission of HIV-1. It 
is perhaps naive to suggest that only one variable will determine the outcome of at risk 
pregnancies, but more likely that an interplay of factors will be involved. These factors 
have previously been discussed (Introduction, section 1.8). In addition, antibodies 
against other regions of the gpl20 and the specificity of the maternal cytotoxic T cell 
response may also play a role in the transmission of HIV-1 to the foetus.
To determine the factors involved in maternal-foetal transmission it may be 
important to define the time point at which transmission occurs. In this study, the blood 
samples were taken from the mothers immediately before, during or after the birth of 
the child. It is possible that at transmission, the levels of antibodies against the V3 
region between the two groups may have been different. This possibility is unlikely as 
transmission is believed to occur in the later stages of pregnancy and it is difficult to
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imagine that the antibody levels at this time will be significantly different from those at
birth. It would, however, be interesting to measure maternal antibody levels throughout
the entire pregnancy to determine whether they remain relatively constant and if not,
I the
whether they correlate with the outcome of child.A
5.11.3 Future Studies
The findings of Wolinsky et al., (1992), that only certain variants observed in the 
mother were detected in the infected child and the findings that on initial infection of 
haemophiliacs with HIV-1, the envelope sequences in the V3 region are completely 
homogenous (Zhang et al., 1993), suggest that there is a selection for specific env 
sequences either upon transmission or in the interval between infection and 
seroconversion. Perhaps the presence of a specific env determinant is required to allow 
transmission of the virus. In addition to this initial genotypic homogeneity, the viruses 
that are found in infected individuals early in infection appear to be predominantly of 
the same biological phenotype; slow low, NSI and macrophage tropic. Specific regions 
of gpl20, including V3, have been shown to be involved in these phenotypic 
characteristics. It would therefore be of interest to isolate the viruses from infected 
infants early after infection and if possible prior to seroconversion, to determine their 
phenotypic properties. The findings from such experiments should indicate whether the 
virus(es) involved in vertical transmission of HIV-1 have properties similar to those 
transmitted by other modes.
The results presented in this chapter do not lend support to the notion that 
immunotherapy aimed at increasing anti-V3 antibody titres in pregnant HIV-1 infected 
mothers would have an effect on the clinical status of the child. Moreover, these results 
demonstrate that the level of anti-V3 antibodies in infected mothers could not be used 
to serve as a prognostic marker in predicting the outcome of at-risk pregnancies. It is 
however important to note that in this study, the levels of neutralising antibody against 
the principal neutralising determinant were not measured, anlindeed it has not yet been
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determined what role neutralising antibodies play in HIV-1 infection. Although no 
correlation has been shown between the levels of antibodies against gpl20 and an 
clinical status of the patient (Holmback et a l, 1993), two groups have shown that the 
titres of neutralising antibodies against the V3 region in infected children did not 
correlate with p24 antigen levels, CD4 count, age and sex but showed a significant 
correlation with an improved clinical status (Robert-Guroff, et al., 1987, 1993; 
Ljunggren et al.f 1990). In addition, the presence of antibodies capable of inhibiting 
syncytium formation may also improve the clinical status of the HIV-1 infected child 
(Brenner et a l, 1991). Their study involved 34 children born to HIV-1 infected 
mothers: infants who had syncytium-inhibiting antibodies had an overall better clinical 
outcome than infants with lower titres of these antibodies. Because the V3 region is 
involved in the SI phenotype, induction of V3-specific antibodies in infected infants 
may improve their clinical status. This hypothesis remains to be tested, but raises the 
possibility that hyperimmunoglobulin therapy or subunit vaccines derived from the V3 
region may have a therapeutic effect in infected infants. Further, larger studies will be 
necessary to confirm these findings.
The work described in this chapter was done to determine whether support could 
be found for the view that antibodies against the V3 region of HIV-1 gpl20 might 
protect against maternal-foetal transmission and/or whether such antibodies might serve 
as a prognostic marker for transmission. The results obtained have clinical relevance in 
that they provide no support for a protection strategy aimed at raising anti-V3 antibody 
titres and indicate that measuring anti-V3 titres is not useful in predicting the outcome 
of an HIV-1 infected mother giving birth to an infected child.
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Chapter 6 Results: Section 3
Do antibodies play a role in selecting sequence variants within the V3 
region of HIV-1 gpl20.
The work presented in this chapter was undertaken to investigate whether the 
sequence variants that arise in the third hypervariable region (V3) of HIV-1 gpl20 
during infection, represent antibody escape mutants. This work was conducted as part 
of a collaboration with Dr Peter Simmonds and Dr Andrew Leigh Brown from the 
University of Edinburgh.
On infection with HIV-1 the virus population appears to be relatively 
homogenous in the V3 region of the envelope protein (Wolfs e ta i,  1991,1992; Zhang 
et a l, 1993), with only certain genotypes being passed from individual to individual 
(Wolinsky et al, 1992). This homogeneity is believed to be due to the existence of 
strong selection for specific env sequences either upon transmission or in the interval 
between exposure and seroconversion in the infected individual. The homogeneity is 
maintained prior to seroconversion for reasons that are not yet clear but could be due to  
little or no immunoselective pressure exerted by the host on the virus, resulting in the 
clonal outgrowth of the most viable isolate. Following seroconversion and during the 
long asymptomatic phase, the virus population displays considerable genetic diversity, 
particularly in the external glycoprotein gpl20 (Hahn et a l, 1986; Simmonds et a l, 
1990, 1991; Balfe et a l, 1990), not only in terms of genetic composition but also in 
terms of cell and tissue tropism, syncytium-inducing properties and replication ability 
in-vitro (Levy e ta l ,  1985; Anand et al, 1987; Asjo et al, 1986; Evans et a l, 1987; 
Briesen e ta l ,  1987; Tersmette e ta l,  1988; Fenyo e ta l ,  1988). The viral-specific 
antibody and T-cell responses which can be readily demonstrated during the 
asymptomatic period are consistent with the possibility that continuous replication of 
the virus is accompanied by immune selection.
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To test the hypothesis that sequence variation in the V3 region of HIV-1 gpl20 
is driven by humoral immune selection, peptides corresponding to the variants found 
during the natural course of infection in one patient were synthesised. The peptides 
were tested in ELISA for reactivity against sequential serum samples taken from that 
individual.
6.1 Study patient
The HIV-1 V3 sequence variants which emerged during the natural course of 
infection of patient 82, a member of the Edinburgh haemophiliac cohort had previously 
been identified (Simmonds e ta l , 1991) and were made available to me before their 
publication. These sequences were obtained by extraction of viral RNA from the 
plasma of serum samples taken at intervals from the time of seroconversion in 1984 
through to 1991. The viral RNA was reverse transcribed to give cDNA copies of the 
replicating virus genomes found in patient 82. The cDNA was diluted to give single 
copies for amplification by nested PCR. (Simmonds et a l , 1990). Nested PCR involves 
two rounds of amplification using primers having the sense and antisense orientations. 
The first round utilises primers spanning the V3 region and the second involves internal 
primers. This procedure yielded sufficient DNA from single isolated molecules for 
direct sequencing. The DNA products obtained from the amplification were purified 
and then sequenced to deduce the amino acids at residues 297-330, which are listed in 
Table 6.1 (adapted from Holmes et al., 1992). The predominant V3 sequence found at 
the time of seroconversion is termed the seroconversion sequence and the variants are 
defined as having amino acid substitutions deviant from this sequence. Table 6.1 
shows the 24 V3 sequencies detected in patient 82 over the sampling period. Only the 
amino acid residues, deviant from the seroconversion sequence are represented by their 
appropriate single letter amino acid code and identical residues are denoted with a dot. 
The frequency in each year, that an individual sequence was detected is shown, with a 
value of 1.000 representing 100% of the sequenced population. The total number of
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sequenced V3 regions for each time point is shown along the bottom of the table. 
These sequencies have been placed in a theoretical evolutionary tree (Figure 6.1), with 
proposed relationships between the different sequences represented by arrows (Holmes 
et al., 1992). Each of the 24 sequences have thus been assigned to specific lineages 
(listed in Table 6.1) termed A (the seroconversion sequence) through to F, making the 
assumption that all of the sequencies have evolved from the seroconversion sequence 
(Holmes et al., 1992). This assumption is based on the observation that at the time of 
seroconversion the V3 region is highly homogenous (Wolfs et al., 1991,1992; Zhang et 
a l, 1993).
Seven sequential serum samples were taken from patient 82 over the period 
1984-1991. These samples were coded and are listed in Table 6.2. During the period 
of sampling patient 82 remained asymptomatic for the clinical symptoms of HIV-1 
infection, but showed a continual decline in CD4 counts to below 200 at the latter time 
points.
Before beginning the study, preliminary experiments were done to firstly, define 
the region of V3 which is reactive with sera from patient 82, so that peptides shorter 
than 33 amino acids could be synthesised and secondly, to determine the optimal form 
of peptide to best detect V3 specific antibody in the sera of patient 82.
6.2 Defining the region of V3 reactive with sera from patient 82
To define the region of V3 reactive with HIV-1 infected sera, four overlapping 
peptides spanning the region between amino acids 297 and 330 were synthesised in the 
monomeric form. The sequence of these peptides is shown in Table 6.3. Peptide 344A, 
synthesised by Dr Susan Graham, and peptide 416 were soluble in PBS, however, 
peptides 353A, 353B and 353C with basic properties had to be dissolved in lOOul of 
10% formic acid and made up to the required volume with PBS. Figure 6.2 shows each 
of the five peptides titrated in a series of eight, 10-fold dilutions from a concentration of 
50ug to 5xl0"6ug peptide per well. All four peptides were tested in ELISA for
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Table 6.2
Serum samples taken from patient 82 (1984-1991) 
Sample number Sample code Date sample taken
1 JA53190 4-12-84
2 H5640/87 30-7-87
3 H530/88 26-1-88
4 H5326/88 27-7-88
5 HI 094/89 15-2-89
6 H6092/89 18-8-89
7 HI 164/91 8-2-91
Table 6.3 Peptides corresponding to regions of patient 82
seroconversion sequence
Seroconversion sequence
TR PNNNTRKSIHIG PGRAFYTTGE11GDIRQAH
Peptide No
416 TRPNNNTRKSI
344A RKSIHIGPGRAFY
353A G PGRAFYTTGE11GDIRQAH
353B RAFYTTG EliGDIRQAH
353C YTTGEIIGDIRQAH
All peptides were synthesised as monomers
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figu re 6.2 Reactivity of the monomeric peptides (shown in Table 6.3) spanning the 
^reconversion sequence of patient 82 in an ELISA. Peptide 416 with sequence 
jlRPNNNTRKSI ( • ) ,  344A with sequence RKSIHIGPGRAFY O .  353A with sequence 
PPGRAFYTTGEIIGDIRQAH (▲ ). 353B with sequence RAFYTTGEHGDIRQAH ( A )  and 
353C with sequence YTTGEIIGDIRQAH (■) were titrated in a series of eight 10-fold dilutions 
from a concentration of 50ug to 5xl0-6ug peptide per well and screened for reactivity with the 
serum sample (diluted 1:100) taken at seroconversion (JA53190, Table 6.2). The reactivity of 
peptide 344A with an HIV-1 negative serum is shown (O)*
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reactivity with the 1984 serum sample JA53190 and an HIV-1 negative control serum 
at a 1:100 dilution. The HIV-1 positive serwiwas highly reactive against the 344A 
peptide, still detecting antibody at KHug of peptide, giving an absorbance at 405nm of 
0.4 OD units. Peptides 416, 353A, B and C showed very little reactivity with the serum 
however, peptides 353A and B showed reactivity at the highest peptide concentrations. 
The HIV-1 negative control serum showed no reactivity with any of the peptides 
though only the data from peptide 344A is shown. These findings confirm previously 
published work showing that the immunodominant region of V3 maps to the highly 
conserved GPGR motif at the tip of the loop and the surrounding amino acids 
(Goudsmit et a l,  1988a; Javaherian et a l, 1989; Meloen et a l,  1989). Peptides 
spanning this immunodominant region of V3 (gpl20 aa 304-316) containing all variant 
sequences found in patient 82 were subsequently made.
6.3 Reactivity of the short 13-mer seroconversion peptide in the 
monomeric, branched and branched form with a four glycine spacer
The short V3 monomeric seroconversion peptide (344A), sequence 
RKSIHIGPGRAFY, highly reactive with the initial sample from patient 82, was 
synthesised in branched form with and without four glycine spacers. Both peptides like 
344A, were soluble in PBS. Figures 6.3A, B and C show each form of peptide titrated 
in a series of twelve, 10-fold dilutions from 5xlO"10Ug/well to 50ug/well and tested in 
ELISA with HIV-1 positive and negative control sera at a dilution of 1:100. Both 
forms of branched peptide showed greater reactivity with the HIV-1 positive control 
sera than did the monomeric peptide. Using a cut-off absorbance value of 2.2 (= 5x the 
mean of the absorbance values of the negative serum), the monomeric and branched 
peptide without glycine spacers could detect specific antibody at peptide concentrations 
as low as 5xl0"^ug per well whereas, the branched peptide with the four glycine spacer 
could detected antibodies in one serum with 5x1 (Hug peptide per well and in the other 
serum with 5x1 (H ug peptide per well. From the graphs , the concentration of all three
Figure 6.3 Comparison of the reactivity in an ELISA, of the short V3, seroconversion 
peptides, synthesised in the following forms, monomeric (A), branched (B), and branched 
with a four glycine spacer (C) with control HIV-1 positive (■ ,* )  and negative sera ( • )  at a 
dilution of 1:100. Peptides were titrated in a series of twelve, 10-fold dilutions from a 
concentration of 50 ug to 5x10-lOug per well.
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peptides required to give the optimal reactivity with minimal background against HIV-1 
negative control sera was considered to be 10'lug per well.
6.4 Sensitivity of the V3 monomeric and branched G4 peptides
The branched G4 and monomeric seroconversion peptides, were compared in 
ELISA for sensitivity in detecting antibody in HIV-1-infected sera. The peptides were 
dissolved in PBS and coated to microtitre plates at the optimum concentration of lOOng 
per well and the sera titrated in a series of doubling dilutions from 1:25 to 1:51,200. 
The serum titre was defined as the reciprocal of the maximum dilution which would 
give an absorbance of 0.3. The data shown in Figure 6.4A and B and summarised in 
Table 6.4 demonstrate that the branched G4 peptide has an 8-fold greater sensitivity 
than the monomeric peptide for detection of antibodies in one of the sera and a 32-fold 
greater sensitivity for the other. Based on these data, the branched form of the peptide 
with four glycine spacers was considered the best form of peptide for detection of 
antibodies against the V3 region.
6.5 V3 variant peptides
Peptides corresponding to all the variants in the V3 region between gpl20 aa 
304-316 that had been identified in patient 82, during the period 1984-1991, were 
synthesised in the branched form with four glycine spacers. The sequence, relative 
frequency and the years in which the variants were found in the circulating virus 
population are shown in Table 6.5. The frequency at which each individual sequence 
was present has been deduced from the values shown in Table 6.1, taking into account 
only amino acids between residues 304-316. The peptides were designated V3(l)- 
V3(17), V3(l) being the seroconversion sequence peptide. Peptides V3(2)-V3(12) 
correspond to all the variants found in patient 82 over the seven year period. Some of
102
Figure 6.4 Comparison of the sensitivity of the short branched V3 peptide with a four 
glycine spacer (B) and the monomeric V3 peptide (A) coated to microtitre plates at a 
concentration of lOOng of peptide per well. The peptides were screened against doubling 
dilutions of control HIV-1 positive (■  , A ) and negative sera ( • )  from 1:25 to 1:51,200.
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Table 6.4
Titration of HIV-1 positive sera against a branched peptide with a 
glycine spacer and a monomeric peptide , both corresponding to 
residues 304-316 of HIV-1 gpl20.
Serum Titre againsta
monomeric peptide branched peptide
EBH4 100 3200
EBH6 800 6400
a The titre is defined as the reciprocal of the maximum dilution giving an 
absorbance of 0.3 OD units at 405nm
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these variants, V3(5)-V3(ll), contained multiple changes from the founder amino acid 
sequence. For this reason a further 5 peptides, V3(13)-V3(17), were synthesised, with 
sequences not detected in patient 82, but which contain single changed amino acids 
found in the variants with multiple amino acid substitutions. All the peptides were 
purified by reverse phase HPLC to greater than 93% homogeneity with the exception of 
the V3(17) peptide (85.8%). The composition of the peptides sequences was confirmed 
by amino acid analysis (Cambridge Research Biochemicals). All peptides with the 
exception of V3(9) were soluble in PBS. Thus to avoid possible complications arising 
from the need to use a different solvent to dissolve this peptide it was not included in 
the study.
6.6 Antibody titres in patient 82 against the V3 peptides
All sixteen V3 peptides were then tested in ELISA against the seven serum 
samples taken from patient 82. The peptides were screened two at a time for reactivity 
against a series of eleven doubling dilutions (from 1:100 to 1:102,400) of the seven sera 
plus an HIV-1 negative control serum. The twelfth well on each of the plates was 
incubated with PBS alone to provide a "no antibody" control. To allow for any non­
specific binding of sera to the microtitre plates, each serum dilution was incubated 
against wells with no peptide prebound and the optical density at 405nm subtracted 
from each of the appropriate test readings . A typical value was 0.166 +/- 0.129, 
obtained on the day that the seroconversion peptide was titrated. As a control for day- 
to-day variation the long branched V3 peptide (peptide 306) was screened daily against 
additional HIV-1 positive and negative control sera. This control allowed any increase 
or decrease in reactivity of the sera to be attributed to real change in their titres and 
discount experimental factors. In practise, over the 3 weeks taken to screen the sera, 
the titre against this peptide varied within a two-fold range and the maximum 
absorbance varied by less than 10%.
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Representative data from two peptides V3(l) (RKSIHIGPGRAFYG4 )8K7 A and 
V3(6), (RKRIHIGPGRAVYG4 )8K7A, with all the patient 82 sera are shown in Figure 
6.5. All of the peptides with the exception of V3(4), (RKSIHIGPGRAVYG4 )8K7A 
and V 3(ll), (RKGIHIGPGSAVYG4 )8K7A, show reactivity with the sera similar to 
that seen with the V3(l) and V3(6) peptides. The reactivity of peptides V3(4) and 
V 3(l 1) with patient 82 sera are shown in Figure 6.6. The titre of each of the seven sera, 
defined as the reciprocal of the maximum dilution giving an absorbance of 1.0 OD units 
at 405nm was determined by interpolation of the data from the graphs obtained for each 
of the peptides (Table 6.6) and is plotted in Figure 6.7A and B. Figure 6.7 A shows the 
titres obtained for the peptides V3(l)-V3(12), corresponding to all the variants that 
were detected in patient 82 and Figure 6.7B shows the reactivity of the peptides 
V3(13)-V3(17), the sequences of which were not detected in patient 82.
All seven sera were reactive to varying degrees with the eleven peptides V3(l)- 
V3(12). In each case, with the exception of peptide V3(12), the initial serum sample 
showed low reactivity against the peptides. This observation is consistent with the 
existence of a limited immune response to the virus around the time of seroconversion. 
The reactivity of the seroconversion sample with peptide V3(12) may represent some 
fortuitous cross-reaction with pre-seroconversion antibodies as has been suggested by 
Davis et al. (1990) but this speculation could not be tested. Similar reactivity, again 
with the exception of the seroconversion sample with peptides V3(14)-V3(17) was 
observed for the patient 82 sera against the five peptides corresponding to the single 
changed amino acids in the variants with multiple substitutions (Figure 6.7B).
The data summarised in Figure 6.7A can be used to test the hypothesis that newly 
emerged variants represent antibody escape mutants. The hypothesis would suggest 
that peptides corresponding to such variant sequences should show lower reactivity 
with sera taken around the time that variant arose. This is clearly not so for patient 82. 
High titres of antibodies are present against most of the variants prior to their first 
detection in the circulating virus population. This effect is particularly marked for 
peptides V3(5) and V3(6), the sequences of which first became detectable in 1988, yet
104
a>
r *
c
*<*-n
• w T3 □
/-V 43 —»
< CO43 r -oo
43
G
03 243
CU £ ro
C/3
43T3 ■
CT)
> D .43
4) CU oo
CN•Ud
CU <
4) r - t3-
CU CN
OS oo OOi—i
43c/3 a
4—»
G
43
CN >*
• ^ 4 +-»
OO > 1
C3
cu
G.2 <& so—»
cd o cip
CU Pu c0
JG—1
aH-*
XH-H
t-
43
C/3
13
£  w  
&ioC3su CQH
JG "OJ ao C 
*G ^  ■C Q,
£  ^  
E  §c/3 c n
JS >o  
jG 
£  
C/3 43 T3 * ^
CU0)CU
m>
43-C
43
>
c
43c/3
£CU43C4
IT)
SO
Vu
s
CD
G0)scr43C/3
G43>43c/3
43JG
CU 0) CU
■o c
OS
< 
r"
oo
a  
>< tu 
<
a
PmaM
3  X
03"O ^
OeS
« .s
§  s
a)
V 3
a>_>
as
OO4)G
>  >—<
X
G
•acc3
■o X
3  CN
§T3
to <1 a  w  
’c3 os 
©0 oo
«  ^  
13 ^  
£  ~1
4) ^CU 3
«> ON 
©  2® O  CN
^  loC^-H 1-H
O
c C"
.2 Q
G o3
CU4)CU
c
o
43>G
oo
ol-l4)c/3
c4343C
o4)
c3
<00
OO
oo
r -CN
OO
oo
I-J VO 
W  CN
Dilution 
of patient 82 
sera
Absorbance at 405nm
1 : 100 - 
1 : 2 0 0 - 
1 : 4 0 0 -  
1 : 8 0 0 -  
1 : 1 6 0 0 -  
1 : 3 2 0 0 -  
1 : 6 4 0 0 -  
1 - . 1 2 8 0 0 -  
1 : 2 5 6 0 0 -  
1 : 5 1 2 0 0 -  
1 : 1 0 2 4 0 0 -  
No Antibod
1 : 1 0 0 - 
1 : 2 0 0 - 
1 : 4 0 0  
1 : 8 0 0 -  
1 : 1 6 0 0 ^  
1 : 3 2 0 0  
1 : 6 4 0 0  
1 :1 2 8 0 0 -  
1 : 2 5 6 0 0 -  
1 : 5 1 2 0 0 -  
1:1 0 2 4 0 0 -  
No Antibod
1
CQ 3
— , O'
03 2®S <nCO ^  
G , ^
w  OO m oo
ooc
O
euoc
X
3O•o
•oc
ed
CN
0 5tc
'edOOed
<
oo
■'d'
o
Eh
>1<
e*
oooo
VO
cn
□  2
r»oo
r-
rj-oo
00 
■U
w   ^
CN 
00 
 *" 4—)
^  c  
<  .£2 
ed
— O-
= Ied PO- d  
w  ed
03
£
U-i
03o-
OOcoo
o
e
o
•4—>ed
.bc03oeo
cd
ed
wed
T3
£05
03
» ->
0)
<5
£OO
03
12
G.
03
ft.
0 5
03
•o
<*»>
G .CD
G ,
03
0 5
CDX
cn
>
0 5
03
•o
4—>
o ,
CD
Cu
<
c/3
ed
C
033cro>
0 5
c
CD>
0 5
03
X
a  *
.2 < «-» r—-
2  »  
1-1
o
>1 
J  <  U Cfll
o
s©
vC
EE 
£  Ol5)  ^
E  f e
edUh
03
0 5
03_>
ed
oo
03C
Ov
cn
oo
Oh
2  3
O voo
oo
oo
oX
4-->OOc
’edOOed
03
EE -
3ed
•oced
"3
03
£o
X
05
CN
OO
wc
03
ed
ft.
edWh
03eo
ced
3
X
Dilution 
of patient 82 
sera
Absorbance at 405nm
No
1 : 1 0 0 ’ ?
1 :2 0 0 -?
1 : 4 0 0 -
1 : 8 0 0 ’ ?
1 : 1 6 0 0 ’
1 : 32 0 0 * ?
1 : 6 4 0 0 ’
1 : 1 2 8 0 0 -
1 : 2 5 6 0 0 ’
1 : 5 1 2 0 0
1 : 1 0 2 4 0 0
A n t i b o d
«
o
1 : 1 0 0 -  
1 : 2 0 0 -  
1 : 4 0 0 -  
1 : 8 0 0 -  
1 : 1 6 0 0 -  
1 : 3 2 0 0 -  
1 : 6 4 0 0 -  
1 : 1 2 8 0 0 -  
1 : 2 5 6 0 0 -  
1 : 5 1 2 0 0 -  
1 : 1 0 2 4 0 0 i  
No Antibod
Table 6.6
Titres of sequential sera from patient 82 a 
Peptide Sample date
4/12/84 30/7/87 26/1/88 27/7/88 15/2/89 18/8/89 8/2/91
V3 (1) <100 1100 1700 1700 2100 1900 1100
V3 (2) <100 1000 1500 1250 1250 1250 380
V3 (3) 540 1000 1150 1600 470 580 580
V3 (4) 190 320 540 300 250 200 200
V3 (5) 290 1700 2900 2900 2400 1700 1500
V3 (6) 310 1900 3100 3100 2700 1900 950
V3 (7) <100 1100 1200 900 1000 900 750
V3 (8) <100 800 900 900 750 750 560
V3 (10) <100 700 1500 600 1700 1600 1600
V 3 (11) <100 200 360 180 320 410 120
V 3 (12) 3200 2800 4200 1900 4200 3400 2800
V3 (13) 2200 2300 3200
V 3 (14) <100 780 1400
V 3 (15) <100 950 2300
V 3 (16) <100 1020 1700
V 3 (17) 200 1800 2400
2900 2900 2800 2900
1400 1050 950 950
1600 1050 950 950
900 1100 1200 950
1800 1800 1500 1100
a The titre is defined as the reciprocal of the maximum dilution giving an 
absorbance of 1.0 OD units at 405nm
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high titres of antibody (1:1,700 and 1:1,900 respectively) were present against both 
sequences already in 1987. V3(12), the sequence of which was only ever detected in 
1990, already had antibody titres of 1:3200 in 1984 and this high reactivity persisted 
throughout the sample period. The antibody escape hypothesis would predict that 
variants with this sequence would not emerge in the population even if the antibodies 
reactive with V3(12) are only fortuitously cross-reactive. The low reactivity observed 
against the V3(4) and V 3(ll) peptides, according to the antibody escape hypothesis, 
would predict that these variants should persist in the population, yet they did not. 
Their failure to persist could be explained if these sequences were obtained from 
replication defective virus, but argues strongly against the variants being antibody 
escape mutants.
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6.7 DISCUSSION
6.7.1 Antibody responses against the V3 sequence variants detected in 
patient 82
The work presented in this chapter provides a comprehensive study of the 
antibody responses against the V3 region of HIV-1 gpl20 in one patient and aimed to 
determine whether the sequence variants that arose in this region during the course of 
infection represented antibody escape mutants. The experimental protocol used to 
detect the V3-specific antibodies utilised an optimised form of branched peptide 
developed and discussed in chapter four of this thesis. Peptides corresponding to all the 
V3 variants that were detectable^patient 82 during the course of infection were 
synthesised onto a branched lysine core with a four glycine spacer preceding the 
reactive epitope, defined in this chapter and elsewhere (Palker et a l, 1988;Rusche et 
al, 1988; Goudsmit et al, 1988a; Matsushita et a l, 1988) as lying between amino acids 
304-316 of HIV-1 gpl20. These peptides were then screened against doubling 
dilutions of sera taken from patient 82 over a seven year period. Using branched 
peptides in this way, V3-specific antibodies can be detected in very low concentrations 
of human sera. This is of great importance to any retrospective study of the antibody 
responses in HIV-infected individuals as early serum samples are usually in very short 
supply. In this study, only 34ul of each serum sample were needed to obtain all the 
data presented.
The hypothesis that sequence variants that arise during infection represent 
antibody escape mutants, would suggest that peptides corresponding to such variant 
sequences should show lower reactivity with sera taken around the time that variant 
arose. The data obtained for patient 82, summarised in Figure 6.7A and B, clearly 
indicates that this is not the case for this individual. High titres of antibodies were 
present against most of the variants that arose during infection.
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An antibody escape mutant would be expected to be a variant with a novel 
sequence which emerges in the viral population and is then maintained in the absence 
of antibodies which recognise that particular sequence. The data obtained provide clear 
examples of variants which do not behave in this way. For example, the seroconversion 
sequence represented by peptide V3 (1) was found in 1987, 1988, and 1991 in spite of 
good titres of antibodies which recognised the sequence. Another example is the 
variant represented by peptide V3(7) which emerged in 1987 and persisted through to 
1991 in the presence of a constant titre of antibodies which recognised the sequence.
Relevant to these findings is an earlier study by Wolfs et al. (1991), who obtained 
V3 sequence data on two patients and demonstrated that an amino acid substitution at 
position 308 (H to P in one patient and P to H in another) led to a changed antibody 
population within the individual. The data obtained in this chapter are not in conflict 
with this earlier study, as the experiments were not designed to examine whether 
different antibody populations exist within patient 82, nor whether newly emerged 
variants resulted in a new antibody population.
The ability of each of the peptides to compete for the V3-specific antibodies in an 
ELISA would determine whether the antibodies present in each serum sample were 
cross-reactive for the V3 peptides or were specific to individual variant sequences that 
arose during infection. Regardless of the outcome of such experiments, the high titres 
of antibodies observed in patient 82 that react with all of the variants that were detected, 
provide a strong argument that these sequence variants do not represent antibody escape 
mutants.
It would also appear that the amino acids within the V3 peptide do not always act 
independently in determining its reactivity with serum antibodies. This is evidenced by 
the low reactivity of peptides V3(4) and V 3(ll). For V3(4) the low reactivity is 
brought about by the single amino acid substitution f 316_v . xhis same substitution 
occurs in peptides V3(5), V3(6), V3(8), V3(10) and V 3(ll) and reactivity against the 
serum antibodies can be regained by changes elsewhere in all of them except V 3(ll), 
even though all of the changes seen in V 3(ll), can be found in part in those other
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peptides. Moreover, the high titres observed against peptides V3(12),V3(14) and 
V3(16), which each contain one of the amino acid substitutions found in V 3(ll), 
indicate that no single amino acid change can account for the reduced reactivity seen 
against peptide V 3(ll).
6.7.2 Variation in the absence of humoral immune selection
The conclusion from this study, that the sequence variants that emerge in patient 
82 do not represent antibody escape mutants, is perhaps surprising as most of the 
antibodies in HIV-1 infected sera that recognise linear epitopes are directed against the 
V3 region (Moore and Ho, 1993) and this region is the principal neutralising 
determinant of the virus (La Rosa et al., 1990). For these reasons, one would expect 
that extensive sequence variation in a highly immunogenic region of the virus would be 
driven by immune selection and would subsequently have an effect on its recognition 
by antibodies. This however, does not appear to be the case.
Antigenic variation and the emergence of immunological escape mutants has 
been proposed for a number of viruses, including Visna virus and Equine infectious 
anaemia virus, both members of the lentivirus family (reviewed by Clements et al, 
1988). Perhaps the best documented example of a virus demonstrating immunological 
escape is the influenza virus which has the ability to undergo both antigenic drift and 
antigenic shift resulting in the emergence of distinct viruses that are unrecognised in 
previously infected hosts. Sequence variation in the antigenic sites of the 
haemagglutinin (H) and neuraminidase (N) surface proteins can account for this 
antigenic diversity and has resulted in several distinct outbreaks of influenza epidemics 
in Britain, for example the Spanish flu epidemic in 1918 (H1N1), the Asian flu 
epidemic in 1957 (H2N2) and the Hong Kong epidemic in 1968 (H2N3) (reviewed by 
Wiley and Skehel, 1987).
Mutations leading to immunological escape do not necessarily occur as a result of 
immune selection in all RNA viruses. Indeed, extensive antigenic variation in the
108
Chapter 6
absence of any immune selection has been reported for the Foot-and-Mouth Disease 
Virus (FMDV), a member of the picornaviridae family (Diez et al., 1989, 1990; 
reviewed by Domingo et a l, 1993) that causes an economically important disease in 
cattle. In one study in which plaque purified FMDV was passaged in cell culture, 
viruses emerged with single amino acid substitutions in antigenically important sites of 
the viral proteins. These variant viruses when characterised by an in situ plaque 
immunotest were not recognised by specific monoclonal antibodies directed against 
regions of antigenic importance (Diez e ta l,  1989). In addition, repeated passage of the 
virus resulted in an outgrowth of the viruses displaying this antigenic diversity, despite 
the absence of any immune selection. It has been proposed that this antigenic variation 
arose randomly by the quasispecies evolution of viral sequences and the variants 
displaying the observed antigenic variation were selected for because of properties 
unrelated to their antigenicity. A recent extension to this study , in which the same 
FMDV isolates were passaged in the presence of a limited amount of neutralising 
polyclonal antisera showed that substitution of an antigenically critical amino acid 
occurred only in the clones passaged with antibody (Borrego et al., 1993). These 
results suggests that antigenic variation in this virus occurs in both the presence and 
absence of immune selection.
6.7.3 Basis for emergence of V3 variants
How do the observations described above relate to the sequence variation that 
arises in the V3 region of HIV-1 gpl20? Apparently, the sequence changes that emerge 
in patient 82 are not driven by the humoral immune response and are unlikely to 
represent random fluctuations in the viral population. The variants may play an 
important role in other properties that are selectively advantageous for the virus or 
could represent CTL escape mutants. As discussed previously, the V3 region is 
involved in a number of important biological features of the virus. Sequence variation 
in the V3 region of this patient occurs at amino acid positions known to be important
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for the ability of the virus to induce syncytia and display altered cell tropisms. As these 
amino acid changes have no apparent effect on the recognition of these variants by 
specific antibodies, it would be interesting to examine whether the substitutions have 
any effect on the biological properties of the virus. To test this, molecular clones of 
these variant V3 sequences in a common background virus would have to be made and 
screened for their ability to induce syncytia and to replicate in different cell types.
6.7.4 Future studies
To provide a more general basis for the conclusion that sequence variants that 
arise in the V3 region do not represent antibody escape mutants, it is important that this 
study be extended from a single individual to a number of patients.
This work does not exclude the possibility that the newly emerged variants 
represent mutants escaping from a subset of antibodies, such as neutralising antibodies. 
Indeed, mutations arising in vitro have been identified which are resistant to 
neutralisation by anti-V3 loop antibodies (McKeating et a l,  1989; Masuda eta l., 1990). 
However it is perhaps unlikely that the variants detected in patient 82 are neutralisation 
escape mutants, for two reasons. Firstly, of the sixteen monoclonal antibodies which 
have been mapped to the V3 loop, all are neutralising (Scott et al., 1990; Gorny et al., 
1991; Tilley et al., 1991; Laal and Zolla Pazner, 1993). Second antibodies from other 
species, directed against the V3 loop are also invariably neutralising (Rusche et a l,  
1988; Palker et al., 1988; Goudsmit et al., 1988a, b; Zagury et al., 1988). However, the 
neutralising ability of antibodies detected in patient 82 has not been directly measured. 
Construction of HIV-1 clones in which the variant sequences are inserted into a 
constant HIV-1 background are required to test this hypothesis.
The neutralising activities of serial samples with sequential virus isolates from 
HIV-1 infected individuals have been examined by Adrenup et al. (1993). In contrast 
to the conclusions from this study, these authors suggest a participation of the 
neutralising antibody response against the V3 loop in the immunoselection of escape
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virus. However, in that study, viruses were isolated from the PBMCs, where proviral 
genome would be inaccessible to antibody selection, whereas virus sequences in the 
study of patient 82 were obtained from virus in the plasma. Second, the V3 sequence of 
only one virus isolate was obtained, which does not permit the frequency with which 
the sequence was present in the individual to be estimated. Third, the observed 
differential neutralisation by an anti-V3 monoclonal antibody of sequential isolates 
confirms the existence of antigenic variation but does not constitute evidence for lack of 
recognition of the V3 variant sequences by the patients own sera.
It is also possible that sequence variation in the V3 region is accompanied by 
variation in other regions of the gpl20 protein and that an interaction of the V3 region 
with other such regions is important for escape from immune recognition. If this is 
the case, then the study described here, which examined only small regions of the 
protein will not be able to determine what effect these individual changes have on the 
antigenicity of the virus. One way to investigate this possibility would be to clone the 
entire gpl20 from each individual virus isolate into a general background virus and test 
its ability to be neutralised by autologous sera. Although this would undoubtedly be a 
very difficult and laborious task, I feel that it would provide a better understanding of 
the mechanisms involved in viral pathogenesis. However, such considerations do not 
affect the finding that V3 variants are not antibody-escape mutants.
The amino acid changes observed in the V3 variants in patient 82 could also 
represent mutants escaping from cytotoxic T cells. Indeed, the V3 loop contains 
epitopes that elicit cytotoxic T cell responses, where the amino acid at residue 325 
(three amino acids C-terminal of the conserved GPGR motif) can define peptide 
epitope specificity (Clerici et a l,  1991; Takahashi et a l,  1988, 1989, 1990). CTL 
escape mutants in V3 have yet to be demonstrated in vivo.
I l l
6.8 GENERAL DISCUSSION
Chapter 6
The question that arises from the studies described in the previous two chapters is, 
what role do V3-specific antibodies play in the control of HIV-1 infection ? The 
answer to this question and indeed what role, if any, do anti-HIV-1 antibodies in 
general play in the control of HIV-1 infection, is one of increasing controversy. Some 
researchers believe that determining the regions of the virus that are important in 
eliciting a protective antibody response will be useful in developing vaccines. The 
findings of this thesis lead me to believe that the development of potential vaccines that 
involve immunisation with V3 peptides which elicit only V3-specific antibodies will be 
of little use in protecting against transmission of HIV-1. The study described in chapter 
5 showed no correlation between the levels or affinities of V3-specific antibodies and 
protection of the child from vertical transmission of the virus. Additionally (chapter 6), 
there appears to be no effect on antibody recognition of the immunodominant V3 
region of extensive sequence variation, suggesting either that the virus does not need to 
escape from the humoral immune response to persist in the host or that the mechanisms 
by which the virus escapes humoral immune recognition are much more complex than 
those investigated . It is however, important to note that this patient had high titres of 
V3-specific antibodies throughout the sampling period and although remaining 
asymptomatic for the clinical symptoms of AIDS, had shown a continual decline in 
CD4+ cells to below 200 at the latter time points. Holmback et al. (1993) report no 
correlation between the stage of disease progression and the titres of V3-specific 
antibodies.
It has been argued that a vaccine which induces only an antibody response will 
not be sufficient to protect against the transmission of virus in virally infected cells that 
bear none of the viral antigens on their surface (reviewed by Sabin, 1992). For a 
vaccine to be effective against HIV infection it should probably stimulate both arms of 
the immune response. The cytotoxic T cell response generated against the virus has not 
been investigated in this thesis but will perhaps play an important role in the
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development of potential vaccines against HIV-1. It has become apparent that there 
are some individuals, in high risk behavioural groups, that have been exposed to the 
virus yet appear not to be infected. Studies performed on individuals of this kind have 
shown that some of them (two out of five sexual partners of HIV-infected individuals 
and 8 out of 24 uninfected children born to HIV-infected mothers) had CTL activity in 
response to HIV peptides, despite having no detectable virus by PCR or antibody 
reactivity against HIV proteins (Levy, 1993). In other studies (reviewed by Salk et al, 
1993), as many as 49% of a total of 97 presumed exposed individuals , compared with 
2% of 163 individuals not known to be exposed to HIV, displayed CTL activity against 
HIV-derived peptides in the absence of detectable virus or antibodies against HIV-1 
proteins. The question then arises as to whether these individuals are immune to HIV- 
infection or whether they were perhaps exposed to defective virus or HIV proteins and 
therefore, infection was not established ? What can be derived from such a study is that 
the antibody response and the cytotoxic T cell response appear to be induced separately.
It is known that two subtypes of CD4+ T-helper cells are induced in response to 
antigen (reviewed by Levy, 1993; Salk et a l, 1993). These different cell types secrete 
specific cytokines which stimulate different arms of the immune response. T-helper 1- 
type cells (TH-1) secrete cytokines, such as interferon-gamma and interleukin-2, which 
stimulate the production of cytotoxic T cells. T-helper 2-type cells (TH-2) secrete 
cytokines such as interleukin-4 and 10, which stimulate a humoral response. These 
different responses are believed to be in some way competitive, in that stimulation of 
one type will eventually lead to a down-regulation of the other. If cytotoxic T cell 
activity against HIV provides a protective response against the virus then strategies 
aimed at increasing the levels of neutralising antibody response against HIV envelope 
proteins, could lead to a susceptibility to infection, rather than having any protective 
effect. It is interesting to note that during the asymptomatic stage of HIV-infection the 
levels of CD8+ cells, remains high and falls off on progression to AIDS, suggesting that 
the CTL response may play a role in the control of HIV-infection during the 
asymptomatic phase. It is the opinion of some researchers that a prophylactic vaccine
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designed to induce a strong CTL response will provide better protection against 
infection (Salk et a l, 1993).
It is also argued that the symptoms and features, characteristic of HIV-1 infection, 
are similar to those observed in autoimmune diseases and that progression to AIDS may 
not be caused directly by viral infection, but by the immune response against the virus 
destroying its own uninfected cells (Hoffman et a l, 1991; reviewed by Weiss, 1993). 
Such a process could account for the massive depletion of CD4+ cells in the apparent 
absence of high numbers of infected cells. If this is the case then stimulating the 
immune response against the virus will have detrimental effects and indeed speed the 
progression to AIDS. Perhaps then, selective immunosupression of certain subsets of 
immune effector cells will slow the onset of disease. This theory though highly 
speculative is one to be considered when developing therapeutic vaccines against HIV.
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